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ABSTRACT 
STRUCTURAL AND MECHANISTIC STUDIES OF α-GALACTOSIDASE A 
AND PHARMACOLOGICAL CHAPERONES 
 
FEBRUARY 2010 
 
ABIGAIL IDA A. GUCE, B.S., UNIVERSITY OF THE PHILIPPINES-DILIMAN 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Scott C. Garman 
 
 
 
 
Human α-galactosidase (α-GAL; EC 3.2.1.22) is a lysosomal enzyme that 
hydrolyzes of terminal alpha-linked galactosyl residue of glycosphingolipids. 
Deficiencies in α-GAL leads to Fabry disease, which is characterized by the build-up of 
globotriaosylceramide and other neutral substrates in cells, ultimately leading to a multi-
systemic organ failure in patients. Hundreds of distinct mutations have been found in the 
α-GAL gene of Fabry disease patients. One current treatment for Fabry disease is 
Enzyme Replacement Therapy (ERT), which restores the missing α-GAL function. An 
alternative treatment, called Pharmacological Chaperone Therapy (PCT), utilizes a small 
molecule substrate analogue, 1-deoxygalactonojirimycin (DGJ).  
In order to better understand molecular basis of Fabry disease, this work 
addresses structural and mechanistic studies of the α-GAL glycoprotein. First, we have 
determined crystal structures of each stage in the catalytic mechanism of the α-GAL 
enzymatic reaction. These studies reveal a novel strained conformation of the sugar when 
it is covalently bound to the enzyme. Second, we examine the molecular mechanism of 
 ix 
chaperoning by pharmacological chaperones. A combination of biochemical and 
biophysical approaches reveals that the high potency of the DGJ chaperone is due to an 
interaction with α-GAL residue D170. Third, we have investigated mutant α-GAL 
proteins for their response to pharmacological chaperones, leading to a set of structure-
based rules for predicting the effect of pharmacological chaperone on every Fabry disease 
patient. Fourth, we use rational design approaches to interconvert the specificity of α-
GAL into that of a related enzyme, α-N-acetylgalactosaminidase (α-NAGAL). Structural 
and enzymatic experiments show that the engineered enzyme contains new substrate 
specificity, as predicted by the design. 
The structural and mechanistic details we present in this thesis provide better 
understanding of the catalysis of the human α-galactosidase enzyme as well as define the 
molecular basis for pharmacological chaperone therapy in Fabry patients. Since α-GAL 
is one of the best studied lysosomal storage disease, it might be used as a model to better 
understand other lysosomal storage diseases and as well as other diseases related to 
misfolded proteins, including Alzheimer’s and Parkinson’s diseases.  
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CHAPTER 1 
 
STRUCTURE AND FUNCTION OF α-GALACTOSIDASE A 
 
1.1.   α-Galactosidase A and Fabry disease  
Human α-galactosidase A (α-GAL: EC 3.2.1.22) is a lysosomal enzyme that 
catalyzes the hydrolysis of a terminal alpha-linked galactosides from oligosaccharides, 
glycoproteins and glycolipids in cells (Figure 1.1a) (Brady 1967; Desnick 2001). α-GAL 
is also known to recognize the terminal α-galactosyl moiety of the human blood group B 
antigen and enzymatically convert it to the universal donor, blood group O (Figure 1b) 
(Wherett 1973; Zhu, Leng et al. 1996). 
The 1.45 kb α-galactosidase A gene (GLA A, NM000169) is localized to the X-
chromosome region, Xq22.1, and encodes a glycoprotein of 429 amino acids including a 
31 amino acid signal sequence (Calhoun 1985; Bishop 1986). Molecular mass analysis by 
gel filtration revealed α-GAL is a obligate homodimer with an apparent molecular weight 
of about 100 kDa (Dean and Sweeley 1979; Dean and Sweeley 1979; Bishop and 
Desnick 1981). Biochemical assays show a 46 kDa mature monomer polypeptide which 
undergoes dimerization, co-translational cleavage of the secretion signal, N-linked post-
translational carbohydrate attachment at the ER, and glycosylation modification in the 
Golgi before it traffics to the lysosome through the mannose-6-phosphate receptor (Dean 
and Sweeley 1979; Lemansky 1987; Dahms, Lobel et al. 1989; Ioannou, Bishop et al. 
1992). 
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Figure 1.1 α-galactosidase A natural substrates 
 
α-GAL catalyzes the hydrolysis of terminal α-linked galactosyl residue. (a) Fabry 
disease substrate globotriaosylceramide is cleaved by α-GAL to form 
lactosylceramide. (b) Industrial application for purified α-GAL is the conversion of 
blood group B to the universal donor, blood group O.  
Blood group B Blood group O 
a. 
b. 
 α-GAL 
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 In humans, inherited mutations in GLA gene causes Fabry disease (FD), a 
lysosomal storage disease, which is characterized by the absence or shortage of 
functional α-GAL enzyme in cells. The deficiency of functional α-GAL enzyme leads to 
the progressive build up of neutral substrates, predominantly globotriaosylceramide (GL-
3), in the plasma and in lysosomes of tissues throughout the body (Figure 1a) (Brady 
1967; Desnick 2001).  
Among more than 50 lysosomal diseases, Fabry disease is the second most 
common disorder after Gaucher disease (a deficiency of β-glucosidase) (Brady 1965; 
Platt 2004). Fabry disease is an X-linked recessive lysosomal storage disorder first 
described in 1898, which affects 1 of every 40,000 males of all ethnic backgrounds 
(Anderson 1898; Fabry 1898; Desnick 2001). This number may be a gross underestimate 
due to a number of independent clinical studies showing that ~3-5% of men with left 
ventricular hypertrophy (LVH), a condition with an enlarged heart (Nakao, Takenaka et 
al. 1995; Sachdev, Takenaka et al. 2002); ~5% of men with acute cryptogenic stroke, 
stroke with unknown or undetermined cause (Rolfs 2005); and ~1% of men undergoing 
hemodialysis caused by renal failure (Utsumi 2000; Nakao 2003; Kotanko, Kramar et al. 
2004), have been diagnosed with FD. More recently, a population of newborns at 
northwestern Italy was screened, revealing a higher incidence of 1 in 3,000-4,000 males 
are α-GAL deficient (Spada, Pagliardini et al. 2006). These reports demonstrate that 
Fabry disease has a higher prevalence than previously thought, and there are potentially a 
large number of undiagnosed cases of Fabry disease among the male population. This 
makes it a focus of a number of clinical studies and pharmaceutical pursuits. 
 
  4 
1.1.1. Phenotype and symptoms 
Affected individuals with Fabry disease could either have classical (also called 
severe) or cardiac (also known as mild or variant) phenotype. The classical or severe 
phenotype of the disease is characterized by little or no α-GAL enzyme activity detected 
in the lysosome. Initial symptoms appear during childhood and early adolescence where 
patients complain of episodes of nagging pain in their extremities such as hands and feet, 
a condition known as acroparesthesia (Lockman 1973; Beck 2001; Desnick 2001). This is 
a clinical hallmark of Fabry disease and is mostly referred to in clinical literature as the 
episodic Fabry “crisis” (Mehta 2002). Acroparesthesia is later followed by the visible 
symptom of developing skin lesions (angiokeratoma) that first manifest as a characteristic 
skin rash throughout the body (Wise 1962; Desnick 2001). In addition, GL-3 build-up in 
the blood vessels near the sweat glands and eye affects the patient’s ability to sweat 
(hypohidrosis and anhidrosis) and causes benign corneal and lenticular opacities (Sher 
1979; Desnick 2001). With age, the disease progresses with the accumulation of GL-3 
substrate in various types of cells in organs, and patients develop major morbid 
symptoms such as cardiomyopathy, gastrointestinal disturbances, kidney dysfunction and 
cerebrovascular complications, typically leading to early demise in their forties (Desnick 
1971; Rowe 1974; Nagao, Nakashima et al. 1991; Desnick 2001). Blood type has also 
shown to influence the severity of the disease, where patients with B blood group antigen 
tend to have a more rapid progression of the disease (Desnick, Brady et al. 2003; Hopkin, 
Bissler et al. 2003). 
In contrast, individuals who have the mild or cardiac form of Fabry disease have 
mutations in the α-GAL gene that lead to less than 5-10% residual enzymatic activity 
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(Beck 2001). These patients are initially asymptomatic because the residual enzyme 
activity is able to remove some of the substrate in the lysosome, preventing its initial 
build up. However with time, slow progressive build up of the substrate causes disease 
symptoms, including late onset of unexplained renal failure, cardiac disease, and/or GL-3 
deposition in myocardial cells (Ferrans 1969; von Scheidt W. 1991; Germain 2002). 
Surprisingly, only 1% of female carriers develop the severe form of Fabry disease 
(MacDermot, Holmes et al. 2001). Most are asymptomatic until they develop symptoms 
associated with the mild/cardiac form (MacDermot 2001; Teragaki 2004). The difference 
between the hemizygote (XY) male and the heterozygote (XX) female in terms of disease 
manifestation is a result of random X inactivation of any of the two X-chromosome in 
females (Redonnet-Vernhet, Ploos van Amstel et al. 1996; Whybra, Kampmann et al. 
2001). Mortality in their 50’s is a result of the mild form of Fabry disease (Desnick 
2001). 
 Fabry disease is a multi-systemic disorder often very difficult to clinically 
evaluate because the initial symptoms are broad and associated with a variety of organs. 
Misdiagnosis or untimely diagnosis is common among Fabry disease making treatment of 
the more complicated symptoms challenging due to disease progression (MacDermot 
2001). Accurate diagnosis is also central to effective health maintenance, vital primary 
care management and treatment choices. Correctly identifying the disease is done through 
the analysis of GL-3 substrate levels in urinary sediments (isosthenuria) and blood; α-
GAL activity assay in plasma or tears; and confirmed through genetic testing to identify 
mutations to the GLA gene (Weibel 2001).  
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1.1.2. Mutations 
Among the nearly 50 distinct lysosomal storage diseases, Fabry disease is one of 
the best documented, with over 400 mutations reported in patients. To date, a variety of 
mutations have been identified including missense, nonsense, splicing mutation, small 
deletion and insertion as well as large gene rearrangement (Human Gene Mutation 
Database) which frequently causes the severe form of Fabry disease. These mutations can 
lead to a defective synthesis of the polypeptide chain, loss of catalytic capability, 
degradation of unstable or misfolded protein or a combination of these possibilities (Fan 
and Ishii 2007). Approximately 70% of the described mutations are single point amino 
acid substitutions and are considered private mutations, those unique to a single or few 
families. This complicates clinical predictions based on genotype-phenotype correlation 
alone. What is clearly established however is that clinical manifestation is directly related 
to the GL-3 substrate accumulation and the phenotype of the disease (severe or mild) is 
directly related to the level of residual enzyme activity measured in patients (Schaefer 
2005). 
Genome sequencing and transcription studies of patient fibroblasts, insect cells, 
and mammalian cells enabled researchers to investigate the effect of FD mutations on α-
GAL mRNA level (Ioannou, Bishop et al. 1992). Studies have shown that in most cases, 
mRNA levels are comparable for both normal and the patients’ cells. Therefore, most 
mutations that result in the disease affect protein levels and/or activities (Ishii, Sakuraba 
et al. 1992; Ishii 2000; Kase, Bierfreund et al. 2000). Because the mRNA levels are 
typically unaffected by the mutations, Fabry disease is caused by the non-transcription of 
mRNA, 
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Figure 1.2 Fabry disease causing mutations 
 
Amino acid sequence of wild-type α-GAL with the mutations reported by Fabry disease 
patients listed below. Amino acid residues in red indicate the mild form of the disease. 
This list shows the heterogeneity of the type and location of the mutations for Fabry 
disease. 
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defective biosynthesis, protein folding, loss of the catalytic capability of the enzyme, or a 
combination of these effects. Figure 1.2 shows the wild-type human α-GAL sequence 
and a current list of amino acid substitutions reported by patients, indicating the 
heterogeneity of mutations causing Fabry disease (Garman 2006). For Fabry disease, the 
connection or pattern between the nature of the inherited mutation (genotype) and the 
symptoms of the disease (phenotype), organ involvement or disease severity is not very 
obvious. Clearly, a better understanding of the genotype-phenotype relationship in α-
GAL would be of immense clinical benefit. 
 
1.2. Fabry disease treatment 
 Prior to 2001, there was no specific treatment for Fabry disease, with patients 
receiving entirely palliative treatment (also called supportive management treatment) to 
either reduce the severity of the symptoms or alleviate the pain. Palliative care is the 
standard treatment for other lysosomal storage diseases with no known cure (Fan 2003). 
The goal of this type of treatment is to improve the quality of life of the patients but does 
not address the source of the disease. Another option for end-stage symptoms such as 
major organ failure is an invasive surgery such as kidney and heart transplant to replace 
the damaged organ. Although these procedures have elevated risks associated with the 
surgery, transplants have shown promising results with notable clinical improvement 
(Erten 1998; Simonaro 1999; Desnick 2001). Other potential therapies include 
experimental gene-mediated enzyme replacement therapy and adeno-associated virus-
mediated muscle-directed gene transfer. These trial treatments are done by using an 
expression vector for α-GAL A to insert into the patient cells through bone marrow 
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transplant or intravenous injection to the liver (Takenaka, Hendrickson et al. 1999; 
Ziegler, Li et al. 2002). However, careful safety and toxicity studies have not been done 
(Takahashi, Hirai et al. 2002). A different treatment option is prophylactic therapy to 
prevent the progression of disease (Desnick 2001). The goal of a prophylactic treatment 
is protective and preventative through lifestyle modifications to minimize harmful disease 
progression (Weibel 2001). The aforementioned treatments are nonspecific, addressing 
symptoms rather than curing Fabry disease.  Although these interventions manage and 
can mitigate the symptoms, these treatments do not increase enzyme concentration or 
activity in the lysosome to break down accumulated GL-3 substrate in cells and tissue.  
 
1.2.1. Enzyme replacement therapy (ERT) 
For three decades now, research on lysosomal storage diseases has focused on a 
disease-specific therapy that tackles the fundamental cause of the disease, explicitly the 
deficiency of an active lysosomal enzyme that breaks down toxic substrates in the cell. 
Enzyme replacement therapy (ERT) was first proposed by de Duve in the early 1960’s in 
order to supplement missing or defective enzyme with a normal and functional 
counterpart to potentially stop and reverse disease progression (Desnick 2004). The 
groundwork of Brady and co-workers on Gaucher disease provided the “proof of 
concept” of ERT, which was approved for Gaucher disease by the US FDA in 1991 
(Barton, Brady et al. 1991; Parker, Barton et al. 1991).  Clinical trials have successfully 
established the positive correlation of the GL-3 substrate clearance and improvement of 
clinical manifestation with enzyme replacement therapy for Fabry disease and other 
lysosomal storage diseases (Ioannou 2001; Schiffmann 2001; Beck 2002; Germain 2002; 
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Desnick, Brady et al. 2003). This paved the way for ERT as a treatment for Fabry 
disease, which was approved by the FDA in 2003.  
Currently Fabry disease patients’ main treatment is enzyme replacement therapy 
where recombinant human α-GAL produced in CHO or engineered human cell lines is 
intravenously administered to restore the missing enzyme function. ERT has successfully 
demonstrated the reduction and clearance of accumulated glycosphingolopids in FD 
patients accompanied by the reversible manifestation of the disease such as reducing 
pain, heart and renal complications (Eng, Banikazemi et al. 2001; Beck 2002). The small 
increase of intracellular α-GAL activity in the lysosome lessens metabolic defects and 
significant improves the quality of life of patients (Schiffmann 2001; Germain 2002). 
Preclinical studies have shown lowered GL-3 accumulation in major organs such as heart 
and kidney (Eng, Banikazemi et al. 2001; Breunig, Weidemann et al. 2006). In addition, 
the discovery of the mannose-6-phosphate receptor-mediated pathway allowed for 
targeting of recombinant enzyme to the lysosome of cells and tissue (Lemansky, Bishop 
et al. 1987; Dahms and Kornfeld 1989; Dahms, Lobel et al. 1989).  
However, progress of ERT is still limited by the large quantity of enzyme needed.  
The difficulty of expression of highly purified therapeutic enzymes results in high costs, 
approximately $250,000/year/patient, one of the most expensive treatments available in 
the US (Desnick, Brady et al. 2003). Another pitfall of replacement therapy is that when 
enzyme is administered exogenously, only 1% of the injected enzyme makes it to specific 
tissues such as the heart and kidney. Most of the enzymes have a short biological half-
life, necessitating frequent injections of a high dose of enzyme. This is accompanied by a 
high risk of developing immune reaction to the injected glycoprotein (Schellekens 2002). 
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About 65-85% of Fabry disease patients can develop immune responses ranging from 
mild to severe and as a consequence require additional medication with the infusion, such 
as anti-histamine or steroids (Eng, Guffon et al. 2001; Vedder, Breunig et al. 2008). 
Safety and toxicity studies have demonstrated that the majority of males receiving ERT 
produce antibodies, rendering ERT less effective (Eng, Guffon et al. 2001; Schiffmann, 
Ries et al. 2006; Vedder, Breunig et al. 2008). Lastly, ERT is limited to non-neurologic 
symptoms due to the fact that enzymes are unable to cross the blood-brain barrier 
(Desnick 2004). Although enzyme replacement therapy is a therapeutic option for both 
phenotypes of Fabry disease, there are clearly limitations associated with this treatment 
option.  
 
1.2.2. Pharmacological chaperone therapy (PCT) 
An alternative treatment for enzyme replacement therapy for Fabry disease is 
pharmacological chaperone therapy (PCT). This treatment, which utilizes a small 
molecule to help stabilize the mutant enzyme, is proposed for patients having residual α-
GAL activity (Asano, Ishii et al. 2000; Fan 2003). There are two types of 
pharmacological chaperones, one called a chemical chaperone that binds non-specifically 
to the enzyme and another known as active-site specific chaperone (ASSC) where the 
small molecule binds to the active site. In both cases the small molecule binds to the 
enzyme and prevents protein aggregation or assists the enzyme to fold to its proper 
conformation ultimately leading to restoration of enzyme function (Kolter 2003). In 
particular, ASSC’s are of interest to researchers and clinicians since these small 
molecules are usually enzyme inhibitors or substrate analogues that bind with high 
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affinity to the active site of a specific target enzyme. A potent inhibitor binds efficiently 
to the specific enzyme at a lower concentration and therefore serves as a better folding 
template for the unstable mutant (Fan, Ishii et al. 1999; Fan 2003). Studies have shown 
that the binding affinity of a pharmacological chaperone is proportional to its ability to 
chaperone proper folding (Asano, Ishii et al. 2000). Because lysosomal enzymes fold in 
the ER, pharmacological chaperones must also cross lipid bilayers to be able to rescue 
unstable mutant enzyme and promote proper folding (Yam, Bosshard et al. 2006). 
Chapter 3 discusses in detail a model for the molecular mechanism of pharmacological 
chaperone therapy.  
A pharmacological chaperone, the tight binding substrate analogue, 1-
deoxygalactonojirimycin (DGJ), is currently in clinical trials for Fabry disease (Asano, 
Ishii et al. 2000; Fan, Ishii et al. 2000; Sugawara, Tajima et al. 2009). Additionally, the 
enzymatic product galactose has also been investigated for treatment of Fabry disease. 
DGJ is an imino sugar with a similar structure to galactose, the α-GAL product (see 
Figure 1.3) (Legler and Pohl 1986; Frustaci, Chimenti et al. 2001). Cellular uptake of 
DGJ and galactose is independent of receptors and then diffuse easily in the cells. In vivo 
and in vitro studies have demonstrated that sub-saturating amounts of DGJ bind to the 
active site of the mutant enzyme, facilitating trafficking out of the ER and increasing 
enzyme concentration and activity at the lysosome (Ishii, Chang et al. 2007; Shimatori 
2007; Shin 2007; Shin 2008; Benjamin 2009; Ishii, Chang et al. 2009). This increase in 
enzyme activity translates to the clearance of the accumulated substrate in cells and 
organs, resulting in a positive clinical outcome for patients. For lysosomal enzymes in 
vivo, normal substrate turnover occurs with a threshold level of greater than 
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Figure 1.3 Galactose and DGJ structure 
Both α-galactose and DGJ have very similar structure and are known to bind to the 
active site of α-GAL however DGJ is known to bind tighter to the active site than 
galactose.  
 
 
α-galactose
 
1-deoxygalactonojirimycin  
               (DGJ)  
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10-15% of normal enzyme activity (Leinekugel 1992; Ries, Gupta et al. 2005). Short and 
long term toxicity studies have shown DGJ to be well tolerated and to have no known 
adverse effect (Ishii, Chang et al. 2009). DGJ is also orally administered and could 
potentially cross the blood-brain barrier and could have a significant therapeutic effect on 
neurological symptoms (Desnick 2004).  
 FD is one of the first lysosomal storage diseases to show promising results with 
PCT. However the biochemical mechanism of the compound is not fully understood. 
Chapter 3 and 4 will focus on investigating the molecular mechanism of DGJ as a 
pharmacological chaperone. Chapter 3 will focus on characterizing interaction of the 
small molecule with wild-type α-GAL to improve our understanding on the basis of 
chaperone therapy. Chapter 4 explores other chemical chaperones, focusing on known 
Fabry-disease causing mutations. Since there are a large number of mutations that cause 
Fabry disease, we also seek to identify mutations that would respond favorably to PCT 
and determine the full clinical spectrum of DGJ therapy through existing mutant studies 
and structural analysis. 
 
1. 3.   Overall structure of human α-galactosidase A  
Interest in the molecular structure of human α-galactosidase A in order to 
understand the mechanism, phenotype-genotype relationship and physiology of Fabry 
disease has lead to several crystal structures of the enzyme since the first α-GAL 
structure at 3.25 Å resolution was published in 2004 (Garman and Garboczi 2004; Guce 
2009; Lieberman, D'Aquino J et al. 2009).  
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Superposition of all the three-dimensional structures mentioned above reveals 
similar overall tertiary and quaternary arrangement with a root mean square deviation 
between 0.3 to 1.0 Å (for 390 Cα). The mature polypeptide comes together to form an 
obligate homodimer, after removal of the N-terminal 31 amino acid signal sequence. 
Each monomer is composed of two domains: the N-terminal, (β/α)8 domain and the C-
terminal β sandwich domain.  Residues 32-330 make up domain one with alternating β 
strands and α helices to form a classic β	  barrel. Eight parallel β strands make up the 
center of the barrel where the active site is located.	  In the C-terminal domain, residues 
330-429 form eight anti-parallel β strands on two sheets in a β sandwich to make a Greek 
key motif. This domain does not have any known function, but truncating the C-terminal 
domain abolishs the catalytic activity (Miyamura, Araki et al. 1996). The C-terminal 
domain packs against the (β/α)8 barrel,	  burying an extensive surface area of 2500 Å2, 
while the dimer interface is approximately 2200 Å2 with mostly hydrophobic contacts 
(see Figure 1.4) (Garman and Garboczi 2002; Garman and Garboczi 2004; Garman 2006; 
Guce 2009; Lieberman, D'Aquino J et al. 2009).  
Each monomer contains 12 cysteines, 10 of which participate in disulfide bonds 
(C52-C94, C56-C63, C142-C172, C202-C223, and C378-C382). C90 and C174 are free 
cysteines. There are three sites for N-linked glycosylation (N139, N192 and N215), 
located in the N-terminal domain, away from the active site (Garman and Garboczi 2002; 
Garman and Garboczi 2004; Garman 2006). In humans and mammalian cell lines the 
enzyme mass is approximately 5-15% carbohydrate in the form of N-linked 
oligosaccharide chains, which make up 70 different glycoforms (Lee, Jin et al. 2003). The 
heterogeneity at the glycosylation site makes crystallization of the protein challenging. 
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Figure 1.4 Overall structure of human α-galactosidase A  
 
The α-galactosidase A polypeptide trace is shown in rainbow from blue at the N-
terminus to red at the C-terminus. The N-linked carbohydrates are shown as sticks, 
and the galactose ligand is shown as spheres, marking the active site in the first 
domain.  
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However, these carbohydrates are physiologically important for the enzyme to target the 
lysosome through the mannose-6-phosphate receptor pathway (Dahms, Lobel et al. 
1989). The enzyme has 11 more acidic residues than basic residues per monomer, 
generating an electrostatic surface potential that is highly negative (see Figure 1.5, red 
patches), suitable for the acidic environment of the lysosome.  
The structural fold of human α-GAL is also well conserved among the other 
members of the α-galactosidase family, including rice and Trichoderma reesei α-
galactosidases, which both share 34% amino acid sequence identity with the human 
sequence respectively (Fujimoto, Kaneko et al. 2003; Golubev, Nagem et al. 2004).  
 
1.3.1.   Active site and ligand binding  
α-GAL binds and selects terminal α-galactosides by making specific contacts 
with the functional groups on the substrate. Residues from seven loops of domain one are 
assembled to form the active site at the middle of the (β/α)8 barrel. The active site of α-
GAL is composed of 15 residues: W47, D92, D93, Y134, C142, K168, D170, C172, 
E203, L206, Y207, R227, D231, D266, and M267. There is an internal disulfide bond 
between C172 and C142.   This disulfide bond and Y134 would clash with a terminal β-
linked galactoside, thus human α-GAL selects and binds only α-galactosides. The related 
enzyme α-N-acetylgalactosaminidase (α-NAGAL, E.C. 3.2.1.49) recognizes a similar 
substrate except for an N-acetyl instead of a hydroxyl at position 2 on the sugar (Garman, 
Hannick et al. 2002; Clark and Garman 2009). In α-GAL, the larger side chains E203 and 
L206 recognize the smaller hydroxyl at the 2 position of the sugar, and the side chains 
sterically occlude N-acetyl at position 2 on the larger substrate, α-N- 
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Figure 1.5 The electrostatic potential surface of α-galactosidase A 
 
The dimer surface is colored by electrostatic potential as calculated by the program 
CCP4mg (from -10 kBT/e (red) to +10 kBT/e (blue), and with galactose and N-linked 
carbohydrates colored green and yellow respectively. The overall dimer is markedly 
negatively charged, consistent with a molecule that resides in the low pH of the 
lysosome. 
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acetylgalactosamine. E203 and L206 are located on the “recognition loop” that sets the 
substrate specificity between the two related glycosidases. Other than those two residues, α-GAL and	  α-NAGAL share 13 active site residues in common. W47 packs against C4, 
C5 and C6 and discriminate the 4-axial hydroxide of galactose from the equatorial 
hydroxide of glucose. The rest of the residues make contact with the ligand, stabilizing 
the terminal galactose in the active site pocket through an extensive H-bonding network 
(see Figure 1.6). The two monomers come together placing the two active sites on the 
same side of the dimer approximately 50 Å2 apart. Based on the structure, there is no 
evidence of cooperativity between the two active sites (Garman and Garboczi 2002; 
Garman and Garboczi 2004; Garman 2006). Chapter 5 will detail experiments probing 
the recognition loop and its consequence to the activity, function and structure of the 
enzyme. D170 and D231 are the two residues at the active site that catalyze the 
hydrolysis of the terminal α-galactosyl moiety from α-GAL substrates. 
 
1.3.2.   Fabry disease mutation  
The α-GAL structure solved in 2004 enabled for the first time mapping of the 
Fabry disease-causing mutations and this provided insight into the nature of the enzyme 
defect leading to the protein deficiency (Garman and Garboczi 2002; Garman and 
Garboczi 2004). In this section we focus on and examine only the mutations that affect 
the structure of the protein. Point mutations were mapped as substitutions in the protein, 
allowing classification of the mutations by their expected effect on the protein. Three 
groups of mutations emerged: First, those mutations that disrupt the active site of the  
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Figure 1.6 The α-galactosidase A active site and binding interactions  
 
Top: The α-galactosidase A active site is shown with a galactose ligand (green) bound. 
The surface indicates the complimentary shapes of the protein and the ligand in the 
active site. The residues in the active site and the interactions between the protein and 
the ligand are shown as dash lines.  
Bottom: The interaction between the protein and the ligand are detailed. Red dash lines 
represents hydrogen bonds, and blue dash lines represent van der Waals interactions. 
Note that the protein makes contacts to every functional group on the ligand. 
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enzyme leading to loss of enzyme activity, second, those mutations that perturb the 
hydrophobic core of the protein leading to folding defects and possible degradation of 
unstably folded protein, and last in those mutations that have other effects on the folded 
state of the protein, which include broken disulfide bonds, loss of N-linked glycosylation 
site or exposed mutations with no obvious explanation. Figure 1.7 maps the point 
mutations in the Fabry disease database revealing that the mutations are distributed 
throughout the structure. About 90% of the missense mutations are buried residues that 
might disrupt the three dimensional structure of the protein. Combining the genetic data, 
the clinical phenotype classification data of Fabry disease mutations and the three-
dimensional structure of the glycoprotein, leads to new structural insights and gives a 
better molecular understanding of the disease. 
 
1.4.   Catalytic mechanism  
Based on the sequence and structure of α-GAL, it is classified into glycoside 
hydrolase family 27 and clan D (in the systematic classification of glycoside hydrolases, 
GH’s) (Vocadlo and Davies 2008). The reaction catalyzed by α-GAL is classified as a 
retaining glycoside hydrolysis and uses a double displacement mechanism first described 
by Koshland in 1953 (Koshland 1953). In the active site, two carboxylic acids (D170 and 
D231) are positioned on opposite sides of the glycosidic bond to be cleaved (see Figure 
1.8). The substrate undergoes two successive nucleophilic attacks on the anomeric 
carbon. First, D170 makes a nucleophilic attack on the anomeric carbon and cleaves the 
glycosidic bond of the bound galactose generating a galactosyl-enzyme intermediate. 
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Figure 1.7 α-galactosidase A protein and Fabry disease mutations  
 
The α-galactosidase A dimer is shown in cartoon form. The residues affected in the 
severe form of Fabry disease are colored blue, and those affected in the variant 
phenotypes of Fabry disease are colored yellow. Overall, more than half of the 
residues in the protein have been implicated in Fabry disease. The residues affected in 
the variant phenotypes tend to be more exposed than those found in the severe 
phenotype. 
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Figure 1.8 The α-galactosidase A catalytic mechanism 
 
α-galactosidase A uses a double displacement mechanism, where the substrate 
undergoes two successive nucleophilic attacks on the same chiral carbon. First, D170 
makes a nucleophilic attack on the anomeric C and cleaves the glycosidic bond of the 
bound galactose generating a covalent intermediate. Second, D231 deprotonates water 
that attacks C1, breaking the covalent bond, and resulting in the retention of the α 
anomeric conformation of the product. 
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Second, D231 deprotonates a water molecule, which in turn attacks the C1 of the 
galactosyl-enzyme intermediate resulting in the cleavage of the covalent intermediate and 
the retention of the α anomeric conformation (Hart 2000; Ly 2000). D170 of the active 
site acts as a nucleophile and D231 as a proton donor and then acceptor. Prior to the 
determination of the three- dimensional structure, covalent labeling of the nucleophile 
with a mechanism-based inhibitor followed by proteolysis and LC/MS identified the 
catalytic aspartic acid residue of a homologue α-GAL enzyme. This technique was used 
to identify the nucleophile of other α retaining glycosydases (belonging to other GH-
clans), including α-glucosidase (family 13), α-mannosidase (family 38) and coffee α-
galactosidase (family 27) (Ly 2000). Chapter 2 will present a snapshot of the stages of the 
double displacement mechanism by a series of α-GAL structures. These new high-
resolution structures provide new insight and mechanistic detail into the entire α-GAL 
family.  
 
1.5.   Statement of thesis  
The clinical studies and structural knowledge serve as the groundwork for the 
research described here. We seek to broaden our knowledge of one of the well-studied 
lysosomal storage disorders, Fabry disease, through high-resolution crystal structures and 
biophysical techniques. Despite the intense clinical interest in this enzyme or industrial 
appeal for blood group conversion, high-resolution structures of the catalytic mechanism 
remained elusive. We seek to characterize each step in the catalytic cycle of the enzyme 
through x-ray crystallography. The high-resolution crystal structures of α-GAL at 
different stages of the catalytic cycle provide structural insight into the double 
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displacement mechanism for α-GAL as well as other proteins belonging to the same 
family. The characterization of each step of the catalytic cycle of the enzyme is presented 
in Chapter 2.  
With the various treatments for Fabry disease, the research described here will 
seek to define the molecular basis for pharmacological chaperone therapy in Fabry 
disease patients. Little is know about the atomic basis as well as the biochemistry of 
pharmacological chaperone therapy. Here, we studied the effects of the binding of the 
small molecule to the stability of the enzyme under various pH conditions. The 
characterization of the interaction between α-GAL and the small molecule DGJ is 
described in Chapter 3. Biophysical techniques and mutagenesis identified the important 
residue for binding the small molecule and its chaperoning effect. The analysis of DGJ 
binding described in Chapter 3 is used as a model for other lysosomal storage disease and 
protein misfolding diseases.  
We extend the work on the pharmacological chaperone DGJ described for wild-
type α-GAL to mutant enzymes that cause protein deficiency. We used the assay 
established in Chapter 3 to assess DGJ chaperoning effect on mutant enzymes. In Chapter 
4, predictions of the response of mutant enzyme to DGJ are presented. This gives an 
indication of the applicability of DGJ therapy to various Fabry disease mutations. 
Lastly, the recognition loop at the active site of α-GAL protein will be probed in 
greater detail to determine the ligand specificity of two homologous enzymes, α-GAL 
and α-NAGAL. α-GAL with an engineered recognition loop is an excellent tool to 
investigate the structure-function of the protein. Chapter 5 presents the kinetic studies and 
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the structure of the active site engineered α-GAL to provide an evidence for inter-
conversion of the specificity of α-GAL.  
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CHAPTER 2 
 
CATALYTIC MECHANISM OF HUMAN α-GALACTOSIDASE A 
 
This work was performed in collaboration with Nathaniel Clark and Eric Salgado. 
Portions of this chapter derive from a paper written in collaboration with them and other 
collaborators (Abigail I. Guce, Nathaniel E. Clark, Eric N. Salgado, Ivanen, D.R., 
Kulminskaya, A.A., Harry Brumer 3rd, and Scott C. Garman. The catalytic mechanism of 
human α-galactosidase. J. Biol. Chem. 2010) 
 
 
2.1.  Introduction 
Degradation of macromolecules in the cells is essential for cell survival and proper 
cellular functions. Selective cleavage of macromolecules in the lysosome is specifically 
regulated and catalyzed by a number of enzymes, including glycosidases. The loss of 
functional endo- and exoglycosidases in the lysosome results in the accumulation of 
substrates in the cells, characteristic of a family of diseases collectively known as 
lysosomal storage diseases (Platt 2004). One of these exoglycosidases is α-GAL, which 
catalyzes the hydrolysis of a terminal alpha-linked galactosyl residue from 
macromolecules such as oligosaccharides, glycoproteins and glycosphingolipids (Desnick 
2001). Deficiency in α-GAL enzyme in humans causes Fabry disease, resulting in the 
build up of a neutral substrate, globotriasylceramide, in the vascular endothelium and 
other tissues (Brady 1967).  
Mechanistically, glycosidases are generally classified according to the 
stereochemistry of the anomeric carbon of the glycosidic bond (Hart, He et al. 2000). The 
“inverting” glycosidases cleave the glycosidic bond in a one-step mechanism, with 
simultaneous nucleophilic attacks and leaving group departure. The “retaining” enzymes 
catalyze the cleavage via the double displacement mechanism where a covalently linked 
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glycosyl-enzyme intermediate is formed (Sinnott 1990). α-GAL is considered an α-
retaining glycosidase, because it selectively binds substrates with terminal α-galactosidic 
bonds and then releases α-galactose as product.  
The double displacement mechanism first described in 1953 by Koshland 
involves two successive nucleophilic attacks of the anomeric carbon of the terminal α-
galactoside. D170 of the active site acts as a nucleophile and D231 as a proton donor 
(acid) and then acceptor (base). D170 makes a nucleophilic attack on the anomeric 
carbon and cleaves the glycosidic bond of the bound substrate. This results in a galactosyl 
intermediate covalently linked to D170, and the release of the aglycone portion (R-OH). 
Next, the negatively charged D231 deprotonates a nearby water molecule, which in turn 
attacks C1 of the covalent intermediate, resulting in the breakage of the covalent bond to 
D170. The two consecutive inversions of the anomeric carbon lead to an overall retention 
of the α anomeric conformation in the product (see Figure 1.8).  
A structural description of the steps in the catalytic mechanism has not been 
studied in detail. The goal of this study is to elucidate the catalytic cycle of α-GAL using 
three-dimensional crystal structures. The conformation change induced by the enzyme to 
the ligand as the reaction proceeds is not known (Vasella, Davies et al. 2002). The 
discovery of a new conformation of the covalent intermediate opens doors to rational 
design of a more potent transition-like inhibitors. These inhibitors could be designed with 
great selectivity and affinity towards the target enzyme. The recognition of role of α-
GAL in Fabry disease might lead to an alternative treatment that uses a small molecule 
that binds tightly to the enzyme.  
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2.2.   Experimental Strategy 
A series of four new structures of human α-GAL that represent each stage in the 
double displacement mechanism provides a snapshot of the catalytic mechanism. In this 
study, we determined crystal structures of α-GAL representing the four steps in the 
double displacement mechanism (see Figure 2.1). A combination of genetic engineering, 
microseeding techniques and synthetic mechanism-based inhibitors was used to improve 
the resolution of human α-GAL crystals to 1.9 Å. These structures provide the first 
complete picture of the structural mechanism of glycoside hydrolase family 27 enzymes. 
 
2.3.   Results 
 We determined the structures of an empty, substrate-bound, covalent intermediate 
and product-soaked α-GAL. All of the structures show very little structural change with a 
root mean square deviation of 0.4-0.5 Å for the 390 Cα. All four structures share a (β/α)8 
barrel N-terminal fold with the active site at the center and the C-terminal β sandwich 
(Garman and Garboczi 2004). Table 2.2 summarizes the structural statistics of the data 
collection. 
 
2.3.1.   Empty enzyme 
Using glycerol and ethylene glycol (a common choice for cryoprotectant) resulted 
in the small cryoprotectant bound to the active site. Therefore, to obtain the empty 
enzyme structure, it was necessary to use a cryoprotectant (lactose) sterically occluded 
from the active site. Several water molecules mimic the positions of galactose atoms in 
the active site instead. The water molecules are close to the positions of the O2 (0.92 Å 
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Figure 2.1 Trapping different steps in the catalytic cycle 
 
Empty enzyme used cryoprotectants excluded from the active site. The substrate 
bound structure used deletion of the active site nucleophile. The covalent intermediate 
used a difluoro-substituted galactose compound. The product bound structure used 
product inhibition on the enzyme. Color scheme are consistent with the succeeding 
figures in this chapter. 
  31 
              Table 2.1 Crystallographic statistics of the α-galactosidase A in the catalytic cycle 
Active site: Empty Substrate Intermediate Product 
PDB code: 3HG2 3HG3 3HG4 3HG5 
Protein     
Protein Sequence Wild-type D170A Wild-type Wild-type 
Expression system P3221 P212121 P3221 P3221 
Cell lengths, Å 90.8, 90.8, 217.2 59.5, 106.1, 
181.7 
90.2, 90.2, 216.6 90.8, 90.8, 217.2 
Cell angles, ° 90, 90, 120 90, 90, 90 90, 90, 120 90, 90, 120 
 
X-ray data 
    
X-ray source Cu anode BNL X25 Cu anode Cu anode 
Wavelength, Å 1.54 1.0085 1.54 1.54 
Resolution (last shell) 50-2.3 (2.48-2.3) 50-1.9 (1.97-1.9) 50-2.3 (2.38-2.3) 50-2.3 (2.38-2.3) 
Observations 637,404 1,248,391 739,029 398,547 
Unique observations 45,612 90,308 46,337 47,076 
Completeness, %  
(last shell) 
97.2 
(95.4) 
98.6 
(88.4) 
99.7 
(100.0) 
99.9 
(100.0) 
Multiplicity (last shell) 14.0 (14.2) 13.8 (9.9) 15.9 (16.0) 8.5 (8.4) 
Rsym (last shell) 0.115 (0.818) 0.088 (0.755) 0.112 (0.944) 0.099 (0.989) 
I/σI (last shell) 25.2 (3.5) 30.2 (3.1) 28.3 (3.4) 21.4 (2.3) 
 
Refinement 
    
Rwork/Rfree, % 17.6/20.2 16.5/19.7 16.5/22.1 19.1/22.7 
No. of atoms 6767 7539 7251 16694 
   Protein 6255 6377 6262 6255 
   Carbohydrates 156 216 276 167 
   Water 329 893 682 236 
               
• Table 2.1 is continued onto the next page 
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   Others 27 53 31 36 
Ave. B, Å2 36.4 23.1 49.8 43.4 
 
Ramachandran Plot 
    
   Favored (%) 90.7 92.1 90.0 90.5 
   Allow (%) 8.4 7.0 9.4 8.4 
   Generous (%) 0.6 0.9 0.4 0.7 
   Forbidden (%) 0.3 0.0 0.1 0.3 
 
RMS deviations 
    
   Bonds (Å) 0.008 0.006 0.008 0.008 
   Angles (°) 1.128 1.058 1.159 1.175 
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away), O3 (0.27 Å) and O6 (0.21 Å) oxygens of galactose, and two other water 
molecules are close to the position of C1 (0.51 Å) and C4 (1.1 Å) carbons of the 
galactose. The empty enzyme structure of α-GAL solved at 2.3 Å shows no global 
movement as well as major rearrangements at the active site residues compared to the 
earlier structures of α-GAL. 
 
2.3.2.   Substrate-bound 
To trap an intact substrate in the active site, a D170A α-GAL mutant was 
engineered to delete the nucleophilic residue that attacks the anomeric carbon. We 
expressed and purified the mutant protein D170A α-GAL, which showed no detectable 
enzyme activity. Melibiose, a D-galactose-α1-6-D-glucose disaccharide, was used as a 
terminal α-galactose linked substrate. Melibiose binds to the active site of α-GAL with 
the galactose saccharide in the active site and the glucose saccharide extending out of the 
active site pocket.  The galactoside portion of the melibiose substrate is in standard 4C1 
chair conformation. Residues in the active site make specific interactions with the 
galactoside of melibiose with no specificity beyond the glycosidic linkage. No interaction 
between the residues in or near the active site is found making specific contacts to the 
next sugar residue beyond the galactose. The 1.9 Å resolution structure shows that α-
GAL binds the terminal galactose and the sugar assumes the low-energy 4C1 
conformation. This conformation aligns the anomeric carbon with the syn lone pair of the 
catalytic nucleophile D170, allowing a direct in-line attack by the nucleophile. The 4C1 
conformation of galactose is shown in Figure 2.2a. The 1.9 Å substrate-bound enzyme is 
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the first structure of any enzyme from glycoside hydrolase family 27 that shows the 
unprocessed substrate in the active site of the enzyme. 
 
2.3.3.   Covalent intermediate 
To trap a covalent intermediate, a synthetic substrate 2’,4’,6’-trinitrophenyl-2-
deoxy-2, 2-difluoro-α-galactopyranoside (TNP-2,2-di-F-α-Gal, see Figure 2.2d) was 
soaked into wild-type α-GAL crystals. TNP-2,2-di-F-α-Gal is a mechanism-based α-
GAL inhibitor used to trap transient intermediate species, analogous to other fluoro 
sugars extensively studied in the Withers laboratory (Withers, Rupitz et al. 1988; Street, 
Kempton et al. 1992). The fluoro substituted galactopyranoside ring destabilizes the 
oxocarbenium ion-like transition state of the double displacement mechanism (Zechel 
2000). TNP is an excellent leaving group that allows the first nucleophilic attack to 
proceed. However, the second nucleophilic attack by the deprotonated water molecule is 
slowed considerably by the inductive effects of the fluoro substituents, allowing capture 
of the covalently linked intermediate at subsequent low temperature x-ray data collection 
(see Figure 2.3d) (Ly 2000; Zechel 2000). The covalent intermediate is in a 1S3 twist boat 
conformation with strain in the sugar ring.  The high-energy conformation is covalently 
bound to the Oδ2 of D170 and is held on the other end by van der Waals interaction 
between W47 and the 4-, 5- and 6 carbons of the sugar.   
 
2.3.4.   Product-bound 
To obtain a product bound enzyme, galactose was used as a cryoprotectant. Although the 
galactose solution contains a 70:30 mixture of β and α anomers of galactose, the human
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Figure 2.2 Covalent intermediate and ligand deformation 
 
 (a), (b), and (c) show close up views of the substrate-bound, covalent intermediate, 
and product-bound ligands. The catalytic nucleophile D170, the catalytic acid/base 
D231, and the conserved W47 are labeled. (d) The reaction mechanism for the TNP-
2,2-di-F-α-Gal substrate. The first step of the reaction remains fast because of the 
good leaving group, but the second step is slow, allowing for the trapping of the 
covalent intermediate species. 
 
 
a. b. c. 
d. 
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α-GAL active site selects for the α anomer only. The C142-C172 disulfide bond, Y134 
and D170 would clash with a β-linked galactose at position 1 thus human α-GAL selects 
and binds only to the α form (Garman and Garboczi 2004). The galactose in the active 
site is in a standard 4C1 conformation (see Figure 2.2c). After the second anomeric attack 
by deprotonated water molecule, the ligand returns to a low energy conformation from its 
high-energy state in the covalent intermediate structure. The crystallographic snapshot of 
the double displacement mechanism is summarized in Figure 2.3. 
 
2.4.   Discussion 
Interest in using the molecular structure of human α-galactosidase to understand 
the mechanism of α-GAL has lead to several crystal structures of the enzyme since the 
first α-GAL structure at 3.25 Å resolution was published in 2004 (Garman and Garboczi 
2004). Higher resolution α-GAL with different substrate soaks revealed molecular details 
of the double displacement mechanism (recent α-GAL structures compiled in Table 2.2) 
(Garman and Garboczi 2004; Guce 2009; Lieberman, D'Aquino J et al. 2009). The 
substrate bound and covalent intermediate structures are among the first known structures 
for glycosidase family 27. α-GAL belongs to the family 27 and clad D (representing over 
1900 proteins from different species) of glycoside hydrolases with active site residues  
strictly conserved, therefore the entire family is most likely to use an identical mechanism 
(Cantarel, Coutinho et al. 2009). 
The structures reveal there is no major rearrangement or movement of active site 
residues upon binding of substrate and throughout the stages of the double displacement 
mechanism, unlike what is seen in the β-glucocerebrosidase family, for example, where a 
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Figure 2.3 Double displacement mechanism snapshot  
  *Figure 2.3 caption is continued on the next page 
 
 
90° 
90° 
90° 
90° 
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Panels A and B shows side (A) and top (B) views of the electron density for the ligand 
in the four different structures. The four rows correspond to the empty, substrate-
bound, covalent intermediate, and product-bound structures respectively. The electron 
density corresponds to a σA-weighted 2Fo-Fc omit map calculated in SFCHECK 
(contoured at 1.5 σ in the first row and 2.0 σ in the other three rows) with a cover 
radius drawn around residues and/or waters in the active site. 
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Table 2.2 Human α-galactosidase A structures published 
 
 
α-GAL structures 
 
Active site contents 
Resolution, 
Å 
PDB 
code 
year 
published 
Empty Glycerol 3.25 1R46 2004 
 - 3.0 3GXN 2009 
 Water(s) 2.3 3HG2 2009 
Substrate Melibiose (D-Gal-α1-6-D-
Glu) 
1.9 3HG3 2009 
Covalent 
Intermediate 
TNP-2,2-di-F-α-Gal 2.3 3HG4 2009 
Product Galactose 3.45 1R47 2004 
  2.2 3GXP 2009 
  2.3 3HG5 2009 
  2.0 - 2009* 
Inhibitor DGJ 2.7 3GXT 2008 
  2.1 - 2009* 
      * PDB code not yet available  
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flap closes down on the active site after substrate binding. Here we present the first 
complete mechanism of a retaining α-galactosidase. The substrate binds to the active site 
in a low-energy 4C1 conformation that allows the D170 nucleophile to have access to the 
anomeric carbon. After cleavage of the substrate, the glycosyl-enzyme covalent 
intermediate structure assumes a strained 1S3 twist boat conformation. Most of the known 
β-retaining enzymes distort the substrate into a high energy 1S5 conformation to gain 
assess to the anomeric carbon upon binding, and the covalent intermediate of those 
enzymes have a 4C1 conformation. This high-energy 1S3 twist boat conformation is a 
sharp contrast to the other low-energy 4C1 covalent intermediates seen in the α amylase 
family (Uitdehaag, Mosi et al. 1999; Barends, Bultema et al. 2007).  TNP-2,2-di-F-α-Gal 
had been used to modify and identify the catalytic residue of other glycoside hydrolase 
family 27 enzymes, but those studies were mass spectrometry studies, not 
crystallographic experiments, so they did not show the distorted conformation of the 
covalent intermediate until recently (Hart, He et al. 2000; Ly 2000).  
We have also provided structural evidence of a transition-like inhibitor for α-GAL 
and other alpha-retaining enzymes. A more potent inhibitor would be a great candidate to 
as a pharmacological chaperone, which will be discussed in details in Chapter 3 and 4. 
Additionally, the structures reveal a second sugar-binding site away from the active site. 
In all the four structures, there is either a β-galactose or a PEG molecule that packs 
against the plane of Y329 and hydrogen bonds with K374 and D255. Binding of the  
second molecule buries about 107 Å2 surface area (see Figure 2.4). The interaction 
between Y329 and the β-galactose is weak since the contacts are not optimized, and 
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Figure 2.4 The second ligand-binding site in human α-GAL 
 
The second ligand-binding site is centered on Y329, at the interface between domain 1 
and domain 2 of the structure. A surface drawn around all the atoms reveals a pocket 
that is selective for β-galactose. The electron density from the galactose-soaked crystal 
shows a σA-weighted 2Fo-Fc omit map calculated in SFCHECK, contoured at 1.1 σ 
with a cover radius drawn around the ligand. Residues E251, D255, Y329, and K374 
are shown. 
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the occupancy at this site is due to high concentration of the small molecule. The second 
binding site could be a possible site pharmacological chaperone binding without 
competitively inhibiting the enzyme function. The second binding site is in a location that 
might be exploited for pharmacological chaperone therapy. 
 
2.5.  Methods 
2.5.1.  Wild-type α-GAL TOPO plasmid generation and amplification 
The human α-galactosidase A gene (GLA) was obtained from an 8% glycerol 
stock of a recombinant pOTB7 vector (OpenBiosystems) transformed into a culture of 
DH5α e. coli. cells. These cells were re-streaked into a fresh LB/chloramphenicol (34 
µg/mL) plates and used as a starter culture of sterile LB broth with 34 µg/mL 
chloramphenicol. The stock pOTB7-α-GAL vector was extracted and purified from an 
overnight culture using the Wizard® Plus SV Minipreps DNA Purification System 
(Promega). The α-GAL gene was cloned out of pOTB7-α-GAL vector using Phusion® 
High-Fidelity DNA Polymerase (Finnzymes) with forward (5’-
ACAATGCAGCTGAGGAACCCAGAACTACAT-3’) and reverse (5’-
TTAATGATGATGATGATGATGAAGTAAGTCTTTTAATGACAT-3’) primers and 
was purified using the Wizard® SV Gel and PCR Clean-Up System (Promega) according 
to the manufacturer’s specifications. The PCR-purified amplification product was then 
incubated at 72ºC for 15 minutes with Taq polymerase (New England Biolabs) in order to 
ensure the addition of a single 3’-deoxyadenosine overhangs for subsequent TOPO® TA 
cloning experiments. The amplification product with single 3’-deoxyadenosine overhangs 
were annealed into a pIB/V5-His-TOPO® vector (Invitrogen), and One Shot® TOP10 
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chemically competent E. coli (Invitrogen) was transformed with pIB/V5-His-TOPO® 
vector containing the α-GAL gene (pIB/V5-His-TOPO-α-GAL). The TOP10 cells were 
plated on LB agar plates containing 100 µg/mL ampicillin (amp) and grown overnight at 
37°C. Plasmid mini preps using the PureYield™ Plasmid Midiprep System (Promega) 
were performed from a 50 mL LB (+ 100 µg/mL amp) overnight culture grown from a 
single colony. pIB/V5-His-TOPO-α-GAL  construct containing the α-GAL native signal 
sequence and a C-terminal His6-tag was used as a parental DNA.  
 
2.5.2.   D170A α-GAL expression and purification 
A mutation coding for replacement of D170 with Ala (D170A) was incorporated 
into the pIB/V5-His-TOPO-α-GAL construct with PhusionTM site-directed mutagensis kit 
(Finnzymes). PCR amplification using forward primer (5’-
[PO4]CTGCTAAAATTTGCTGGTTGTTACTGTGACAG-3’, bold letters highlights the 
mutation) and reverse primer (5’-[PO4]ATCTACTCCCCAGTCAGCAAAGGTCTG-3’) 
introduced the mutation to the parental DNA. Mutation was confirmed by sequencing the 
isolated and purified pIB/V5-His-TOPO-D170A DNA.  
Transfection of insect cells with pIB/V5-His-TOPO-D170A was initiated by 
allowing approximately 2.0 x 106 Tn5 cells to adhere in a 60mm tissue culture plate. 
Cells were transfected using 2 mL transfection mixture containing SFx media, 1.8 µg 
plasmid DNA and Hilymax (Dojindo Labs). Transfection was performed following the 
manufacturer’s specifications. Selection was done by adding 100 µg/mL blastocidin to 
fresh Sfx media after 3 days of transfection.  The supernatant were collected to test for 
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protein expression. Stable adherent cells were re-suspended in SFx media and were 
grown in suspension for scale up.  
Stable cells were grown to 5-6 x 106 for three days and the supernatant was 
collected after spinning down the cells. The supernatant was concentrated and buffer 
exchanged with Ni-NTA binding buffer (50 mM sodium phosphate, 500 mM sodium 
chloride and 20 mM imidazole, pH 7) using Millipore Prep/Scale TFF cartridge. The 
sample was loaded onto a column containing Ni SepharoseTM 6 Fast Flow resin (GE 
Healthcare). D170A α-GAL mutant was eluted using a gradient of 0-50% elution buffer 
(50 mM sodium phosphate, 500 mM sodium chloride and 1 M imidazole, pH 7). 
Fractions containing pure α-GAL, as determined by SDS-PAGE analysis, were pooled 
and concentrated to 2.0 mg/mL by using Vivaspin spin concentrator with 10 kDa 
molecular weigh cut off (Sartorius Biolab) and stored in 10 mM sodium phosphate 
buffer, pH 6.5.  
 
2.5.3.   Crystallography and x-ray data collection 
 Empty, Intermediate and product: Crystals were grown as previously described, 
except that macroseeding techniques were used (Garman and Garboczi 2004). In the 
original report, the P3221 crystals were 100 µm in the longest dimension; macroseeding 
techniques increased the size of the crystals to 400 µm, leading to a much-improved 
diffraction. Small crystals were grown in 25% PEG 4000, 200 mM ammonium sulfate, 
and 100 mM sodium acetate pH 4.6 mixed with 9 mg/mL α-GAL stock. The crystals 
were crushed, diluted 1:100,000, and added to 1:1:1 mixture of crystallization buffer, 
protein stock, and water. Crystals appeared in the seeded solution after a few days. 
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Crystals were harvested into buffer containing 30% PEG 4000, 200 mM ammonium 
sulfate, and 100 mM sodium acetate. Crystals were transferred to similar solutions 
supplemented with ligand: 15% α-lactose (empty structure), 20 mM 2’,4’,6’-
trinitrophenyl-2-deoxy-2, 2-difluoro-α-galactopyranoside (covalent intermediate), or 5% 
D-(+)-galactose (product bound). For the covalent intermediate structure, the soak salts 
were reduced to 100 mM ammonium sulfate and 50 mM sodium acetate. Five crystals 
were transferred into the TNP-2,2-di-F-α-Gal solution; all but one shattered immediately 
after transfer. Ice rings limited the quality of the galactose soaked crystals. 180° of 
diffraction data were collected on a RU-H3R rotating anode generator (Rigaku) and 
processed with HKL2000 (Otwinowski 1997). The P3221 crystals diffracted highly 
anisotropically, with approximately 1.9 Å resolution limit along the c axis compared to 
approximately 2.8 Å diffraction limits in the perpendicular directions; we limited the 
overall isotropic resolution to 2.3 Å based upon I/σI criteria. The isotropic integration of 
the anisotropic diffraction data resulted in poor merging statistics. The structures were 
phased by Fourier synthesis using the 3.25 Å human α-GAL coordinates (PDB code 
1R46) (Garman and Garboczi 2004). 
 Substrate: The crystals of D170 α-GAL mutant were obtained by the hanging-
drop vapor diffusion technique at 20°C. Crystals were obtained from 1:1 mixture of 
reservoir solution (12% (w/v) PEG 8K, 0.1 M sodium cacodylate pH 6.5, and 0.022 M 
Magnesium acetate) with a 2.0 mg/mL protein solution (10 mM sodium phosphate buffer, 
pH 6.5). Prior to freezing and data collection, crystals were transferred stepwise into a 
reservoir solution with 100 mM melibiose (D-galactose-α1-6D-glucose, Sigma), and then 
into a cryoprotectant solution containing 40% (w/v) PEG 8K, 22 mM magnesium acetate, 
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100 mM sodium cacodylate pH 6.5, 20% ethylene glycol and 100 mM melibiose 
(Sigma). Crystals were flash frozen in liquid nitrogen and x-ray data were collected at 
100K at beamline X25 at the Brookhaven National Laboratory. X-ray images were 
processed using HKL2000 software package. The diffraction data were scaled in space 
group P212121, leading to a solvent content of 57% and a dimer in the asymmetric unit. 
The structure was phased by molecular replacement in the CCP4 program AMoRe using 
the coordinates of the galactose soaked crystals. 
 For all structures: Atomic models were built into electron density using the 
program O, and refinement and water placement were done using REFMAC (Jones, Zou 
et al. 1991). Coordinates were superimposed using LSQMAN, and surface accessible 
areas were calculated in AREAIMOL (Kleywegt 1997). Molecular docking studies were 
performed in O and in Pymol (Jones, Zou et al. 1991; DeLano 2008). Figures were made 
in MolScript and POVScript+ (Kraulis, Fenn). Coordinates and structure factors are 
under PDB accession codes 3HG2 (empty), 3HG3 (substrate-bound), 3HG4 (covalent 
intermediate), and 3HG5 (product-bound). 
 Sugar and sugar analogues: TNP-2,2-di-F-α-Gal was prepared as described 
previously (Brumer 1999; Hart, He et al. 2000). Thioethyl-α-galactose was prepared from 
2,3,4,6-tetraacetyl-thioethyl-α-D-galactose (Toronto Research Chemicals) by treatment 
with HCl for 1 hour Mass spectrometry was performed to confirm that the hydrolysis of 
the four acetyls had run to completions. The thioethyl-α-Gal was lyophilized and used at 
20 mM concentration for crystallization soaks. Galactose, lactose, and melibiose were 
obtained from Sigma. 
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CHAPTER 3 
 
MECHANISM OF A SMALL MOLECULE DGJ AS 
PHARMACOLOGICAL CHAPERONE FOR FABRY DISEASE 
 
This chapter is part of a paper in preparation. (Abigail I. Guce and Scott C. Garman. 
Mechanism of a small molecule DGJ for pharmacological chaperone) 
 
3.1.   Introduction 
Lysosomal enzymes such as α-GAL are synthesized, folded and processed in the 
endoplasmic reticulum (ER) at near neutral pH, then exported to the pH 6.5 Golgi 
apparatus for carbohydrate modification and sorting, and finally trafficked to the pH 4.5 
lysosome. α-GAL is among the many glycosidases in the lysosome that break down a 
complex macromolecules into smaller components for the cells to reuse. Single point 
mutations to the polypeptide chain of α-GAL are most likely to disrupt the hydrophobic 
core of the protein leading to protein misfolding and degradation at the ER. Interestingly 
most of these mutations are located far away from the active site and yield active or 
partially active enzyme (Leinekugel 1992; Garman and Garboczi 2002; Sugawara, 
Tajima et al. 2009). However, these misfolded enzyme fail to reach the lysosome due to 
the quality control machinery of the ER (Remeo, D'Urso et al. 1975; Bishop and Desnick 
1981; Okumiya 1995; Fan, Ishii et al. 1999). Protein deficiency due to degradation of 
unstable protein is also common to other inherited disease, beyond Fabry disease.  
Beyond enzyme replacement therapy, an alternative treatment, pharmacological 
chaperone therapy (PCT), has been proposed for Fabry disease. PCT uses the enzyme 
product, galactose, and a tight-binding substrate analogue inhibitor, 1-
deoxygalactonojirimycin (DGJ), as chaperones. The current model for the mechanism of 
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pharmacological chaperoning hypothesizes that DGJ binds at neutral pH to the unstable 
protein in the ER. By binding the native state, it shifts the folding equilibrium toward 
properly folded protein, and thus the protein avoids ER-associated degradation (ERAD) 
(Fan, Ishii et al. 1999; Asano, Ishii et al. 2000; Frustaci, Chimenti et al. 2001; Yam, 
Zuber et al. 2005). The small molecule can then dissociates at low pH (Fan, Ishii et al. 
1999; Asano, Ishii et al. 2000; Frustaci, Chimenti et al. 2001; Yam, Zuber et al. 2005). 
Once the active site is free, α-GAL can now cleave its substrate. Based on the structure 
and electrostatic potential of α-GAL, the protein is hypothesized to be more stable at 
lower pH due to the excess of negative charge (Garman and Garboczi 2004; Yam, 
Bosshard et al. 2006; Guce 2009). Pharmacological chaperone treatment is presumed to 
rescue unstable protein from degradation at the ER, and improve the transport of mutant 
α-GAL to the lysosome (Fan, Ishii et al. 1999; Cohen and Kelly 2003; Kolter 2003; Yam, 
Bosshard et al. 2006).  
 
 3.2.  Experimental Strategy  
In this study, the effect of pH on the different binding affinities of galactose and 
DGJ and its consequence on the stability of the wild-type enzyme will be examined. This 
is the dilemma in pharmacological chaperone we want to focus, how a potent inhibitor 
could increase the activity of an unstable enzyme. Here, evidence will be presented that 
DGJ binds to and stabilizes α-GAL at neutral pH, the same pH where α-GAL protein is 
synthesized. Most of these experiments are done at pH 6.5 instead of a more neutral pH 
because α-GAL has very little activity at pH 7 and above (based on the optimal activity 
profile, data not shown). We provide evidence that tighter binding between the inhibitor 
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and the enzyme at neutral pH is vital for the chaperoning effect of DGJ. We developed 
different assays to assess the kinetics of unfolding, stability and global conformation of 
α-GAL in the presence of a pharmacological chaperone. Moreover we have solved the 
structure of α-GAL with bound galactose and with DGJ at a higher resolution than 
previously reported. These will give us a better insight into the molecular mechanism of 
pharmacological chaperoning for Fabry disease. By studying the D170A mutant, we 
identified a critical interaction responsible for the high potency of DGJ as a chaperone. 
 
3.3.   Results 
3.3.1.   Resistance to unfolding monitored by fluorescence 
Fluorescence was employed to monitor the rate of unfolding of α-GAL under 
various pH conditions (pH 6.5 where the enzyme is inactive and pH 4.5 where the 
enzyme is optimally functional). The tryptophan fluorescence emission signals of α-GAL 
at pH 6.5 and 4.5 are shown in Figure 3.1a and d. After addition of 7.5 M urea, the 
fluorescence signal was measured over time. Upon unfolding, the fluorescence at λmax 
shows a decrease intensity relative to the folded protein and a red shift from 335 nm to 
350 nm. This assay allowed us to measure the rate of unfolding of α-GAL, which we fit 
to a first order exponential.  We calculated an unfolding half time t of 2.2 and 1.3 hours 
for pH 6.5 and 4.5 respectively. This shows that at pH 6.5, α-GAL unfolds more slowly 
than at pH 4.5, contrary to expectations. Next, we added DGJ and galactose to the 
fluorescence experiment to measure the effect of the pharmacological chaperones on the 
rate of unfolding of α-GAL at pH 6.5 and 4.5 (see Figure 3.1b, c and e, f respectively). 
Upon the addition of 50 µM DGJ at pH 6.5, the unfolding is significantly slowed and the 
  50 
      
 
 
Figure 3.1 Fluorescence signal of unfolding α-GAL in 7.5 M urea  
 
(a), (b) and (c): Fluorescence measurement of 1.2 µM α-GAL over time in phosphate 
buffer/urea solution, pH 6.5 without  pharmacological chaperone, + 50 µM DGJ and 
+50 mM Gal respectively; d, e and f: Fluorescence measurement of 1.2 µM α-GAL 
over time in sodium acetate buffer/urea solution, pH 4.5 without pharmacological 
chaperone, + 50 µM DGJ and +50 mM Gal respectively. Emission scans at 0 hrs (, 
red) in buffer/urea solution, subsequent scans were measured each hour up to 8 hours, 
and after 24 hrs (, blue) in buffer/urea solution. 
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Figure 3.2 First order kinetics of unfolding of α-GAL 
 
Pharmacological chaperone slows down the kinetics of unfolding of α-GAL.  
Rate of unfolding of α-GAL at pH 6.5 (a and b) and pH 4.5 (c and d) upon 
addition of 50 µM DGJ and 50 mM galactose respectively.  
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protein remains primarily folded even after 24 hours in urea (Figure 3.2a), so we 
conclude the t  > 24 hours. DGJ greatly slows the kinetics of unfolding because there is 
little change in the fluorescence intensity at λmax over 24 hours in 7.5 M urea and 50 µM 
DGJ at pH 6.5. In comparison, at pH 4.5, the addition of DGJ slows the rate of unfolding 
of α-GAL from a t of approximately 1.3 hrs to 6.5 hrs (Figure 3.2c). The experimental 
data demonstrate that, i) α-GAL unfolds more rapidly at pH 4.5 than at pH 6.5, ii) DGJ 
slows down the rate of unfolding of α-GAL, and iii) DGJ is more effective in preventing 
the decrease in the fluorescence signal of α-GAL at pH 6.5 than at acidic pH.  
Next, we repeated the fluorescence experiments in the presence of 50 mM 
galactose. Galactose also slows the unfolding of α-GAL, increasing the t from 2.2 to 8.0 
hours at pH 6.5 and from 1.3 to 2.5 hours at pH 4.5 (see Figure 3.1 c and f; Figure 3.2b 
and d). Although the same trend was also seen upon the addition of galactose to α-GAL it 
is less potent and less effective at preventing unfolding than DGJ. Comparing the two pH 
conditions, galactose slows the unfolding better at pH 6.5 than at pH 4.5. Galactose 
requires higher concentrations than DGJ to slow the unfolding, 50 mM galactose 
compared to 50 µM DGJ.  In general, it is observed that addition of a pharmacological 
chaperone to α-GAL has a considerable effect on the kinetics of unfolding of the enzyme 
and resistance to unfolding of α-GAL is a consequence of the binding of DGJ and 
galactose. 
 
3.3.2.   Increase in apparent thermal stability of α-GAL measured by CD 
We developed an assay to measure the secondary structure of α-GAL under 
different conditions by monitoring the CD signal of the protein from 210-240 nm. To 
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evaluate the stability of α-GAL in the presence of varying concentrations of 
pharmacological chaperone, the CD signal was measured at wavelength 222 nm as the 
temperature was increased. The CD data allowed us to calculate the fraction denatured 
(Fd), and the temperature where Fd equals 0.5 was labeled the apparent melting 
temperature (Tm). The Tm value serves as a measure of the thermal stability of the protein 
(Acosta, Beldarrain et al. 2000; Fitter and Haber-Pohlmeier 2004; Sanchez-Ruiz 2007). 
To examine the effects of DGJ and galactose on the stability of wild-type α-GAL, the Tm 
of α-GAL was measured with increasing concentration of the pharmacological chaperone 
at pH 6.5 and pH 4.5. The CD data show that there is little difference in the thermal 
stability of α-GAL at pH 6.5 and 4.5, but α-GAL is less stable at pH 7.2, in agreement 
with differential scanning calorimetry studies (see Table 3.1) (Lieberman, D'Aquino J et 
al. 2009). 
We next tested the effect of pharmacological chaperones on the Tm of α-GAL. 
Upon the addition of increasing concentrations of either DGJ or galactose, the Tm of α-
GAL significantly increases. Figure 3.3 illustrates the increasing Tm of α-GAL with 
increasing concentrations of DGJ and galactose. At pH 7.2 and 6.5, a detectable increase 
in the Tm of α-GAL is observed at concentrations as low as 500 nM DGJ and about 5 mM 
galactose. When galactose is added to the enzyme, there is a smaller change in the Tm of 
α-GAL (Figure 3.3; Table 3.1). This result suggests that DGJ is more potent and 
efficacious than galactose at increasing the stability of the enzyme. To achieve the same 
increase in α-GAL Tm, approximately 104 times more galactose than DGJ is required. 
This trend is in agreement to the fluorescence experiments, where DGJ is markedly more 
potent at decreasing the rate of unfolding of the enzyme. 
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Figure 3.3 Apparent melting temperature of α-GAL as measured by CD 
 
Increasing apparent melting temperature (Tm) of α-GAL (1.2 µM) in 10 mM 
phosphate buffer (pH 7.2 and pH 6.5) and 10 mM sodium acetate (pH 4.5) in the 
presence of pharmacological chaperone. (, black) – 0 DGJ or Gal; (, cyan) – 50 
nM DGJ; ( , green) – 500 nM DGJ or Gal; ( , red) – 50 µM DGJ or Gal; ( , 
yellow) – 5 mM Gal; ( , blue) – 50 mM Gal. Observed CD signal is measured at 
222 nm at 1°/min. 
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Table 3.1. Apparent melting temperature (°C) of α-galactosidase A with  
                  pharmacological chaperones 
 
[chaperone] +DGJ +Gal +DGJ  +Gal  +DGJ  +Gal  
 pH 7.2 pH 6.5 pH 4.5 
0 56 56 60 62 61 60 
50 nM 57  62  61  
500 nM 62 56 65 61 63 62 
5 µM   76  70  
50 µM 78 56 82 62 74 62 
5 mM    62  62 
50 mM  64  67  69 
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Both the CD and fluorescence experiments show that the stabilizing effect of the 
pharmacological chaperones is greater at higher pH than at pH 4.5. Although α-GAL is 
less stable at pH 7.2 compared to pH 6.5 or 4.5, the effect of pharmacogical chaperone 
(as measured by increase in Tm) is greater at pH 7.2. Table 3.1 summarizes the Tm of α-
GAL and highlights in bold the significant increase in thermal stability in comparison to 
the Tm of α-GAL measured in the absence of a pharmacological chaperone.  
 
3.3.3.   Confers protection from protease digestion monitored by pulse proteolysis 
A third assay we developed to measure the stability of α-GAL is pulse 
proteolysis, which assesses the resistance to protease digestion, a measure of global 
foldedness. We assessed the protease sensitivity of α-GAL after incubation with urea. We 
first performed the experiment on α-GAL, and then we repeated the experiment in the 
presence of pharmacological chaperones.  
When incubated overnight with urea, α-GAL is susceptible to digestion by 
thermolysin and pepsin in 5 minutes, suggesting that α-GAL is in a flexible conformation 
that allows digestion by protease. However in the presence of pharmacological 
chaperone, α-GAL resists digestion (see Figure 3.4). In these experiments, we interpret 
protease sensitivity as unfolded/misfolded or flexible protein while protease resistance 
implies a compact folded state. We quantified the intensity of the undigested α-GAL 
band, allowing us to calculate the concentration of chaperone leading to 50% protection 
from protease. DGJ is more potent at pH 6.5, because 50% protection from digestion 
requires 400 nM DGJ at pH 6.5 and 3.0 µM DGJ at pH 4.5 (see Figure 3.4a and c). In 
contrast, galactose shows similar potency in this assay at pH 6.5 and 4.5, where 3 mM 
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                     pH 6.5 (+DGJ)                    pH 6.5 (+Gal) 
       
      
                          pH 4.5 (+DGJ)                        pH 4.5 (+Gal)           
      
 
Figure 3.4 Pulse proteolysis experiment 
 
Effects of DGJ and galactose on α-GAL stability through resistance to protease. (a) 
and (b): Thermolysin digestion (pH 6.5) of 1.2 µM α-GAL in 8M urea with DGJ 
and galactose respectively; (c) and (d): Pepsin digestion (pH 4.5) of 1.2 µM α-GAL 
in 3M urea with DGJ and Gal respectively. 
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galactose is required to see 50% protection from digestion (see Figure 3.4b and d).  Once 
again, DGJ is vastly more potent than galactose, where 104-105 less concentration of DGJ 
is required to see comparable protection. 
 
3.3.4.   Effect of pharmacological chaperones on enzymatic activity  
A fourth assay we developed to examine the effect of pharmacological 
chaperones is an enzymatic inhibition assay. We measured the enzymatic activity of α-
GAL in the presence of increasing amount of pharmacological chaperone. Since the 
structure of DGJ is very similar to the α-GAL catalytic product galactose (with just imino 
and hydroxyl group differences), it is expected to exhibit competitive inhibition of the 
enzyme (Legler and Pohl 1986; Yoshimizu, Tajima et al. 2008; Sugawara, Tajima et al. 
2009). One contradiction in the use of pharmacological chaperones for the treatment of 
lysosomal storage diseases is that in order to increase the activity of a defective enzyme, 
a competitive inhibitor is used. Since both DGJ and galactose are expected to be 
competitive inhibitors of the enzyme, we measured the inhibition constant Ki for the 
pharmacological chaperones at different pH values. When the enzyme activity is plotted 
versus concentration of DGJ or galactose, increasing the concentration of the 
pharmacological chaperone leads to a subsequent loss of enzyme activity. DGJ inhibits α-
GAL at a lower concentration than galactose. Similar to the results and observations 
mentioned above, DGJ is approximately 105-fold more potent as an inhibitor than 
galactose (Figure 3.5). However, we also have observed that at sub-stoichiometric 
concentration of DGJ (~500 pM-100 nM), α-GAL activity increases (see Figure 3.5a). 
Thus the effect of DGJ can be split into a chaperoning effect of DGJ at low concentration 
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Figure 3.5 Inhibition assay of α-GAL with DGJ and galactose  
 
(a) and (c) α-GAL activity is inhibited by DGJ at ~ 500 nM DGJ for both pH 6.5 and 
4.5; while galactose (b) and (d) inhibits enzyme activity at ~ 300 mM galactose for 
both pH 6.5 and 4.5. The specific activity of 1.2 µM enzyme was measured by the 
absorbance of the para-nitrophenylate ion at 400 nm. 
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Figure 3.6 Determination of DGJ and galactose Ki for α-GAL enzyme 
 
Pharmacological chaperones are usually competitive inhibitors of the enzyme. α-
GAL is inhibited by the substrate analogue DGJ and the substrate galactose. 
Based on the Ki values, DGJ is a more potent inhibitor than galactose.  
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and an inhibitory effect at higher concentration. In the CD and pulse proteolysis 
experiments above, there is a critical concentration (around 1 µM for DGJ and 10 mM for 
galactose) above which α-GAL becomes more resistant to thermal and chemical 
denaturation (Table 3.1 and Figure 3.4). These values are close to the concentrations 
where enzyme inhibition is seen. 
In addition to the activity assays, full enzyme kinetic measurements were made in 
the presence of increasing concentrations of DGJ and galactose (Figure 3.6). Although 
the activity assays above showed that the pharmacological chaperones were inhibitors of  
α-GAL, they did not allow calculation of the Ki for the pharmacological chaperones. A 
full treatment of the enzyme kinetics allowed for calculation of the Ki for DGJ as 
approximately 150 nM while galactose is 105-fold less potent at around 20 mM. 
 
3.3.5.   Active-site nucleophile (D170) is responsible for the pharmacological 
            chaperoning effect of DGJ 
 
The two pharmacological chaperones we have tested here differ by only two non-
hydrogen atoms, yet they show very different potencies. Because the active site 
nucleophile D170 interacts with a ring oxygen in galactose and with a ring nitrogen in 
DGJ, we examined the role of the active-site nucleophile D170 in the binding of the 
pharmacological chaperones. We engineered a mutant α-GAL D170A with the active site 
nucleophile removed and replaced by an alanine, and measured the effect of the removal 
of the carboxylate on the chaperoning effects of pharmacological chaperones. First, we 
checked the stability of the D170A mutant using CD to measure the apparent melting 
temperature (Tm) as described above. The D170A mutant shows comparable stability to 
  62 
the wild-type. This is consistent with surface exposed location of D170 in the active site, 
where amino acid substitution is not expected to have a major effect on the conformation 
of the protein. Next, the apparent melting temperature of D170A α-GAL mutant was 
measured in the presence of DGJ. Contrary to the wild type α-GAL, the D170A mutant 
shows no subsequent increase in Tm at 2 mM DGJ (Figure 3.7a). In comparison, the Tm 
of the wild-type protein is raised by 20° at similar DGJ concentration.   
Second, we tested the stability of the D170A mutant in the pulse proteolysis 
experiment. The resistance of the D170A mutant to protease digestion was examined 
through pulse proteolysis. Without pharmacological chaperone present, the D170A 
mutant protein shows comparable digestion to wild type. However, in the presence of 
DGJ, the D170A mutant shows resistance to protease only at a much higher concentration 
of DGJ, where approximately 1.5 mM DGJ is required to achieve 50% resistance to 
proteolytic digestion under the assay conditions (Figure 3.7b). Surprisingly, D170A 
requires approximately 105-fold more DGJ than wild type α-GAL does. The D170A 
mutant makes the pharmacological chaperone activity of DGJ approximately the same as 
galactose.  
When galactose is used in the pulse proteolysis experiment with the D170A 
mutant, 5mM galactose is necessary to protect 50% of D170A mutant, so the D170A 
mutant behaves similarly to wild type in the presence of galactose. When alanine replaces 
aspartic acid 170, the DGJ chaperoning is affected but the galactose chaperoning is not. 
Thus, we conclude that deletion of the carboxylic acid side chain of the aspartic acid 
(D170  A) eliminates the specific protective effect of DGJ. 
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Figure 3.7 CD and pulse proteolysis experiments for D170A mutant 
 
Effects of DGJ and galactose on α-GAL mutant D170A stability through resistance to 
protease. (a) CD thermal melt of D170A in the absence () and presence (, 2mM) 
of DGJ in 10 mM phosphate buffer pH 6.5; (b) and (c): Thermolysin digestion at pH 
6.5 of α-GAL in 8M urea with DGJ and galactose respectively.  
a 
b c 
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Table 3.2: Crystallographic statistics of α-galactosidase A with  
                  pharmacological chaperones bound 
 
Active site contents: DGJ Galactose 
   
Protein   
Space group P21212 C2221 
Cell lengths, Å 136.8, 182,6, 47.7 89.3, 140.6, 182.5 
Cell angles, ° 90, 90, 00 90, 90, 90 
 
X-ray data 
  
X-ray source  BNL X6A BNL X6A 
Wavelength, Å 1.000 1.000 
Resolution (last shell) 50-2.18 (2.18-2.1) 50-2.0 (2.07-2.0) 
Observations 412,904 1,058,992 
Unique Observations 66,778 77,091 
Completeness, % (last shell) 95.0 (92.4) 99.4 (96.2) 
Multiplicity (last shell) 5.8 (6.2) 13.7 (10.0) 
Rsym (last shell) 0.115 (0.818) 0.115 (0.782) 
I/σI (last shell) 17.2 (2.1) 23.3 (2.2) 
 
Refinement 
  
Rwork/Rfree , % 18.8/23.6 23.1/25.9 
No. of atoms 7137 6913 
  Protein 781 780 
  Carbohydrate 21 21  
  Water 441 298  
  Other 14   53 
Average B, Å2 25.8 25.3 
 
Ramachandran Plot  
  
  Favored (%) 90.8 88.8 
  Allowed (%) 8.1 9.5 
  Generous (%) 1.0 1.0 
  Forbidden  (%) 0.0 0.7 
 RMS deviations   
  Bonds (Å) 0.007 0.006 
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3.3.6.   Crystal structure of α-GAL bound to a pharmacological chaperone 
To address the effect of the pharmacological chaperones on the structure of α-
GAL, we determined crystal structures of the enzyme with DGJ and with galactose bound 
in the active site. The crystal structures of human α-galactosidase A with DGJ and  
galactose bound were solved at 2.1 and 2.0 Å resolution respectively (see Table 2.2). We 
compared those structures to the structure of the D170A mutant described in chapter 2. 
Superimposition of the two structures, the high-resolution wild-type α-GAL (PDB 
code 3GH2) and D170A mutant (PDB code 3GH3) shows no major structural 
rearrangement upon binding DGJ and galactose with a root mean square deviation 
(RMSD) of 0.22 Å for 736 Cα atoms of the dimer and 0.20 Å for the 15 active site 
residues (Figure 3.8a, b and c). Although there are no large changes between the DGJ- 
and galactose-bound structures of α-GAL, there are slight differences around the D170 
active site nucleophile. The N5(DGJ)- δO(170) distance is slightly shorter than the O5(Gal)- 
δO(170) distance at 2.8 and 3.0 Å respectively (see Figure 3.8b and c). The O5(Gal) has two 
lone pairs that are in close proximity to the deprotonated δO(170). The protonated N5(DGJ), 
on the other hand, is able to form hydrogen bonding and electrostatic interactions with 
the deprotonated δO(170). The protonated N5(DGJ)  in the imino sugar is likely to interact 
with the D170 carboxylate more favorably than the unprotonated O5(Gal) , thus the  
greater potency of DGJ as a pharmacological chaperone for α-GAL.  
 
3.4.  Discussion 
DGJ or 1-deoxygalactonojirimycin is an imino sugar with a structure very similar 
to the α-GAL product, galactose (Legler and Pohl 1986; Yoshimizu, Tajima et al. 2008).  
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Figure 3.8 Overlay of α-GAL dimer and active site with DGJ and galactose 
                  bound 
 
(a) The superimposition of human α-GAL structures with DGJ (gray) and galactose 
(yellow) soak and empty (magenta) shows an rsmd of 0.20 Å. DGJ (b) and galactose 
(c) at the active site of α-GAL shows that the N5(DGJ)- δO(170) appears to be short than 
the O5(Gal)- δO(170) at 2.8 and 3.0 Å respectively most likely due  to the chemistry 
between the small molecule and the D170. 
a. 
b. c. 
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DGJ is a small molecule that belongs to a class of chaperones called active-site specific 
chaperones (ASSC). As chaperones, these molecules help stabilize the native fold 
conformation. For a small molecule to be an effective ASSC, it must be able to 
selectively bind to the active site of an enzyme but not so tightly that it inhibits enzyme 
activity. Enzyme inhibitors are especially good chaperones because of their strong 
affinity and specificity for the active site of a particular enzyme. However, inhibitors 
acting as chaperones must also be able to dissociate from the active site of the enzyme in 
the presence of the substrate in order to allow substrate binding. Upon pharmacological 
chaperone binding, the native state is stabilized, helping the protein avoid degradation by 
ER-associated degradation (Fan, Ishii et al. 1999; Asano, Ishii et al. 2000; Frustaci, 
Chimenti et al. 2001; Yam, Zuber et al. 2005). DGJ is hypothesized to bind only to the 
native protein, lowering the energy of the protein. This shifts the folding equilibrium in 
the ER toward the proper folded protein. The 15 residues at the active site from seven 
different loops select and bind the substrate (Garman and Garboczi 2004). The energy 
added by pharmacological chaperone binding helps hold the mutant protein in its proper 
conformation allowing trafficking to the lysosome. Once the α-GAL molecule traffics to 
the lysosome, it is stable for days (unpublished results by Khanna, R., et.al.; Desnick 
1979; Eng, Banikazemi et al. 2001). Most α-GAL missense mutations that cause FD lead 
to protein with an intact catalytic domain with some residual enzyme activity (Remeo, 
D'Urso et al. 1975; Beck 2001). However, these mutations tend to lead to misfolded or 
aggregated α-GAL, thus they would be good candidates for pharmacological chaperone 
therapy.  
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Even wild-type α-GAL shows dose-dependent increase in enzyme activity upon 
addition of sub-stoichoimetric amounts of DGJ (Figure 3.5a). In vivo experiments 
demonstrate that the observed improvement of enzyme activity of wild-type α-GAL is a 
result of increased folding efficiency of a stably folded protein (Fan, Ishii et al. 1999). A 
number of α-GAL mutants have also been assessed for activity enhancement by DGJ in 
cell culture experiments (Spada, Pagliardini et al. 2006; Shimatori 2007; Shin 2007; Shin 
2008; Benjamin 2009). For α-GAL, 10-15% of wild-type enzyme activity is sufficient to 
prevent the appearance of Fabry disease symptoms (Desnick 2001; Ries, Gupta et al. 
2005). Since FD symptoms vary depending on the amount of residual enzyme activity 
(from no residual activity to 3-5%), even a small enhancement of the residual enzyme 
activity will reduce FD substrate in cells and most likely alter the clinical manifestation 
of the disease. A small increase in the residual activity of α-GAL greatly reduces the 
progression of FD symptoms in patients (Desnick 2001; Eng, Banikazemi et al. 2001; 
Eng, Guffon et al. 2001). 
Our experiments identify four important observations supporting DGJ as an 
effective active-site specific chaperone for α-GAL. First, DGJ binds to the wild-type α-
GAL and stabilizes the enzyme. It helps stabilize even the well-folded and stable wild-
type α-GAL. The additional stability that DGJ provides is apparent by the rise in the 
apparent melting temperature of α-GAL monitored by CD (see Figure 3.3 and Table 3.1). 
This was paralleled with the noticeable resistance to protease digestion by pulse 
proteolysis (Figure 3.4) and the slow unfolding kinetics by fluorescence (Figure 3.1 and 
3.2) in the presence of pharmacological chaperone. Second, in all of the experiments 
above, the pharmacological chaperone works better at neutral pH than at acidic pH. 
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Third, the pharmacological chaperone galactose works like DGJ but at a higher 
concentration (about 105-fold more galactose than DGJ). This suggests that DGJ binds to 
the active site of the enzyme more tightly than galactose. This suggests that only active 
site specific chaperoning could stabilize α-GAL but not the more general non-specific 
chemical chaperoning. Lastly, the higher potency of DGJ over galactose is due to the 
tight binding of the chaperone, and this tight binding requires the active site nucleophile 
D170. When we measured the chaperoning effect of DGJ to both wild-type and D170 
mutant using our biochemical assays mentioned previously, we did not see the same 
effect (the mutant requiring more DGJ to see chaperoning), indicating the importance of 
the aspartic acid to the chaperoning effect of DGJ.  
The standard model for the mechanism of chaperoning of α-GAL by DGJ 
assumes that the imino nitrogen of DGJ is deprotonated in the ER and then protonates in 
the low pH of the lysosome, leading to dissociation of the ligand from the protein. 
However, our experiments contradict this model. First, a large fraction of DGJ remains 
bound to α-GAL at the lysosomal pH 4.5, as shown by the thermal melt CD experiments. 
Second, the pKa of DGJ is measured to be 7.1 in solution, so it is unlikely to undergo 
change in protonation state as the pH goes from 6.5 in the Golgi to 4.5 in the lysosome 
(Legler and Pohl 1986; Butters 2005). Third, the binding site of α-GAL contains an 
excess of negative charges over positive charges, so it is not clear why protonation of the 
DGJ would lead to dissociation of the sugar from the complex. Fourth, in the high-
resolution (1.65Å) structure of isofagomine bound to Thermotoga maritima family 1 α-
glucosidase, shows that the imino sugar is protonated and charged when bound to the 
glycosidase (Gloster, Meloncelli et al. 2007).  
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Our experiments lead us to propose a new model for the mechanism of 
pharmacological chaperoning of α-GAL by DGJ. We predict that the DGJ remains 
protonated and positively charged when bound to α-GAL, and that the pH dependence of 
the interaction is due to protonation of the catalytic nucleophile D170 of α-GAL. In our 
model, the pKa of the carboxylate of D170 is raised by the excess of negative charges in 
the active site. We hypothesize that at ER and Golgi pH (pH 7.2 and 6.5 respectively), the 
D170 carboxylate is deprotonated while DGJ is protonated and carries a positive charge, 
and the ionic interaction leads to tight binding of DGJ to α-GAL. However, at lysosomal 
pH (4.5), the D170 carboxylate protonates, leading to the loss of the ionic interaction and 
weaker binding of the DGJ. Upon the removal of the carboxylic side chain of D170 in the 
D170A mutant, the ion pair is lost and the potency of DGJ is greatly diminished. Thermal 
denaturation of the D170A mutant monitored by CD (Figure 3. 6c) shows no increase in 
Tm upon addition of DGJ.  
An ideal lysosomal pharmacological chaperone candidate should be a small 
molecule that could diffuse readily into the cell and ER membrane and must be able to 
bind to the active site of a specific enzyme in the ER where proteins are folded. Once the 
pharmacological chaperone-bound enzyme escapes the quality control of the ER and is 
transported to the lysosome, the natural substrate must be able to out-compete the PC at 
the active site (Figure 3.9).  
The experiments mentioned above demonstrate the mechanism of action of DGJ 
as a pharmacological chaperone. An enzyme bound to DGJ is very stable and unfolds at a 
slow rate. Since the Ki for DGJ and the amount of enzyme is known, we could calculate 
how much α-GAL enzyme that remains unbound to DGJ. Only unbound to DGJ α-GAL  
  71 
  
 
Figure 3.9 Pharmacological chaperone therapy for wild-type and mutant α-   
                   GAL 
 
Protein folding in the ER is an equilibrium process. As the wild-type polypeptide 
chain is being synthesized in the ER, it folds to its proper conformation with the help 
molecular chaperones. At time times the folding protein samples the wrong 
conformation, misfolds and is degraded through ERAD. In the presence of the 
pharmacological chaperones like DGJ, it binds more favorably to the active site at 
neutral pH, shifts the folding equilibrium to proper folded and facilitates proper 
trafficking of the fully function protein to the lysosome. Strong binding of the 
pharmacological chaperone is key to the chaperoning effect of the small molecule. 
This increases the folding efficiency of wild-type protein. Similarly when the 
polypeptide chain with an amino acid substitute is being synthesized at the ER, it tries 
folds to the proper conformation with the help molecular chaperones. The folding 
equilibrium of a mutant protein is shifted more towards the non-native fold. Most of 
these mutants have intact active site and remain active or partially active however due 
to the amino acid substitution the mutant misfolds. The misfolded protein is 
recognized by the cell and is degraded. In the presence of the pharmacological 
chaperones like DGJ, it binds favorably to the active site at neutral pH, shifts the 
folding equilibrium to proper folded and facilitates proper trafficking of the fully 
function protein to the lysosome. This increases the folding efficiency of mutant 
protein.  
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unfolds. Given that DGJ is a potent inhibitor (Ki in the nanomolar range), most of α-GAL 
in the solution is bound to DGJ thus slow rate of unfolding, increased thermal stability 
and resistance to protease digestion is detected in the experiments mentioned above. 
Additionally, this also suggests that the pharmacological chaperone is not limited to mild 
phenotype as initially thought. Most mutant with intact active site and could bind DGJ 
tightly could be rescued by DGJ from ERAD. Fabry disease is the first lysosomal storage 
disease that shows promising results for PCT and could be used as a model for other 
storage diseases as well as other protein-folding disease such as Alzheimer’s disease and 
Parkinson’s disease. 
 
3.5.  Methods 
3.5.1.   D170A α-GAL expression and purification 
α-GAL active site mutant, D170A was expressed and purified as previously 
described in Chapter 2. 6. 1 and Chapter 2. 6. 2.  
 
3.5.2.   Fluorescence 
To measure the kinetics of chemical denaturation of α-GAL in the presence of 
pharmacological chaperones, tryptophan fluorescence measurements were carried out on 
PTI QM1 spectrofluorometer (PTI, Inc., Birhamton, NJ). Recombinant WT α-GAL (12 
µM; FabrazymeR, Genzyme Corp) was incubated with 500 µM DGJ (Toronto Research 
Chemicals Inc., D236500) or 500 mM galactose (Sigma Aldrich, G5388). After 2-4 
hours, chemical denaturation was initiated by ten-fold dilution into 10 mM sodium 
phosphate/7.5M urea, pH 6.5 or into 10 mM sodium acetate/7.5M urea, pH 4.5. The 
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kinetics of unfolding was measured by monitoring the fluorescence emission hourly for 
10 hours after dilution and then at 24 hours. Tryptophan fluorescence signal was 
monitored at 25°C by excitation at 295 nM (1 nm slit width) and emission at 300-400 nm 
(3 nm slit width). Fluorescence intensity at 335nm, the peak in the spectrum of the folded 
protein, was normalized against the initial reading (Io). The rate constant for unfolding 
(kU) was obtained assuming first order kinetics from the exponential fit of the 
fluorescence data using Igor Pro software: 
      kU  =  ln 2/t     (3.1)  
where t is half-time of the unfolding.  
 
3.5.3.   Circular dichroism (CD)  
To measure the stability of α-GAL in the presence of pharmacological 
chaperones, we used circular dichroism (Jasco J715 spectropolarimeter) monitor the 
secondary structure of α-GAL as the protein denatured. α-GAL samples were prepared by 
incubating 12 µM protein alone and with varying concentrations of pharmacological 
chaperone (50 nM - 50 µM DGJ and 50 nM - 50 mM galactose). The solutions were then 
diluted ten-fold into 10 mM phosphate buffer (pH 6.5) or 10mM sodium acetate buffer 
(pH 4.5) and incubated overnight at 20°C prior to CD analysis. CD wavelength scans and 
thermal melts were carried out on a Jasco J715 spectropolarimeter equipped with a PTC-
348WI temperature controller. To examine the secondary structure of the samples, they 
were first scanned from 190-240 nm at 25°C at a scan rate of 20 nm/min using a 0.1 cm 
quartz cuvette. Then, the CD signal at 222 nm was monitored while raising the 
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temperature from 25-90°C at a rate of 1°C/min. The molar ellipticity (Θ) of each solution 
was calculated using: 
 
 (3.2)  
where C is the protein concentration in mM, n is 418, the number of amino acid residues 
per monomer, and l is 0.1 cm, the cell path length. The molar ellipticity data was 
converted into fraction denatured, Fd according to:    
 
   
      (3.3) 
 
 
where Θobs is the calculated molar ellipticity and ΘN and ΘU are values characteristic of a 
fully native and fully denatured states respectively. The Tm is the temperature at which Fd 
is equal to .  
 
3.5.4.   Pulse Proteolysis  
To monitor the resistance of α-GAL to proteolytic digestion in the presence of 
pharmacological chaperones, we adapted a published pulse proteolysis protocol (Park and 
Marqusee 2005). For the pH 6.5 experiments, 1.2 - 2 µM α-GAL was incubated for 2-4 
hours alone or with 0.5 nM-50 µM DGJ or 0.5 µM-50 mM galactose in 10 mM 
phosphate buffer (pH 6.5). The solution was then diluted ten-fold into 10 mM 
phosphate/8M urea and incubated at 20°C overnight. Digestion was initiated by the 
addition of 0.13 mg/mL thermolysin (Sigma T7902) in 10 mM CaCl2, 50 mM NaCl, 20 
mM Tris•HCl, pH 8.3. After 5 minutes at 37°C, the reaction was quenched by the 
addition of 50 mM EDTA (pH 8.0) to a final concentration of 12.5 mM. For the pH 4.5 
experiments, 1.2 - 2 µM was incubated for 2-4 hours alone or with 0.5 nM-50 µM DGJ or 
! 
Fd =
"N #"obs
"N #"U
! 
Molar ellipticity, " = CD signal@222 nm # 100C # n # l
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0.5 µm-50 mM galactose in 100 mM sodium acetate (pH 4.5). The solution was then 
diluted ten-fold into 10 mM sodium acetate/3M urea, pH 4.5 and incubated at 20°C 
overnight. Digestion was initiated by the addition of 0.16 - 0.25 mg/mL pepsin. After 5 
min, the reaction was quenched by the addition of 2M Tris-HCl, pH 9.0 to a final 
concentration of 0.25 M.  
Samples were separated on a reducing 10% SDS/PAGE gel and stained with 
GelCode Blue (Pierce 24592). Band intensities between 43 and 53 kDa were quantified 
using the Syngene GeneTools gel analysis software. Each α-GAL band intensity was 
normalized against the α-GAL band intensity in the absence of protease. The amount of 
undigested protein in the presence of DGJ or galactose is a measure of the 
pharmacological chaperone’s ability to stabilize the α-GAL and confer protease 
resistance.  
 
3.5.5.   Activity Assay/Ki determination 
 To determine the enzymatic parameters of α-GAL in the presence of 
pharmacological chaperones, the specific activity of the enzyme was measured using the 
synthetic substrate para-nitrophenyl-α-galactopyranoside (pNP-α-gal; Sigma Aldrich, St. 
Loius Mo, N0877). 1.2 µM α-GAL in 100 mM citrate/phosphate buffer, pH 6.5 or pH 4.5 
was incubated with 0-100 µM DGJ or 0-2 M galactose for 2-4 hours at 20°C. The 
solution was diluted 5-10 fold into 10 mM pNP-α-gal/100 mM citrate/phosphate buffer 
pH 6.5 or pH 4.5. After 10 minutes at 37°C, the reaction was quenched by the addition of 
250 µL of borate buffer, pH 9.8. Absorbance of the para-nitrophenylate ion at 400 nm 
was measured using a microplate reader at room temperature and converted to amount 
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product using 18 mM-1cm-1 as the extinction coefficient. Ki values for DGJ and galactose 
were calculated using the Michaelis-Menten equation.  
 
                    (3.4) 
 
In the presence of increasing concentration of inhibitor (I), DGJ and galactose, KM can be 
replaced with KM(app): 
     (3.5)         
 where KM(app) is observed KM of enzyme in the presence of an inhibitor, [I] is the     
inhibitor concentration, and Ki is the inhibition constant. Upon plotting Km (app) vs [I], Ki 
can be calculated from the slope of the linear fit of the data.  
 
3.5.6.   Crystallography 
 Wild-type human α-galactosidase A expressed in tobacco plants was a gift from 
Large Scale Biology Corporation. Purified α-GAL protein was concentrated to ~8.0 
mg/mL. Crystallization experiments were performed using the hanging-drop vapor-
diffusion method and were grown at 20°C in an incubator. Crystals of the wild-type α-
GAL were obtained by mixing 1µL of reservoir solution  (20 mM magnesium acetate, 
100 mM sodium cacodylate (pH 5.1) and 8-15% (w/v) PEG8K) with 1 µL of a protein 
solution at ~8.0 mg/mL. Prior to freezing and data collection, the crystals were 
transferred stepwise into a cryoprotectant and ligand solution containing 20% PEG400, 
25% (w/v) PEG8K, 20 mM Mg(CH2COOH)2, 100 mM Na-cacodylate (pH 5.1) and 
either 12 mM DGJ or 100 mM galactose. 
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Data collection was performed at the National Synchrotron Light Source (NSLS) 
beamline X6A at the Brookhaven National Laboratory. X-ray images were integrated, 
indexed and scaled using HKL2000 software package (Otwinowski 1997). α-
galactosidase A in space group P3221 (PDB code 3HG5) was used as a molecular 
replacement model in the CCP4 program MolRep/AMoRe and rigid body refinement and 
positional refinement were performed using Refmac5. The atomic models were built into 
electron density using the program O, after which refinement and water placement were 
done using REFMAC (Jones, Zou et al. 1991). Ramachandran plots were computed using 
PROCHECK (Laskowski 1993). Coordinates were superimposed using LSQMAN; the 
surface accessible are were calculated using AREAMIMOL in CCP4 and figures were 
made in PyMOL (Kleywegt 1997; DeLano 2008). 
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CHAPTER 4 
 
SPECIFIC DEFECTS RESPONSIBLE FOR FABRY DISEASE RESCUED 
BY PHARMACOLOGICAL CHAPERONE DGJ 
 
This chapter is part of a paper in preparation. (Abigail I. Guce and Scott C. Garman. 
2009) 
 
4.1.    Introduction 
Fabry disease is a well-documented inherited disorder with over 400 missense 
mutations reported in patients (Human Gene Mutation Database). Mapping the mutations 
into the three-dimensional structure of human α-GAL indicates a breadth of the mutations 
that cause Fabry disease (Garman and Garboczi 2002; Garman and Garboczi 2004; Guce 
2009). Some of these mutations grossly alter the gene sequence such as splicing 
mutations, small deletions & insertions and large gene rearrangements. These mutations 
result in gross modification of the polypeptide product and typically result in a 
completely non-functional protein. Patients with structure-altering mutations present the 
severe form of the disease. The previous chapter focused on the molecular mechanism 
and the interactions of the pharmacological chaperones with wild type α-GAL. This 
chapter focuses on the point mutations that disrupt the α-GAL protein and how they 
respond to DGJ. Most of the mutations lead to deficiency of α-GAL due to misfolding 
and degradation of the mutant protein at the ER (Hartl and Hayer-Hartl 2002; Ellgaard 
and Helenius 2003). The structure of α-GAL allows for the predictions of the effect of 
hundreds of point mutations found in different Fabry patients on the structure of the 
enzyme. Despite numerous effects to study these mutations, there is still no clear 
genotype-phenotype connection established because of the diversity of the mutations.  
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Fabry disease, a protein misfolding disorder, is an excellent candidate for 
pharmacological chaperone therapy. Based on the work described in Chapter 3 on the 
mechanism of the small molecule DGJ, this chapter describes similar approaches, but 
focused on the various categories of mutations that cause Fabry disease. Studies on wild 
type α-GAL and the pharmacological chaperone DGJ demonstrate that sub-inhibitory 
amounts of DGJ stabilize α-GAL. DGJ binds more tightly at neutral pH, presumably 
because of the presence of an extra H-bond and electrostatic interaction stabilizing the 
interaction between the ligand and the protein. The increase in stability of α-GAL in the 
presence of pharmacological chaperone is also demonstrated by the pulse proteolysis, 
tryptophan fluorescence and CD experiments. Several studies have demonstrated an 
increase in enzyme activity of some mutant α-GAL proteins upon addition of DGJ 
(Spada, Pagliardini et al. 2006; Ishii, Chang et al. 2007; Shimatori 2007; Shin 2007; Shin 
2008; Benjamin 2009). However it is not known how many of these mutations that cause 
Fabry disease will respond favorably to pharmacological chaperone therapy (Fan, Ishii et 
al. 1999; Asano, Ishii et al. 2000; Frustaci, Chimenti et al. 2001). Initially 
pharmacological chaperone therapy was proposed exclusively for the mild phenotype of 
the disease (Asano, Ishii et al. 2000; Fan 2003; Yam, Bosshard et al. 2006). However 
recent studies show several severe α-GAL mutations respond favorably to DGJ treatment 
resulting to an increase in enzyme activity or in the degradation of the accumulated 
substrate at the lysosome.  
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4.1.1.  Structural analysis of Fabry disease mutants 
 First, we grouped the mutations into categories, and then chose representative 
mutations from each of the categories. We examined representative mutations, (a) one 
that is a surface exposed substitution and is unlikely to influence the fold of the protein 
(E398K); (b) two that disrupt the enzyme active site (M51I, D170A); and (c) two that is 
likely to affect the fold of the protein (L166V, M51I).  
 
4.1.1.1.  Glutamic acid 398 to lysine (E398K) 
 E398 is a surface-exposed residue with a side chain surface accessible area of 
approximately 21.5Å2. It is located at the C-terminal domain at the end of β14 strand, and 
at the edge of one of the two sheets of the β sandwich. It is also positioned at a small 
positive patch in a surface loop of the protein and packs against atoms mostly from the 
main chain carbonyl group of Thr 400 (see Figure 4.1). E398 is about 54 Å away from 
the active site. Similarly is it also far away from the domain and dimer interface of the 
protein. E398 is somewhat close to the C terminus of the monomer, about 16-18 Å away 
from the last resolved residue Met 423 in the 1.9 Å D170A structure. The E398K 
substitution changes the charge on the residue, but is considered a conservative 
substitution in the BLOSSUM sequence alignment matrix (Needleman and Wunsch 
1970). This residue is not conserved among consensus α-galactosidase sequences 
(Thompson 1994). Structural alignment of four α-galactosidase structures from different 
species (PDB ID: 1UAS, 3A5V, 1T0O, 1SZN) also shows no sequence conservation 
(showing a Gln, Ser or His) at this position (Fujimoto, Kaneko et al. 2003; Golubev, 
Nagem et al. 2004; Golubev, Nagem et al. 2004; DeLano 2008; Fujimoto, Kaneko et al. 
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Figure 4.1 α-galactosidase A mutants 
 
 
Shown are of the chosen Fabry disease-causing mutants and their location as mapped 
to the monomer of α-GAL. E398K is located at the N-terminal loop, exposed to the 
solvent. It is positioned between a cluster of acidic residues. E to K substitution 
changes the charge of the residue but contact analysis show no clashes between other 
nearby amino acid; M51I is a mutation of a buried residue that makes contacts with 
active site residues D92 and D93, and a disulfide bond C52-C94. Although M to I 
substitution is considered a conservative mutation, contact analysis show substitution 
to I causes a structural clashes mostly from the disulfide bond; L166V is located at the 
center of the (β/α)8 barrel at the opposite end of the active site pocket. L to V 
substitution shows structural clash between the β strands that make up the center of the 
barrel. 
 
 
E398K M51I 
L166V 
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2009). Changing the glutamic acid 398 to lysine changes the charge of the surface 
however that is unlikely to be an adverse change in the structure. Since this mutation 
islocated in an exposed loop that could accommodate a bigger residue and a change in the 
charge, it is unknown why this particular mutation is reported to cause a severe type of 
Fabry disease (Shabbeer, Yasuda et al. 2002). 
 
4.1.1.2.  Methionine 51 to isoleucine (M51I)  
 Patients reported with M51I have the severe form of Fabry disease (Spada, 
Pagliardini et al. 2006). M51I is a buried residue near (~4.5 Å away) an active site 
residue, W47. M51I is located near active site residues, Cys52-Cys94, D92 and D93 (see 
Figure 4.2b). The Met to Ile change is a conservative substitution and when Ile is 
modeled into the structure at this position it causes a small structural clash mostly from 
the γ and δ carbons of Ile to the main chain of cysteine (see Figure 4.1). M51 also makes 
contacts to residues at the dimer interface, with I359 at the loop connecting β11 and β12 
of the C-terminal domain. However multiple sequence alignment and structural 
alignment shows this residue is not conserved across related α-galactosidase sequence or 
structures (Thompson 1994; Fujimoto, Kaneko et al. 2003; Golubev, Nagem et al. 2004; 
Golubev, Nagem et al. 2004; DeLano 2008; Fujimoto, Kaneko et al. 2009). By analysis 
of contacting residues, this mutation disrupts structurally important residues and could 
influence the three-dimensional structure of the protein thus affecting the enzyme 
activity.  
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4.1.1.3.  Leucine 166 to valine (L166V) 
 L166V mutation also causes the severe form of Fabry disease (Okumiya, Ishii et 
al. 1995). L166 is another buried residue, with a side chain surface accessible area of only 
1.0 Å2. It is located inside the (β/α)8 barrel at the opposite side of the active site pocket. It 
is at the other end of the β4 strand, the same β strand where the nucleophile catalytic 
residue D170 is located. It is about 13 Å from D170. Although L166V is considered a 
conservative substitution, the branched β carbon of valine clashes with Tyr 88 on β2 
strand and main chain atoms on β3 strand in the β barrel (see Figure 4.1). Sequence 
alignment shows that although Y88 is not strictly conserved, it is most often a Tyr or Leu 
(Thompson 1994; DeLano 2008). Based on the contact analysis, this mutation disrupts 
the three-dimensional structure of the protein, also affecting enzyme activity. However 
the sequence and structural alignment clearly suggests this position can accommodate a 
bulkier group (Thompson 1994; Fujimoto, Kaneko et al. 2003; Golubev, Nagem et al. 
2004; Golubev, Nagem et al. 2004; Fujimoto, Kaneko et al. 2009). 
 
4.2.   Experimental Strategy  
In this section, we sought to test the effect of DGJ on the conformational stability 
of the mutant proteins using pulse proteolysis. In the previous chapter, we described how 
pulse proteolysis on the wild type α-GAL enzyme assessed the effect of DGJ on the 
stability of the enzyme. We applied the assay (optimized against wild type α-GAL) to 
selected mutant enzymes to study the response of the mutants to DGJ. We also 
investigated the effect of other known chemical chaperones other than DGJ and galactose 
on the stability of mutant α-GAL.  
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Beyond these experimental approaches, we sought a general predictive model 
relating changes in α-GAL sequence to response of these mutant proteins to 
pharmacological chaperone. Based upon analysis of the structure and recent experimental 
data on the responsiveness of individual α-GAL mutants to DGJ, we have created a set of 
rules that predict the response of all known α-GAL mutants to DGJ. These predictions 
aim to guide clinicians as to which patients are likely to respond to DGJ therapy, 
depending on their individual DNA sequence, establishing a general genotype-DGJ 
response relationship for Fabry disease. 
 
4.3.  Results 
4.3.1.   Characterization of the activity and kinetic properties of insect cell expressed 
             human α-GAL mutants 
 
We expressed and purified wild type and mutant α-GAL enzymes, then tested 
their specific activity, kinetic properties, thermal stability by CD, and resistance to 
digestion in pulse proteolysis experiments. The apparent melting temperatures measured 
by CD indicate the structural stability of the fold of the enzyme, while the kinetic 
parameters report on the competence of the active site. We also performed these analyses 
in the presence of DGJ, to indicate the effect of pharmacological chaperone on the 
proteins. Wild type α-GAL and the catalytic inactive mutant D170A were used as 
controls for the stability and activity of the other mutants.  Table 4.1 summarizes the 
biochemical and enzymatic characterization of the expressed mutants, E398K and M51I 
(Figure 4.2a and b), as well the wild type and D170A controls. Because the L166V  
mutant has a very low expression level, there is no quantification of the enzyme stability 
and activity.            
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Table 4.1 Stability and kinetic parameters of expressed α-GAL 
 
Kinetics Protein Type of 
mutation 
App Tm, 
°C 
Spe. Act., 
U/mg KM, mM kcat, sec-1 kcat/KM 
E398K Exposed 58 ± 1 415 ± 30 7.3 ± 0.3 22.54 ± 0.05 3.1 
M51I Buried 54.1 ± 0.5 130 ± 20 6.8 ± 0.4 8.92 ± 0.02 1.3 
L166V Buried ND < 10 ND ND ND 
D170A Active site 64 ± 2 ND ND ND ND 
Wild type - 60 ± 1 522 ± 302 8.2 ± 0.2 37.8 ± 0.2 5.1 
ND = not detected 
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Figure 4.2 Reaction rates vs substrate concentration for α-GAL mutants 
 
E398K (a) and M51I (b) Michaelis-Menten plots relating the reaction rate to the 
substrate pNP-α-gal substrate concentration; (insert) absorbace of para-nitrophenolate 
measured at 400 nm collected over time at various pNP-α-gal substrate concentrations: 
50 mM, red; 37.5 mM, orange; 25, brown; 12.5 mM, light orange; 6.25 mM, yellow; 
3.12 mM, light green; 1.56 mM, green; 0.78 mM, light blue; 0.39 mM, blue; 0.20 mM, 
purple; 0.10 mM, pink. 
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Figure 4.3 Apparent melting temperature of expressed α-GAL mutants at pH 6.5 
                  as measured by CD at 222 nm 
 
Comparison of the apparent melting temperature of expressed α-GAL mutants E398K 
(), M51I (), D170A () to wild type () protein. E398K and wild type α-GAL 
have similar stability, D170A is slightly more stable but comparable to the stability of 
wild-type enzyme while M51I is less stable. 
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We predict that E398K α-GAL should behave like the wild type enzyme because 
it is a conservative substitution of an exposed residue. As expected, E398K α-GAL has a 
comparable Tm as wild type (58°C vs 60°C, Figure 4.3) as measured by CD, and the two 
enzymes have similar enzymatic parameters. However, this mutation causes the severe 
phenotype of Fabry disease. It is unknown why the conservative substitution E398K 
causes Fabry disease, because the mutation is unlikely to disrupt the three-dimensional 
structure of the α-GAL mutant protein. Although the purified protein behaves much like 
the wild type, they have very different phenotypes in patients.  
The M51I mutant α-GAL affects a buried residue near an active site residue, 
W47. Unlike E398K, M51I α-GAL is likely to have a disrupted three-dimensional 
structure of the protein near the active site, thus affecting the enzyme activity.  Compared 
to wild type α-GAL and the E398K mutant, this mutant has one third the specific activity 
and comparably reduced catalytic parameters. The decrease in activity of M51I could be 
explained by either disruption of the active site of the enzyme or by a fraction of inactive 
protein combined with active protein. We have observed that some purified M51I protein 
stored in phosphate buffer eventually precipitates over months at 4°C. In contrast, wild 
type α-GAL and other mutants stored comparably remain stable and active over the same 
time period. Thermal melts of M51I monitored by CD show a lower denaturation 
temperature than wild type, showing that the mutant is a less stable protein and more 
susceptible to unfolding. The Michaelis constant (KM), the substrate turnover (kcat) and 
the specificity constant (kcat/KM) of M51I were also measured, and plot of Michaelis-
Menten hyperbola for E398K and M51I are shown in Figure 4.2. Even though the 
Michaelis constant is unperturbed and similar to wild type, the substrate turnover and 
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specificity constant are lower, suggesting an enzyme that is less efficient at converting 
bound substrate into product (see Table 4.1). M51I is not completely catalytically dead 
(like the D170A mutant is) but is less stable and less active enzyme than the wild type 
and E398K mutant.  
The  α-GAL mutant L166V is a replacement in another buried residue, however 
unlike M51I, the expression level of this mutant is very low (<0.1 mg/mL), and no 
mutant protein could be purified from the supernatant, thus characterization of the L166V 
mutant was not possible. The low expression of this mutant suggests that it does not fold 
efficiently, leading to the loss of enzyme activity in Fabry disease patients.  
  
4.3.2.   Protection from protease digestion monitored by pulse proteolysis 
After characterization of the purified mutants as fully (E398K) or partially (M51I) 
active, the response of these two mutants to the pharmacological chaperones DGJ and 
galactose therapy was investigated. The pulse proteolysis assay we developed for wild 
type α-GAL to assess the proper conformation of the protein is easily adapted to measure 
the “foldedness” of the mutant enzymes. We examined the effect of increasing 
concentrations of DGJ and galactose on the susceptibility of wild type and mutant α-GAL 
proteins to protease digestion. Analogous to the wild type experiments, the α-GAL 
mutants E3898K and M51I, were subjected to denaturing conditions that allow digestion 
by protease. The resistance of the mutants to proteolytic digestion was measured by the  
fraction of α-GAL mutant remaining, and the experiment was repeated in the presence of 
pharmacological chaperone.             
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Figure 4.4 Pulse proteolysis experiment of α-GAL mutants 
 
Effects of DGJ and galactose on α-GAL mutant stability through resistance to 
protease. (a) and (b): Thermolysin digestion (pH 6.5) of 1.2 µM E398K mutant in 
8M urea with DGJ and Gal respectively; (c) and (d): Thermolysin digestion (pH 6.5) 
of 1.2 µM M51I mutant in 8M urea with DGJ and Gal respectively. 
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           For the E398K mutant, 50% protection is estimated around 500 nM DGJ and 3.0 
mM galactose, comparable to the concentrations seen for wild type α-GAL at 400 nM 
DGJ and 3.0 mM galactose (Figure 4.4a and b). This shows that critical concentration 
range at which we start to see significant protection between DGJ is once again 
approximately 105-fold less than for galactose.  
On the other hand, 50% protection from proteolytic digestion of M51I mutant is 
observed at a higher concentration DGJ and galactose (600 nM and 50 mM respectively, 
Figure 4.4c and d). Depending on the type of mutation and how the mutation affects the 
3D structure of the protein, different pharmacological chaperone concentrations are 
required to resist proteolytic digestion. Mutations that affect the active site like M51I and 
D170A change their ability to bind pharmacological chaperone. At higher concentrations 
of pharmacological chaperone, when the pharmacological chaperone is fully bound to the 
mutant, the enhanced stability can be seen.  
 
4.3.3.   In vivo assay of the effect of different chaperones to the expression of L166V 
We next examined the in vivo effects of pharmacological chaperones on 
expression and activity of mutant α-GAL. To study the in vivo effect of pharmacological 
chaperones on the expression of α-GAL, the low expressing L166V mutant was used. We 
tested in vivo known pharmacological chaperones such as DGJ (a competitive inhibitor), 
galactose (the catalytic product); glucose (a monosaccharide excluded from the active  
site), and other known non-specific chemical chaperones and osmolytes (including 
DMSO, proline, ficoll and dextran) (Perlmutter 2002; Ignatova and Gierasch 2006). DGJ 
and galactose are active site specific chaperones while glucose, DMSO, proline, ficoll 
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Figure 4.5 Pharmacological chaperones for L166V mutant 
 
(a) Western blot of the supernatant of Tn5 insect cells transfected with L166V DNA; 
lanes 3 and 4 shows the increase in L166V expression upon addition of DGJ; lane 5 
shows the decrease in L166V expression after diluting out DGJ during just one 
passage. (b) Western blot of L166V with different chaperones, and are the 
corresponding activity of the supernatant L166V mutant using X-α-gal (c) and pNP-
α-gal (d) chromogenic substrates.  
 
 
c. 
d. 
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and dextran affect protein stability through non-specific interactions with α-GAL. The 
low basal expression level of L166V improves upon addition of DGJ to the media (Figure 
4.5) as seen by the increased western blot band intensity. However when we take cells 
with high L166V expression in the presence of DGJ and passage them in media without 
DGJ, the expression level return to basal level (Figure 4.5). This result indicates that the 
increase in L166V expression is correlated with the addition of DGJ to the media. In the 
same way, addition of 100 mM galactose to the media does not affect the L166V 
expression level. Non-specific chemical chaperones like glucose, DMSO, proline, ficoll, 
and dextran did not affect the level of expression of L166V in our culture. Overall, the 
western blots demonstrate that DGJ rescues the expression of L166V mutant in insect 
cells, while galactose and other chemical chaperones do not.  
We then tested the correlation between expression of L166V mutant α-GAL and 
activity using two approaches. First, enzyme activity of the insect cell supernatant was 
detected using a dot blot assay, where the enzyme was bound to a nitrocellulose 
membrane, and activity was measured using the X-α-galactose substrate (after removal of 
the small molecule chaperone). In parallel, the dialyzed supernatant was assayed for 
enzymatic activity via quantification of pNP-α-galactose cleavage.  Figure 4.5 illustrates 
the strict correlation between western band intensity and activity of L166V. Following 
incubation with DGJ, the increase in L166V expression in insect cells was matched by 
the increase in activity using the X-α-galactose and pNP-α-galactose substrates. This 
shows that DGJ rescues expression and activity of L166V in vivo as well as in vitro. 
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4.4.  Discussion  
Pharmacological chaperones are proposed to bind to the active site of the mutant 
enzyme to facilitate the proper folding of the protein. The mechanism of pharmacological 
chaperoning of the small molecule DGJ has been explored for the first time, by 
measuring the stability of the wild type α-GAL upon binding to the pharmacological 
chaperone (Chapter 3). DGJ effectively stabilizes the wild type protein, allowing it to 
escape ERAD and traffic to the lysosome. Using the assays developed to monitor the 
stability of wild type protein, we applied the same assays to known Fabry disease-causing 
mutations. Three mutants (representing different genotypes of the severe form of Fabry 
disease) show very different results in biochemical assays for the stability of the protein. 
These amino acid substitutions represent the three categories of missense mutations 
mentioned in Chapter 1 that cause the deficiency of the protein. First, E398K is a stable 
and active enzyme when over expressed in insect cells. It has a comparable apparent 
melting temperature to wild-type enzyme, indicating this enzyme is as stable as wild 
type. The specific activity and kinetics of this mutant also suggest a well-formed active 
site. Although it is known that this amino acid substitution causes Fabry disease, E398K 
has biochemical properties (including Tm and protease resistance) very similar to the 
wild-type enzyme. Second, M51I is slightly less stable than wild type, with an apparent 
melting temperature of about 5°C lower. The specific activity and catalytic parameters of 
M51I suggest a less active enzyme. The response of the M51I mutant to increasing DGJ 
concentration is different from wild type, requiring about twice as much DGJ and about 
10-fold more galactose to achieve 50% protection from digestion. M51I is a destabilized 
mutant, requiring a higher concentration of pharmacological chaperone to stabilize the 
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structure. Once bound to the active site of M51I, DGJ acts as a pharmacological 
chaperone and stabilizes the mutant protein. In both E398K and M51I there is a 
significant difference in the concentrations of DGJ and galactose required to show a 
chaperoning effect, suggesting that the N5-D170 ionic interaction described in the 
previous chapter is relevant in the mutants also. Third, the L166V mutant is a very 
unstable protein that expresses at a very low level. With this mutant, the pharmacological 
chaperone effect of galactose is not detectable, and only the tight binding 
pharmacological chaperone DGJ is capable of improving protein expression. 
Additionally, non-specific chaperones like glucose, DMSO, ficoll, and dextran show no 
chaperoning effect on the destabilized L166V mutant α-GAL.  
Pharmacological chaperone therapy was originally proposed only for patients 
with a mutation that causes a mild form of Fabry disease (Asano, Ishii et al. 2000; Fan 
2003). The subset of mutations that cause a mild form of Fabry disease is very limited, 
making up less than 1% of the total number of mutations found in Fabry disease patients. 
A small number of female carriers who present a mild form of Fabry disease might also 
be candidates for pharmacological chaperone therapy. However, a number of recent in 
vivo and in vitro experiments (including those in this chapter) on the effect of DGJ on 
mutant α-GAL proteins show many of the mutants have a dose-dependent response to 
DGJ (Spada, Pagliardini et al. 2006; Ishii, Chang et al. 2007; Shimatori 2007; Shin 2007; 
Shin 2008; Benjamin 2009). Overall approximately 112 mutants have been assayed for 
their response to DGJ, but about 60% of the reported Fabry disease-causing mutations 
have not been measured for their response to DGJ. Additionally, new Fabry disease-
causing mutations are reported regularly.  
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We developed a set of rules for predicting the response of all Fabry-disease 
causing mutations to DGJ. Examining the considerable experimental data available in the 
literature in light of the detailed structural knowledge of α-GAL, the set of rules (listed in 
Table 4.2) will predict whether a particular mutant α-GAL will respond to DGJ 
chaperoning. The response of a mutant protein to DGJ depends upon 1) the kind of amino 
acid substitution; 2) the location of the mutation; and 3) the amount of structure disrupted 
by the mutation. Table 4.2 lists the mutations or types of mutations that we predict will 
respond favorably to DGJ, leading to an increase in α-GAL activity upon addition of 
DGJ. Mutations that respond favorably to the pharmacological chaperone are not 
restricted to either the N- or C-terminal domains. We predict that pharmacological 
chaperone therapy will be effective on a large fraction of Fabry disease patients. 
Similarly we have also predicted which mutations will be unlikely to respond to 
pharmacological chaperone. Most of these mutations are in to the N-terminal domain 
except for some mutations that fall under the h, i and j category mentioned in Table 4.2. 
Figure 4.6 a-d; g-j show some mutations predicted to be responsive and non-responsive to 
DGJ respectively and a few exceptions to the rules. Figure 4.7a and b plots the 109 
residues where in vivo and in vitro experimental data shows to be responsive (blue) and 
non-responsive (red) to DGJ respectively. Figure 4.7c and f maps the mutations that are 
predicted to be responsive and non-responsive to DGJ. We have divided the predictions 
into those with high confidence and those with lower confidence, based upon how strictly 
they adhere to the rules in Table 4.2. The lower confidence predictions are based on 
sequence alignment as well as the rules in Table 4.2. A complete inventory of the Fabry 
disease-causing mutations, their location, and the predicted DGJ response is listed in 
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Table 4.2 Predictive rules on the response of FD mutations to DGJ 
 
Responsive to DGJ  
a. any conservative mutations i.e. in general polar to polar mutations and  
non-polar to non-polar mutation– Figure 4.6 a1 and a2 
b. any residues mutated to Gly (X  Gly) – Figure 4.6 b 
c. Pro mutated to any residue (Pro  X) – Figure 4.6 c 
d. residues that are exposed with surface with side chain accessible area greater  
than 2Å– Figure 4.6 d 
Non-responsive to DGJ 
e. any of the 13 active site residues that are critical to substrate binding 
f. either of the two catalytic residue responsible for the cleavage of the  
glycosidic bond 
g. any residues around the active site that interact and stabilize the 15 active site  
residues – Figure 4.6 g 
h. all Cys involved in disulfide bond - Figure 4.6 h 
i. any residues that is mutated to Pro except residues that are exposed or  
located at the loop (X  Pro/exposed and loop) – Figure 4.6 i1 and i2 
j. all Gly residue that is mutated to any residue except Val and Ala provided  
there is space for the additional side chain  (Gly  X/A and V) –  
Figure 4.6 j1 and j2 
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A. Responsive to DGJ 
                      
 
 
Figure 4.6A Responsive mutants to DGJ therapy 
 
Responsive mutants: a1 and a2 shows conserved amino acid substitution; b and c shows 
any amino acid mutated to glycine and proline respectively; and d shows a mutations 
that is exposed to the solvent. 
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B. Non-responsive to DGJ 
                 
 
 
Figure 4.6B Non-responsive mutants to DGJ therapy 
 
Non-responsive mutants: g shows a mutation near the active site, a residue that makes 
contact with an active site residue, also shown in sphere is the galactose bound at the 
active site; h shows a cysteine mutation that is involved in a disulfide bonding; i1 and 
12 shows two different leucine mutated to proline where one is buried (1) and the other 
one is expose (2) and the two mutations has different response. The buried one (1) is 
categorized as non-reponsive however when the mutation to proline is located at the 
exposed region, it is considered exception to the rule and is a responsive mutation to 
DGJ; j1 and j2 shows the same buried glycine residue mutated to either a bigger residue 
arginine which is non-responsive, however if the mutation is to a small residue like 
alanine, this becomes a responsive mutation to DGJ. 
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Figure 4.7   Map of mutants that respond and not respond to DGJ therapy 
 
(a) and (b) Experimental data of mutants that are responsive (blue) and non-
responsive (red) to DGJ respectively; (c) and (d) Mutants predicted to be responsive 
(purple) and non-responsive (magenta) to DGJ using the rules formulated above; (e) 
and (f) Mutants predicted to be responsive (cyan) and non-responsive (orange) to DGJ 
using structural analysis. 
 
a. b. 
c. d. 
 
e. f. 
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Table 4.4. Combining both high and low confidence predictions as well as known 
experimental data, this make up around 60% of all the single point missense mutations 
reported to cause Fabry disease could be stabilized by DGJ. For the aprroximately 166 
missense Fabry-disease causing mutations with no experimental information about DGJ 
chaperoning, we have predicted the response of these mutants to DGJ chaperoning. With 
the prediction of which mutations in α-GAL are likely to respond to DGJ treatment, it 
will be easier to direct pharmacological chaperone therapy for Fabry disease patients 
depending on their individual DNA sequence. Additionally, the rules we have developed 
can be applied to newly discovered mutations in α-GAL in yet unidentified Fabry disease 
patients. 
In this chapter it has been established that: a) like the wild type α-GAL, mutant α-
GAL is stabilized by DGJ; b) like the wild-type enzyme as well, there is a difference in 
the concentration of DGJ and galactose to see chaperoning effect; c) different mutants 
have different dose responses to DGJ and galactose; and d) tight binding to the active site 
make for effective chaperoning of mutant α-GAL. Both wild type and mutant α-GAL 
enzymes are capable of pharmacological chaperoning by DGJ. Using the existing 
experimental results on the response of α-GAL mutants to DGJ, we developed a list of 
rules to predict the DGJ response of all known Fabry disease mutants. Our research 
shows that a large number of mutant α-GAL molecules are likely to respond to DGJ 
treatment. The database will aid in the clinical management of patients with Fabry 
disease. 
 
 
  102 
4.5.   Methods   
4.5.1. Determination of assessable surface area (ASA) of amino acid side chain 
 The ASA of each amino acid side chain in human α-galactosidase A (PDB code: 
3HG5) was calculated using AREAIMOL from CCP4i program package. 
 
4.5.2.   Multiple sequence alignment and structural alignment 
The α-GAL multiple sequence alignment (MSA) was made from a PSI-BLAST 
(Altschul, Madden et al. 1997) query for sequences similar to human α-galactosidase A 
(E < 0.005). ClustalW was used to align the sequences (Thompson 1994). Four α-
galactosidase structures (1UAS, rice; 3A5V, Mortierella vinacea; 1T0O, Trichoderma 
reesei; 1SZN, Hypocerea jecorina) deposited at the protein databank (RCSB Protein Data 
Bank) were structurally aligned in PyMOL (DeLano 2008). The structural alignments 
superimpose with RMS deviation between 0.7 – 1 Å.  
  
4.5.3.   Mutant protein expression and purification 
 The α-galactosidase A mutants were obtained from site directed mutagenesis of 
wild type human α-galactosidase A gene (GLA) in pIB/V5-His-TOPO® vector 
(Invitrogen), pIB/V5-His-TOPO-α-GAL. α-GAL mutations were incorporated into the 
pIB/V5-His-TOPO-α-GAL construct with PhusionTM site-directed mutagensis kit 
(Finnzymes) according to the manufacturer’s specifications. Table 4.3 lists the primers 
(synthesized by IDT Inc., Coralville IA) used to generate the mutations. Mutations were 
confirmed by sequencing the isolated and purified DNA (Genewiz Inc., USA).  
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Table 4.3 Table of primers of α-GAL mutants 
 
F: 5’-[PO4]GGAAGCTAGGGTTCTATAAATGGACTTCAAGG-3’ 1. E398K 
R: 5’-[PO4]TTTTCACAGGGAGGAGCTGTGTGATGAAG-3’ 
F: 5’-[PO4]CTGGGAGCGCTTCATCTGCAACCTTG-3’ 2. M51I 
R: 5’-[PO4]TGCAGCCAGCCCATGGTAGGCGTC-3’ 
F: 5’-[PO4]CTGGGGAGTAGATGTGCTAAAATTTGATGG-3’ 3. L166V 
R: 5’-[PO4]TCAGCAAAGGTCTGGGCATCAATGTC-3’ 
* bold letters highlights the mutation 
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  Mutant DNA was transfected into Tn5 cells using Hilymax (Dojindo Labs) 
transfection solution. Transfection was performed following the manufacturer’s 
specifications. α-GAL mutant M51I and E398K expression and Ni–affinity tag 
purification is as described at Chapter 3. E398K mutants were further purified using the 
Source TM 15S column (GE Healthcare, Cat#: 17-0944-10).  Ni fractions containing the 
protein were pooled and buffer exchanged to 20 mM citrate buffer, pH 5.0. α-GAL 
mutant protein was eluted with 20 mM citrate buffer, 1.0 M NaCl, pH 5.0 and was stored 
at ~1.0 mg/mL.  
 
4.5.4.   α-GAL mutant activity assay and kinetics 
The specific activity and kinetic parameters of α-GAL mutants were assayed by 
monitoring the hydrolysis of para-nitrophenyl-α-galactopyranoside (pNP-α-gal; Sigma 
Aldrich, St. Loius Mo, N0877) at 400 nm. All assays were carried out at 37°C. The 
specific activity of purified α-GAL mutants E398K and M51I were initiated by the 
addition of 0.05 mg/mL enzyme to 5 mM pNP-α-gal substrate in 100 mM 
citrate/phosphate buffer pH 4.5.  After incubation for 10 min, the reaction was quenched 
by the addition of 250 µL of borate buffer, pH 9.8. Absorbance at 400 nm was measured 
using a microplate reader at room temperature. All α-GAL samples were corrected by 
subtracting the blank and the final absorbance readings were multiplied by the dilution 
factor.  
The kinetic parameters of the enzymatic reaction were determined by monitoring 
the amount of product cleaved by the α-GAL mutant enzyme over time at varying 
substrate concentrations. The reaction mixture containing 10 µL of α-GAL mutant (0.01 
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mg/mL) and 140 µL of increasing concentration of substrate (0-50mM pNP-α-gal) was 
incubated at 37°C. Aliquots were taken every minute for 10-15 minutes and quenched by 
adding 10 µL of the reaction mixture to 290 µL of borate buffer, pH 9.8. The amount of 
para-nitrophenolate cleaved at each substrate concentration was plotted against time 
yielding initial velocities (V0) for each substrate concentration.  Vmax and Km values were 
calculated as described in Equation 3.1.  
 
4.5.5.   Tm measurement (CD) of α-GAL mutants 
CD wavelength scan and thermal melts were carried out on a Jasco J715 
spectropolarimeter equipped with a PTC-348WI temperature controller. The CD signal at 
222 nm of each α-GAL mutant (1.2 µM in 10 mM phospate buffer pH 6.5) was 
monitored at a temperature speed of 1°C/min from 25-90°C as previously described in 
Chapter 3. 
 
4.5.6. Western blot analysis of α-GAL mutant expression in vivo  
Tn5 insect stable cell line transfected with pIB/V5-His-TOPO-α-GAL-L166V 
mutant DNA were selected in 100 µg/mL blastocidin.  After two weeks of selection, the 
cells are grown in fresh SFx media or SFx media with DGJ (10 µM and 100 µM; Toronto 
Research Chemicals Inc., D236500), galactose (10 mM and 100 mM; Sigma Aldrich, ST. 
Louis MO; G5388), D-glucose (100 mM; Fisher Scientific, Rochester, NY; 50-99-7), L-
proline (100 mM; Sigma Aldrich, ST. Louis MO; P0380), DMSO (10%; Sigma Aldrich, 
ST. Louis MO), ficoll (5 mg/mL; Sigma Aldrich, ST. Louis MO; F9378) or dextran 
(5mg/mL; Fluka; 313-90). Secreted mutant protein was separated on 10% SDS 
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polyacrylamide gels by mixing supernatant samples with 6x SDS loading buffer with β-
mercaptoethanol and boiling for 10 minutes. SDS samples were transferred to a 
nitrocellulose membrane (Millipore). The membrane is incubated with a polyclonal rabbit 
anti-His primary antibody (Genscipt) and detected with alkaline phosphatase labeled anti-
rabbit secondary IgG (Rockland, 611-1502). α-GAL protein runs between 43 and 56 kDa. 
 
4.5.7.  In vivo activity analysis of α-GAL mutant expression 
In parallel, activity of the supernatant with the different chaperones of the low 
expressing L166V mutant was monitored using pNP-α-gal substrate and supernatant 
incubated for 5-6 hours. The reaction was quenched by the addition of 250 µL of borate 
buffer, pH 9.8 and the absorbance is detected at 400 nm. Relative activity was calculated 
from the equation below: 
Relative Activity = (A400nm sample – A400nm blank) x df x VT   (4.1) 
                            ε x t x Vsample 
 
where, df  is the dilution factor, VT   is the total assay volume in milliliters, ξ  is the 
milimolar extinction coefficient of p-nitrophenolate at 400 nm (18 mM-1cm-1), t  is the 
total time of the assay in minutes, and Vsample  is the volume of enzyme 
sample/supernatant in milliliters.    
 The chromogenic substrate 5-bromo-4-chloro-3-indoyl-D-α-galactosidase (X-α-
gal; LabScientific, Inc., 740-90-6) was used to detect small amounts of α-GAL activity 
present in the supernatant using the activity dot blot assay set-up. A stock solution of X-
α-gal dissolved in N,N-dimethyly formamide (DMF, Fisher Scientific, D131-1) solvent 
was diluted in 40 mM sodium acetate. The supernatant containing the protein was passed 
through the nitrocellulose through gravity flow. The nitrocellulose was then incubated 
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with X-α-gal at 37°C overnight. In the X-α-gal assay, blue color indicates the presence of 
α-GAL activity 
 
4.5.8.   Pulse proteolysis of α-GAL mutant 
Pulse proteolysis with thermolysin was performed as previously described in 
Chapter 3 (Park and Marqusee 2005). Thermolysin (0.13 mg/mL from Bacillus 
thermoproteolyticus; Sigma T7902) in 20 mM Tris•HCl buffer (pH 8.3) containing 10 
mM CaCl2, and 50 mM NaCl was used to digest α-GAL mutant (0.02-0.05 mg/mL) at 
37°C. To monitor the stability of α-GAL mutants in the absence or presence of DGJ and 
galactose at pH 6.5, 10-fold of the protein was first incubated with or without DGJ (or 
galactose) in 10 mM phosphate buffer (pH 6.5) for 2-4 hours. The mutant-small molecule 
solution was then diluted in 10 mM phosphate-8M urea solution to 1x concentration and 
incubated at 20°C overnight. The digestion was initiated by the addition of approximately 
0.13 mg/mL thermolysin to the 15 µL solution reaction. After 5 min, the reaction was 
quenched by the addition of 50 mM EDTA (pH 8.0) to a final concentration of 12.5 mM.  
 After quenching, samples were mixed with 6x SDS loading buffer with β-
mercaptoethanol , boiled immediately for 10 min to avoid further digestion. Samples 
were separated on a 10% SDS/PAGE gel and stained in GelCode Blue (Pierce 24592). 
The amount of undigested protein in the presence of DGJ or galactose at pH 6.5 is a 
measure of the effect to the proper conformation of the protein when the small molecule 
binds to α-GAL. The data was processed as described in Chapter 3.
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Table 4.4 Fabry disease mutations 
  
 Response to DGJ: 
Responsive (Res) versus Non-
responsive (NR) 
Prediction 
 
Wild type 
protein 
sequence 
 
Fabry 
disease 
mut’n 
Side 
chain 
accessible 
surface 
area (Å2) 
 
 
 
Mut’n 
category 
 
Expt’l 
data* 
High 
confidence 
Low 
confidence 
 
 
 
 
Reason 
 
 
 
 
Reference 
1 M I  Other     (Blanch, Meaney et al. 1996) 
  T        (Eng, Ashley et al. 1997) 
  R        (Shabbeer, Yasuda et al. 
2002) 
14 L P   Other     (Tse, Chan et al. 2003) 
16 L P   Other     (Garzuly, Marodi et al. 2005) 
19 L P   Other     (Teragaki 2004) 
20 A (P)   Other     (Nakao, Takenaka et al. 
1995) 
31 A V   Other     (Eng, Ashley et al. 1997) 
32 L P  5.7 Other     (Madsen, Hasholt et al. 1995) 
34 N S  1.5 Buried Res     (Eng, Resnick-Silverman et 
al. 1993) 
35 G R  8.3 Exposed  Res  exposed (Davies, Christomanou et al. 
1994) 
40 P S  0.0 Buried Res    (Koide, Ishiura et al. 1990) 
  L     Res  Pro  X in a loop (Ashton-Prolla, Tong et al. 
2000) 
41 T I  0.6 Buried Res    (Benjamin 2009) 
42 M V  0.8 Buried Res    (Davies, Eng et al. 1996) 
  T      Res Small SC (Shabbeer, Yasuda et al. 
2002) 
  L     Res  Conserved mutation (Rosenthal, Lien et al. 2004) 
43 G D  0.0 Buried  NR  Gly  X (Iga 2001) 
              *Table 4.4 is continued onto the next page 
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  R     NR  Gly  X (Germain, Shabbeer et al. 
2002) 
  V     Res  Gly  V/A (Shabbeer, Yasuda et al. 
2002) 
44 W X  0.0 Other     (Sakuraba, Oshima et al. 
1990) 
46 H R  0.0 Buried NR    (Eng, Ashley et al. 1997) 
  Y    NR    (Blaydon, Hill et al. 2001) 
47 W L  2.6 Active  NR  Active site (AS) (Cooper 2000) 
  G     NR  Active site (AS) (Blaydon, Hill et al. 2001) 
48 E K  0.0 Other  NR  Contact with AS residues (Rodriquez-Mari 2003) 
49 R L  2.0  Exposed Res    (Davies, Christomanou et al. 
1994) 
  S     Res  exposed (Davies, Eng et al. 1996) 
  P     Res  X  Pro/exposed and loop (Blaydon, Hill et al. 2001) 
  C   Res    (Benjamin 2009) 
  G     Res  X  Gly, exposed (Germain, Shabbeer et al. 
2002) 
50 F C  0.7 Buried NR    (Shabbeer, Yasuda et al. 
2002) 
51 M K  10.1 Active Res    (Ashley, Shabbeer et al. 
2001) 
  I    Res    (Spada, Pagliardini et al. 
2006) 
52 C S  12.0 Other  NR  Disulfide bond (Eng, Niehaus et al. 1994) 
  R     NR  Disulfide bond (Blanch, Meaney et al. 1996) 
  X        (Topaloglu, Ashley et al. 
1999) 
55 D V 15.2 Exposed Res    (Benjamin 2009) 
56 C G  13.2 Exposed  NR  Disulfide bond (Eng, Resnick-Silverman et 
al. 1993) 
  F     NR  Disulfide bond (Eng, Niehaus et al. 1994) 
  Y     NR  Disulfide bond (Davies, Eng et al. 1996) 
             *Table 4.4 is continued onto the next page 
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  X        (Shabbeer, Robinson et al. 
2005) 
59 E K  7.6 Other Res    (Eng, Niehaus et al. 1994) 
63 C Y  0.7 Other  NR  Disulfide bond (Schafer, Baron et al. 2005) 
65 S T  3.5 Exposed  Res  Conserved mutation, 
exposed 
(Chen 1998) 
66 E Q  3.3 Exposed Res/ 
NR 
   (Ishii, Sakuraba et al. 1992) 
  K     Res  Conserved mutation (Schafer, Baron et al. 2005) 
  G     Res  X  Gly (Spada, Pagliardini et al. 
2006) 
  Double 
mut’n 
R112C 
  NR    (Shimatori 2007) 
68 L F  0.2 Buried  Res  Conserved mutation (Shabbeer, Yasuda et al. 
2002) 
72 M V  0.0 Buried Res    (Okumiya, Kawamura et al. 
1998) 
  R      NR Near R301, clash (Slee, van Boven et al. 2000) 
  I    Res   Conserved mutation (Germain, Shabbeer et al. 
2002) 
73 A V  0.0 Buried Res    (Spada, Pagliardini et al. 
2006) 
76 M T  Buried Res    (Shimatori 2007) 
78 S X  21.7 Other     (Guffon, Froissart et al. 
1998) 
79 E X 13.2 Other     (Takata, Okumiya et al. 
1997) 
81 W X 0.1 Other     (Eng, Smith et al. 1994) 
  S  Buried   Res W  S (Rodriquez-Mari 2003) 
85 G D 7.3 Exposed  NR  Gly  X (Madsen, Hasholt et al. 1995) 
86 Y C 0.0 Other   Res Conserved mutation,        
W  C 
(Eng, Ashley et al. 1997) 
  X       (Lee, Kim et al. 2000) 
             *Table 4.4 is continued onto the next page  
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88 Y D 3.8 Exposed  Res/ NR  Partially exposed (Cooper 2000) 
89 L R 0.0 Buried NR    R(Eng, Niehaus et al. 1994) 
  P    NR  X  Pro (Eng, Ashley et al. 1997) 
91 I (T) 0.0 Buried Res    (Eng, Ashley et al. 1997) 
92 D H 0.0 Active  NR  Active site (Davies, Eng et al. 1996) 
  Y   NR    (Eng, Ashley et al. 1997) 
  N   NR    (Ashley, Shabbeer et al. 
2001) 
93 D G 0.0 Active  NR  Active site (Davies, Eng et al. 1996) 
  N    NR  Active site (Shabbeer, Robinson et al. 
2005) 
  V   NR    (Shimatori 2007) 
94 C Y 0.0 Other  NR  Disulfide bond (Eng, Ashley et al. 1997) 
  S   NR    (Blaydon, Hill et al. 2001) 
95 W S 0.0 Buried Res   W  S (Ashton-Prolla, Tong et al. 
2000) 
  X  Other     (Rodriquez-Mari 2003) 
97 A V 4.7 Exposed  Res  Conserved mutation (Eng, Ashley et al. 1997) 
  P    Res  X  Pro/ exposed and 
loop 
(Kimura 2002) 
99 Q X 27.0 Other     (Eng, Niehaus et al. 1994) 
100 R K 2.5 Other Res    (Eng, Niehaus et al. 1994) 
  T   NR    (Eng, Ashley et al. 1997) 
103 E Q 18.9 Exposed  Res  Conserved mutations, 
exposed 
(Schafer, Baron et al. 2005) 
107 Q X 12.9 Other     (Davies, Eng et al. 1996) 
112 R C 2.2 p. Exposed Res    (Ishii, Sakuraba et al. 1992) 
  (H)       (Eng, Smith et al. 1994) 
  S    Res  Conserved mutations (Shabbeer, Robinson et al. 
2005) 
113 F (L) 0.0 Buried Res    (Eng, Ashley et al. 1997) 
  S   Res    (Blaydon, Hill et al. 2001) 
118 R C 13.3 Exposed Res    (Spada, Pagliardini et al. 
2006) 
            *Table 4.4 is continued onto the next page 
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119 Q  X 17.6 Other     (Davies, Eng et al. 1996) 
120 L P 0.5 Buried NR   Double mutation A121T (Benjamin 2009) 
121 A P 0.1 Buried  NR  X  Pro (Lorenz, Hauser et al. 2003) 
128 G E 8.2 Exposed NR    (Blanch, Meaney et al. 1996) 
129 L P 0.0 Buried  NR  X  Pro (Whybra, Kampmann et al. 
2001) 
131 L P 0.0 Buried NR    (Eng, Smith et al. 1994) 
132 G R 0.0 Buried NR    (Shabbeer, Yasuda et al. 
2002) 
134 Y S 0.0 Active  NR  Active site (AS) (Eng, Ashley et al. 1997) 
  X       (Ashton-Prolla, Tong et al. 
2000) 
135 A V 0.1 Buried  Res  Conserved mutations (Shabbeer, Robinson et al. 
2005) 
136 D H 0.0 Buried   NR Interact with AS (Ashley, Shabbeer et al. 
2001) 
138 G R 0.0 Buried  NR  Gly  X (Eng, Ashley et al. 1997) 
  E   NR    (Germain 2002) 
141 T I 0.0 Active  NR  Active site (AS) (Shabbeer, Yasuda et al. 
2002) 
142 C Y 3.9 Active  NR  Active site (AS) (Okumiya, Ishii et al. 1995) 
  R   NR    (Topaloglu, Ashley et al. 
1999) 
  X       (Topaloglu, Ashley et al. 
1999) 
  W    NR  Active site (AS) (Schafer, Baron et al. 2005) 
143 A P 5.2 Exposed NR    (Eng, Smith et al. 1994) 
  T   Res    (Eng, Ashley et al. 1997) 
144 G V 7.9 Other Res    (Eng, Smith et al. 1994) 
146 P (S) 3.0 Other Res    (Ploos van Amstel 1994) 
147 G R 1.3 Buried  NR  Gly  X, near AS (Schafer, Baron et al. 2005) 
148 S R 0.0 Buried NR    (Eng, Ashley et al. 1997) 
  N   Res    (Ashton-Prolla, Tong et al. 
2000) 
             *Table 4.4 is continued onto the next page 
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151 Y  X 10.8 Other     (Shabbeer, Robinson et al. 
2005) 
152 Y X 1.7 Other     (Shabbeer, Yasuda et al. 
2002) 
155 D H 0.0 Buried   NR Clash with HB (Dobrovolny, Dvorakova et 
al. 2005) 
156 A T 0.0 Buried   Res Same size as Val (Eng, Smith et al. 1994) 
  V   Res    (Okumiya, Ishii et al. 1995) 
157 Q X 15.0 Exposed     (Eng, Smith et al. 1994) 
162 W R 4.2 p. Exposed NR    (Eng, Resnick-Silverman et 
al. 1993) 
  C    Res  Partially exposed (Germain, Biasotto et al. 
1996) 
  X       (Rosenberg 2000) 
163 G V 1.0 Other  Res  Gly  Val (Eng, Ashley et al. 1997) 
165 D V 2.1 p. Exposed  Res/NR  Partially exposed (Davies, Christomanou et al. 
1994) 
166 L V 1.0 Buried Res    (Okumiya, Ishii et al. 1995) 
167 L P 0.1 Buried  NR  X  Pro, contact with AS (Morrone, Cavicchi et al. 
2003) 
168 K R 1.9 Active  NR  Active site (Shabbeer, Yasuda et al. 
2002) 
169 F S 0.0 Buried   Res F  S (Cooper 2000) 
170 D V 0.0 Active Res ??    (Eng, Ashley et al. 1997) 
  H    NR  Active site (AS) (Rodriquez-Mari 2003) 
171 G D 0.0 Buried NR    (Shabbeer, Robinson et al. 
2005) 
  R    NR  Gly  X (Dobrovolny, Dvorakova et 
al. 2005) 
172 C Y 11.7 Active Res??    (Eng, Smith et al. 1994) 
  R    NR  Active site (AS) (Ashton-Prolla, Tong et al. 
2000) 
  F    NR  Active site (AS) (Ashley, Shabbeer et al. 
2001) 
             *Table 4.4 is continued onto the next page 
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  G   NR    (Yasuda, Shabbeer et al. 
2003) 
  W    NR  Active site (AS) (Schafer, Baron et al. 2005) 
177 L X 12.0 Other     (Shabbeer, Robinson et al. 
2005) 
183 G D 0.3 Buried Res    (Topaloglu, Ashley et al. 
1999) 
  S   NR    (Shabbeer, Yasuda et al. 
2002) 
187 M V 0.0 Buried  Res  Conserved mutations (Ashton-Prolla, Tong et al. 
2000) 
191 L P 1.3 Buried  NR  X  Pro (Cooper 2000) 
  Q     NR No space for side chain 
(SC) 
(Ashley, Shabbeer et al. 
2001) 
194 T I 0.4 Buried   Res Accommodate SC (Schafer, Baron et al. 2005) 
199 V M 0.3 Buried  Res  Conserved mutations (Shabbeer, Yasuda et al. 
2002) 
201 S F 2.4 p. Exposed  NR  Interact with AS (Shabbeer, Robinson et al. 
2005) 
202 C W 0.0 Other  NR  Disulfide bond (Ploos van Amstel 1994) 
  Y   NR    (Eng, Ashley et al. 1997) 
204 W X 0.1 Other     (Ashton-Prolla, Tong et al. 
2000) 
205 P T 0.0 Buried Res    (Blanch, Meaney et al. 1996) 
  R   Res    (Shabbeer, Yasuda et al. 
2002) 
  L    Res  Pro  X (Schafer, Baron et al. 2005) 
207 Y S 5.5 Active Res    (Shabbeer, Yasuda et al. 
2002) 
  C   Res    (Benjamin 2009) 
215 N (S) 12.0 Exposed Res    (Davies, Winchester et al. 
1993) 
216 Y D 1.1 Buried   Res Accommodate SC, 
partially exposed,  
(Eng, Ashley et al. 1997) 
             *Table 4.4 is continued onto the next page 
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220 R X 7.0 Other     (Meaney, Blanch et al. 1994) 
221 Q X 17.1 Other     (Shabbeer, Yasuda et al. 
2002) 
222 Y X 4.7 Other     (Yang, Lai et al. 2003) 
223 C G 0.0 Other  NR  Disulfide bond (Germain and Poenaru 1999) 
  R    NR  Disulfide bond (Shabbeer, Yasuda et al. 
2002) 
  Y    NR  Disulfide bond (Shabbeer, Yasuda et al. 
2002) 
224 N D 0.0 Other   Res Accommodate SC, 
maintain H bonding 
(Guffon, Froissart et al. 
1998) 
  S    Res  Conserved mutation (Ashton-Prolla, Tong et al. 
2000) 
225 H R 0.0 Other NR    (Politei, Pagano et al. 2005) 
226 W X 0.0 Other     (Davies, Christomanou et al. 
1994) 
  R  Buried NR    (Ashton-Prolla, Tong et al. 
2000) 
  C     Res W  C (Rodriquez-Mari 2003) 
227 R Q 0.2 Active NR    (Eng, Resnick-Silverman et 
al. 1993) 
  X       (Davies, Winchester et al. 
1993) 
230 A T 45.4 Active  NR  Active site (AS) (Ashton-Prolla, Tong et al. 
2000) 
231 D N 9.2 Active NR    (Redonnet-Vernhet, Ploos 
van Amstel et al. 1996) 
234 D Y 0.1 Other   NR Clash to other residues (Shabbeer, Yasuda et al. 
2002) 
  E    Res  Conserved mutation (Shabbeer, Robinson et al. 
2005) 
235 S C 2.7 p. Exposed Res    (Topaloglu, Ashley et al. 
1999) 
  F   Res    (Shimatori 2007) 
             *Table 4.4 is continued onto the next page 
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236 W C 1.6 Other   Res W  C (Davies, Eng et al. 1996) 
  L    Res  Conserved mutation (Topaloglu, Ashley et al. 
1999) 
  X       (Germain, Shabbeer et al. 
2002) 
  R   NR    (Benjamin 2009) 
239 I T 0.0 Buried   NR buried (Kotanko, Kramar et al. 
2004) 
242 I N 0.3 Buried  NR  Near AS (Takata, Okumiya et al. 
1997) 
243 L F 0.0 Buried  Res  Conserved mutation (Germain, Shabbeer et al. 
2002) 
244 D N 12.4 Exposed Res    (Eng, Smith et al. 1994) 
  H     Res/ NR Exposed but could clash 
with domain 2 HB 
(Topaloglu, Ashley et al. 
1999) 
245 W X 3.6 Other     (Germain, Shabbeer et al. 
2002) 
247 S P 2.8 p. Exposed  NR  X  Pro (Ashley, Shabbeer et al. 
2001) 
  C    Res  Conserved mutation (Germain, Shabbeer et al. 
2002) 
250 Q X 27.3 Other     (Ashley, Shabbeer et al. 
2001) 
257 A P 0.0 Buried  NR  X  Pro (Cooper 2000) 
258 G R 1.5 Buried  NR  Gly  X (Blaydon, Hill et al. 2001) 
  V   Res    (Shimatori 2007) 
259 P L 10.5 Exposed  Res  Pro  X (Topaloglu, Ashley et al. 
1999) 
  R   Res    (Ashley, Shabbeer et al. 
2001) 
260 G A 0.0 Buried Res    (Okumiya, Ishii et al. 1995) 
261 G D 0.0 Buried NR    (Shin 2008) 
262 W C 0.0 Buried   Res/NR W  C but packs against 
P259 
(Schafer, Baron et al. 2005) 
             *Table 4.4 is continued onto the next page 
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263 N S 1.3 Buried Res    (Benjamin 2009) 
264 D V 2.2 Active NR    (Eng, Resnick-Silverman et 
al. 1993) 
  Y   NR    (Shabbeer, Robinson et al. 
2005) 
265 P R 1.8 Buried   Res/NR Pro  X but near AS (Germain, Biasotto et al. 
1996) 
  L     Res/NR Pro  X but near AS (Schafer, Baron et al. 2005) 
266 D V 0.8 Active NR    (Eng, Resnick-Silverman et 
al. 1993) 
  H    NR  Active site (AS) (Ashton-Prolla, Tong et al. 
2000) 
  N    NR  Active site (AS) (Lee, Kim et al. 2000) 
  E    NR  Active site (AS) (Germain, Shabbeer et al. 
2002) 
267 M I 0.3 Active  NR  Active site (AS) (Topaloglu, Ashley et al. 
1999) 
268 L S 0.0 Buried   Res Accommodate SC (Schafer, Baron et al. 2005) 
269 V A 0.0 Buried  Res  Conserved mutation (Davies, Winchester et al. 
1993) 
270 I T 0.0 Buried   Res Accommodate SC (Schafer, Baron et al. 2005) 
271 G C 3.3 p. Exposed NR    (Shabbeer, Yasuda et al. 
2002) 
  V   NR    (Benjamin 2009) 
272 N K 0.0 Other NR    (Eng, Niehaus et al. 1994) 
276 S N 0.9 Other  Res  Conserved mutation (Schafer, Baron et al. 2005) 
  G   Res    (Shabbeer, Robinson et al. 
2005) 
277 W X 6.6 Other     (Topaloglu, Ashley et al. 
1999) 
279 Q (E) 0.2 Other Res    (Ishii, Sakuraba et al. 1992) 
  H     Res Stacks against W232 (Blaydon, Hill et al. 2001) 
  R     NR Clash with W232 (Rodriquez-Mari 2003) 
280 Q H 5.0 Exposed  Res  Exposed (Blaydon, Hill et al. 2001) 
             *Table 4.4 is continued onto the next page 
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  K    Res  Exposed (Dobrovolny, Dvorakova et 
al. 2005) 
282 T N 0.0 Other  Res  Conserved mutation (Ashley, Shabbeer et al. 
2001) 
  A   Res    (Shimatori 2007) 
284 M T 0.3 Buried   Res Accommodate SC (Blanch, Meaney et al. 1996) 
285 A P 0.0 Buried  NR  X  Pro (Shabbeer, Robinson et al. 
2005) 
287 W X 0.0 Other     (Davies, Winchester et al. 
1993) 
  G  Buried  Res  X  Gly (Davies, Eng et al. 1996) 
  C   Res/ 
NR 
   (Ashton-Prolla, Tong et al. 
2000) 
288 A D 0.9 Buried   NR Clash with other AA at 
hydrophobic core 
(Eng, Smith et al. 1994) 
  P   Res    (Shabbeer, Yasuda et al. 
2002) 
289 I F 0.0 Buried Res    (Topaloglu, Ashley et al. 
1999) 
293 P S 0.0 Buried  Res  Pro  X (Cooper 2000) 
  A    Res  Pro  X (Shabbeer, Yasuda et al. 
2002) 
294 L X 0.4 Other     (Blaydon, Hill et al. 2001) 
295 F C  Buried Res    (Shin 2008) 
296 M (V) 0.0 Buried Res    (von Scheidt W. 1991) 
  (I)   Res    (Nakao, Takenaka et al. 
1995) 
297 S F 0.0 Buried   NR No room for F (Eng, Resnick-Silverman et 
al. 1993) 
  C    Res  Conserved mutation (Germain, Shabbeer et al. 
2002) 
298 N K 0.0 Buried   NR Clash with other residues 
at the hydrophobic core 
(Blanch, Meaney et al. 1996) 
             *Table 4.4 is continued onto the next page 
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  H     NR Clash with other residues 
at the hydrophobic core 
(Davies, Eng et al. 1996) 
  S    Res  Conserved mutation (Eng, Ashley et al. 1997) 
300 L H 0.0 Buried  Res  Conserved mutation (Schafer, Baron et al. 2005) 
  F    Res  Conserved mutation (Shabbeer, Robinson et al. 
2005) 
  P   Res    (Benjamin 2009) 
301 R (Q) 4.1 p. Exposed Res    (Sakuraba, Oshima et al. 
1990) 
  X       (Eng, Smith et al. 1994) 
  P    Res  X  Pro at loop (Ashley, Shabbeer et al. 
2001) 
  G    Res  X  Gly G(Lai 2001) 
303 I N 1.7 Buried   Res Accommodate SC, loop (Shabbeer, Yasuda et al. 
2002) 
308 K N  Exposed Res    (Shimatori 2007) 
310 L F 0.2 Buried  Res  Conserved mutation (Calado 2004) 
312 Q R  Exposed Res    (Shimatori 2007) 
313 D Y 7.3 p. Buried NR    (Eng, Resnick-Silverman et 
al. 1993) 
316 V E 0.1 Buried Res    (Schafer, Baron et al. 2005) 
317 I T 2.4 Buried   Res Accommodate SC (Shabbeer, Yasuda et al. 
2002) 
  N     Res Accommodate SC (Schafer, Baron et al. 2005) 
320 N K 0.2 Other   Res/ NR Accommodate SC but 
clash with other SC 
(Okumiya, Ishii et al. 1995) 
  Y   Res    (Ashton-Prolla, Tong et al. 
2000) 
  I     Res Accommodate SC (Schafer, Baron et al. 2005) 
321 Q E 7.0 Other  Res  Conserved mutation (Topaloglu, Ashley et al. 
1999) 
  X       (Schafer, Baron et al. 2005) 
325 G D 0.4 Buried Res    (Schafer, Baron et al. 2005) 
             *Table 4.4 is continued onto the next page 
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327 Q K 0.3 Other   Res/ NR Accommodate SC but 
loses HB with N363 
(Davies, Winchester et al. 
1993) 
  E    Res  Conserved mutation (Schafer, Baron et al. 2005) 
328 G R 0.2 Buried NR    (Ishii, Sakuraba et al. 1992) 
  A   Res    (Eng, Resnick-Silverman et 
al. 1993) 
  V    Res  Gly  V (Shabbeer, Robinson et al. 
2005) 
330 Q  X 3.8 Other     (Dobrovolny, Dvorakova et 
al. 2005) 
333 Q X 18.2 Other     (Lorenz, Hauser et al. 2003)  
338 E  K 1.0 Other   NR Breaks HB network, 
domain interface 
(Shabbeer, Robinson et al. 
2005) 
  X       (Shabbeer, Robinson et al. 
2005) 
340 W X 0.1 Other     (Eng, Resnick-Silverman et 
al. 1993) 
  R  Buried   NR Clash with hydrophobic 
core, domain interface 
(Davies, Eng et al. 1996) 
341 E K 0.1 Other   Res C terminal domain, 
accommodate mutation 
(Beyer, Karpova et al. 1999) 
  D    Res  Conserved mutation (Shabbeer, Yasuda et al. 
2002) 
342 R X 0.0 Other     (Davies, Winchester et al. 
1993) 
  Q   Res    (Ploos van Amstel 1994) 
344 L P 1.3 Buried  NR  X  Pro (Schafer, Baron et al. 2005) 
345 S P 16.5 Exposed  Res  X  Pro, exposed (Schafer, Baron et al. 2005) 
349 W X 2.2 Other     (Ashley, Shabbeer et al. 
2001) 
350 A P 0.0 Buried  NR  X  Pro (Schafer, Baron et al. 2005) 
352 A D 0.0 Buried   NR Domain interface, no space (Morrone, Cavicchi et al. 
2003) 
             *Table 4.4 is continued onto the next page 
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355 N K 0.1 Other   Res Near loop, accommodate 
SC 
(Germain, Shabbeer et al. 
2002) 
356 R W 5.0 p. Exposed Res/ 
NR 
   (Bernstein, Bishop et al. 
1989) 
357 Q X 8.3 Other     (Miyazaki, Kajita et al. 1998) 
358 E K 4.6 Exposed Res    (Miyazaki, Kajita et al. 1998) 
  G    Res  X  Gly (Germain, Shabbeer et al. 
2002) 
  A    Res   (Shabbeer 2006) 
360 G S 0.4 Other  Res  Gly  X, loop, exposed (Dobrovolny, Dvorakova et 
al. 2005) 
361 G R 3.7 Exposed  Res  Gly  X, exposed (Germain, Shabbeer et al. 
2002) 
362 P L 12.1 Exposed  Res  Pro  X (Shabbeer, Yasuda et al. 
2002) 
363 R H 5.3 Exposed Res    (Cooper 2000) 
  C   Res    (Shabbeer, Yasuda et al. 
2002) 
365 Y X 3.9 Other     (Miyamura, Araki et al. 
1996) 
373 G S 0.0 Buried NR    (Okumiya, Ishii et al. 1995) 
  D   NR    (Germain 2001) 
377 A D 0.1 Buried   Res Accommodate SC, loop (Blaydon, Hill et al. 2001) 
378 C Y 0.0 Other  NR  Disulfide bond (Topaloglu, Ashley et al. 
1999) 
382 C W 0.0 Other  NR  Disulfide bond (Galanos 2002) 
  Y    NR  Disulfide bond (Rodriquez-Mari 2003) 
384 I N 0.0 Buried   Res Accommodate SC (Shabbeer, Yasuda et al. 
2002) 
385 T P 6.6 Exposed  Res  X  Pro, exposed (Shabbeer, Yasuda et al. 
2002) 
386 Q X 0.3 Other     (Eng, Ashley et al. 1997) 
396 F X 13.7 Other     (Shabbeer, Yasuda et al. 
2002) 
             *Table 4.4 is continued onto the next page 
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398 E X 21.5 Other     (Eng, Resnick-Silverman et 
al. 1993) 
  K  Exposed  Res  Exposed (Shabbeer, Yasuda et al. 
2002) 
399 W X 10.5 Other     (Eng, Ashley et al. 1997) 
401 S X 10.3 Other     (Shabbeer, Yasuda et al. 
2002) 
403 L S  Buried Res    (Shimatori 2007) 
407 I K 0.1 Buried   NR Clash onto β sheet (Rodriquez-Mari 2003) 
409 P T 0.0 Buried  Res  Pro  X (Blaydon, Hill et al. 2001) 
  A   Res    A(Blaydon, Hill et al. 2001) 
  S    Res  Pro  X (Germain, Shabbeer et al. 
2002) 
410 T K 0.0 Buried   NR Clash onto domain 1 α 
helix 
(Ashley, Shabbeer et al. 
2001) 
  (A)  Buried   Res Accommodate SC (Yang, Lai et al. 2003) 
  P   NR    (Shimatori 2007) 
411 G D 0.1 Buried  NR  Gly  X (Guffon, Froissart et al. 
1998) 
414 L S 0.0 Buried   Res Accommodate SC (Rodriquez-Mari 2003) 
415 L P 0.0 Buried NR    (Serebrinsky, Pascucelli et al. 
2006) 
           * References of the Experimental data: Benjamins (2009); Shin (2008); Shimotori (2007); Ishii (2007); Shin (2007); Spada (2006 
                 p. Exposed = partially exposed 
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CHAPTER 5 
 
INTERCONVERSION OF LIGAND SPECIFICITY OF α-GALACTOSIDASE A 
 
This chapter is part of a paper in preparation written in collaboration with Ivan Tomasic 
and Scott C Garman. (Tomasic, I., Metcalf, M., Guce, A. I., Clark, N., Garman, S.G., 
2010) 
 
 
5.1.   Introduction 
Human α-GAL and α-NAGAL are two closely related lysosomal enzymes first 
thought to be isozymes of α-GAL because α-NAGAL is able to cleave α-glycosylated 
substrates (Crawhall and Banfalvi 1972; Remeo, D'Urso et al. 1975; Bishop, Dean et al. 
1980; Desnick 2001). Differences in electrophoretic migration and isoelectric focusing 
led to the separation of the two enzymes (Bishop, Dean et al. 1980). Both enzymes form 
a N-terminal (β/α)8 barrel and a C-terminal β sandwich fold (Garman, Hannick et al. 
2002; Garman and Garboczi 2004). The two enzymes show 46% amino acid sequence 
identity, and structurally are very similar, with a RMS deviation of 1.5 Å (for 660 αC) 
when the dimmers are superimposed. Both enzymes also belong to the family 27 and clan 
D of glycoside hydrolases (Vocadlo and Davies 2008). Although it has been shown that 
both enzymes have similar structural features, they have completely different 
immunogenic properties, where polyclonal antibodies raised against each enzyme do not 
cross-react (Beutler and Kuhl 1972; Schram, Hamers et al. 1977).  
The purified enzymes show differences in substrate specificity. α-GAL cleaves 
terminal α-linked galactosides while α-NAGAL hydrolyzes the cleavage of terminal α-N-
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acetylgalactosaminides (α-GalNAc, see Figure 5.1) (Garman, Hannick et al. 2002; 
Garman and Garboczi 2004; Clark and Garman 2009). The difference in the specificity of  
the two enzymes is derives from amino acid differences in the active site. Thirteen out of 
the 15 residues at the catalytic center are highly conserved between the homologues 
enzyme, but two are not (Figure 5.2). Therefore substrate specificity between the two 
enzymes appears to be solely dictated by the two non-conserved amino acids found at the 
“recognition loop”. Both α-GAL and α-NAGAL select and bind substrate using the same 
H-bonding and hydrophobic contacts as described in Chapter 1.3.1 but distinguish α-
galactose and α-GalNAc using the two residues at the recognition loop. α-GAL 
recognizes a smaller hydroxyl group at the C2 position of the sugar ring using E203 and 
L206 at the recognition loop. However, α-NAGAL uses smaller side chains, S188 and 
A191, to distinguish a larger N-acetyl group moiety at the same position (Garman, 
Hannick et al. 2002; Garman and Garboczi 2004). Since α-NAGAL utilizes smaller 
amino acid residues at the recognition loop, this enzyme does not exclusively bind α-
GalNAc, but can bind α-galactose as well. α-NAGAL has α-GAL activity, with the 
ability to bind and cleave terminal α-galactose; however the reverse is not observed 
(Schram, Hamers et al. 1977). α-GAL cannot accommodate the bigger α-GalNAc in the 
active site therefore no α-NAGAL activity is detectable in α-GAL. In the lysosome, a 
small part of α-GAL activity can be attributed to α-NAGAL (Beutler and Kuhl 1972). 
However in Fabry disease patients where α-GAL enzyme is deficient, the α-GAL activity 
contained within α-NAGAL is not sufficient to prevent disease development.  
Although the ligand specificity of α-GAL and α-NAGAL has been established by 
the crystal structures of the enzymes, the conversion of the specificity of α-GAL to α- 
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Figure 5.1 Catalytic reaction of α-GAL and α-NAGAL 
 
The reaction catalyzed by α-GAL (a) and α-NAGAL (b). α-GAL hydrolyzes the α1-R 
linkage of a substrate containing a terminal α-galactose and α-NAGAL hydrolyzes the 
α1-R linkage of a substrate containing a terminal α-N-acetylgalactosamine. For both 
enzymes, the substrate and the product are α anomers. 
 
 
a. 
b. 
  126 
 
 
Figure 5.2 Superimposition of the active sites of α-GAL and α-NAGAL  
 
α-GAL and α-NAGAL are two homologous lysosomal enzymes that have a similar fold. 
A close up of the active site of α-GAL (green) and α-NAGAL (blue) with galactose 
bound superimposed to each other with an rmsd of 0.25 Å for the 15 active site residues. 
13 out of the 15 residues are conserved except two residues at the “recognition loop” 
that discriminates a hydroxyl or N-acetyl at the C2 position. The two residues that are 
not conserved are E203, S206 (α-GAL) that recognizes a hydroxyl group (OH) at C2 of 
a galactose and S188, A191 (α-NAGAL) that allows the binding of a bulkier N-acetyl 
group at the C2 position of the GalNAc. 
E203,  
S188  
L206, 
A191  
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NAGAL has never been shown. Based upon the crystal structures of each enzyme, we  
predicted that mutagenesis of two residues would be enough to convert the α-GAL 
enzyme into an α-NAGAL enzyme. We used rational design approaches to interconvert 
the specificity of α-GAL and α-NAGAL.  
The therapeutic relevance of an engineered enzyme with a wild type backbone 
(such as α-GAL and α-NAGAL) but with an altered enzyme activity could be useful for 
an alternative enzyme for enzyme replacement therapy. Clinical studies have shown that 
large percentage of the patients receiving recombinant enzyme as a therapy develop 
immune response and neutralize the injected foreign enzyme. This poses a problem 
because now patients need a higher dose of enzyme as well as additional medication for 
the immune response. By engineering the active site of the protein that is not foreign to 
the patients enable us to circumvent this problem. In particular, comprehension of the 
nature of ligand specificity of α-GAL and α-NAGAL could open doors for clinical 
applications for lysosomal storage diseases, particularly Fabry disease and Schindler 
disease, caused by deficiency of α-GAL and α-NAGAL respectively. 
 
5.2.   Experimental Strategy 
In this study, we examine the role of the recognition loop to the substrate 
specificity, enzyme activity, function and structure of the α-GAL enyzme. Here, the 
active site of human α-galactosidase A was engineered to resemble the α-NAGAL active 
site. Specific activity and kinetic parameters of the engineered α-GAL were interrogated 
to assess the switch in activity of α-GAL. We provide evidence of the conversion of α-
GAL activity and specificity into that of α-NAGAL. We call the engineered α-GAL 
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enzyme with α-NAGAL activity “α-GALSA”, indicating the two amino acids introduced 
into the human α-GAL sequence. We changed E203 and L206 in the recognition loop at 
the active site of α-GAL enzyme to serine and alanine, to mimic α-NAGAL recognition 
loop. To compare and confirm the role of the recognition loop residues in distinguishing 
substrate, our laboratory has also engineered α-NAGAL active site to resemble the α-
GAL active site. Similarly, specific activity and kinetic parameters of the engineered α-
NAGAL were also determined to confirm the switch in activity of α-NAGAL. We call 
the engineered α-NAGAL enzyme with α-AGL activity “α-NAGALEL”, indicating S188 
and A191 in the recognition loop at the active site of α-NAGAL enzyme to glutamic acid 
and leucine. Furthermore, we have determined the crystal structures of α-GALSA with α-
galactose and α-N-acetylgalacosamine bound at the active site, revealing the molecular 
basis for ligand specificity and activity of α-GAL and other enzymes in family 27. 
 
5.3.   Results 
5.3.1.   α-NAGAL activity of α-GAL enzyme  
The inherent activity of α-GAL towards its synthetic substrate (pNP-α-galactose) 
and the α-NAGAL synthetic substrate (pNP-α-GalNAc) was measured to establish the 
baseline of the activity and specificity of the enzyme. In comparison, the activity of α-
GALSA was also measured using pNP-α-galactose and pNP-α-GalNAc substrate. Wild 
type α-GAL shows activity towards pNP-α-gal substrate (as expected) and very little 
cleavage is detected of the pNP-α-GalNAc substrate. Wild type α-GAL shows a strong 
preference for pNP-α-gal only. Engineered α-GALSA, on the other hand, binds both 
substrates, and shows activity towards both substrates as well. Although α-GALSA is not  
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Table 5.1 Specific activity and kinetic parameters of wild type enzymes and α-GALSA  
     and α-NAGALEL 
 
Enzyme Substrate Spe. Act. (U/mg) 
Km 
(mM) 
kcat 
(s-1) 
kcat/Km 
(s-1/mM) 
wt α-GAL pNP-α-Gal 330.07 ± 0.02 6.88 ± 0.07 37.8 ± 0.2 5.49 ± 0.03 
wt α-GAL pNP-α-GalNAc ND ND ND ND 
α-GALSA pNP-α-Gal 3.5 ± 0.0 49 ± 7 1.2 ± 0.1 0.02 ± 0.00 
α-GALSA pNP-α-GalNAc 145.4 ± 0.0 21.0 ± 0.8 21.5 ± 0.7 1.02 ± 0.03 
wt α-NAGAL pNP-α-Gal 20.90 ± 0.03 28 ± 5 10.7 ± 0.9 0.39 ± 0.03 
wt α-NAGAL pNP-α-GalNAc 287.04 ± 0.03 0.68 ± 0.01 15.09 ± 0.06 22.34 ± 0.08 
α-NAGALEL pNP-α-Gal   7.58 ± 0.07 13.71 ± 0.08 1.81 ± 0.01 
α-NAGALEL pNP-α-GalNAc ND ND ND ND 
        ND = not detected 
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as efficient as either wild type enzymes, the engineered enzyme gained α-NAGAL 
activity that was not indigenous to α-GAL. The kinetic parameters KM, kcat, and kcat/KM 
of α-GALSA are not as optimal as the wild type enzyme α-NAGAL, but α-GALSA has 
nearly the same enzymatic activity as α-NAGAL against alpha-linked N-
acetylgalactosamine substrate (see Table 5.2, gained activity and specificity in red). 
Compared to wild type α-GAL, α-GALSA has much improved α-NAGAL activity. α-
GALSA has now greater specificity (kcat/KM) for α-NAGAL substrate, turns over pNP-α- 
GalNAc substrate about 20-fold faster than pNP-α-Gal, and binds both substrates a higher 
concentration (KM) than the wild type enzymes. Since the engineered enzyme is mostly  
α-GAL in amino acid sequence, we hypothesize it will have similar biochemical 
parameters as α-GAL. The apparent melting temperature (Tm) measured for the α-GALSA 
is around 57°C, showing comparable stability to wild type α-GAL (60°C).  
 Similarly, our laboratory has also shown a parallel experiment where a α-NAGAL 
activity and specificity is altered by mutating the α-NAGAL recognition loop residues to 
S188E, A191L. Engineered α-NAGALEL has completely lost its specificity towards its 
substrate (pNP-α-GalNAc) and now has exclusive activity and specificity towards pNP-
α-gal (see Table 5.1). It is known that wild type α-NAGAL has both α-NAGAL activity 
and residual α-GAL activity. α-NAGALEL on the other hand completely and exclusively 
exhibits α-GAL properties. Again the engineered enzyme is not as efficient enzyme 
compared to wild type α-GAL, however it has adopted α-GAL activity and characteristics 
not seen with wild type α-NAGAL enzyme.  
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5.3.2.   Immunogenicity of α-GAL, α-NAGAL and α-GALSA enzymes 
 To assess the immunogenic properties of these enzymes we used western blots to 
demonstrate that the engineered proteins have retained their inherent antigenic 
characteristics. Since only two residues in the active site of both the engineered enzymes 
where changed, it is expected that the antibodies raised against the wild type enzyme 
would recognize the mutant enzymes α-GALSA and α-NAGALEL. To verify the 
specificity of the antibodies, wild-type enzymes were used as controls. The SDS gel with 
all the enzymes (wild type the α-GAL, α-NAGAL; engineered enzymes α-GALSA and α-
NAGALEL) shows that α-GALSA has a similar electrophoretic mobility as the wild-type 
enzyme counterpart; likewise α-NAGALEL also behaves like the wild-type enzyme (see 
Figure 5.3a). The SDS gel also demonstrates a uniform amount of enzyme loaded for the 
succeeding western blot experiment. Next, immunoblots using either monoclonal anti-α-
GAL or polyclonal anti-α-NAGAL as primary antibodies were performed for all the 
enzymes. The western blots show that there is no cross reactivity between the two 
antibodies used. The anti-α-GAL antibody only reacted with the α-GAL and α-GALSA 
enzymes, and the anti-α-NAGAL antibody only reacted with the α-NAGAL and α-
NAGALEL enzymes (see Figure 5.3b). More importantly the western blot has 
demonstrated that both the engineered enzymes α-GALSA and α-NAGALEL retained their 
respective wild type antibody epitope.  
 
5.3.3.   α-GALSA crystal structure 
The structures of the engineered α-GAL with glycerol, α-galactose and α-N-
acetylgalactosamine bound at the active site were solved using x-ray crystallography (see  
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Figure 5.3 SDS and western blots of wild type and engineered enzymes 
 
(a) SDS gel of the four enzyme (wild type α-GAL and α-GALSA; wild type α-NAGAL 
and α-NAGALEL) shows difference in electrophoretic mobility, both engineered 
protein α-GALSA and α-NAGALEL display the same property as the wild type enzyme; 
(b) Western blot of the same four enzyme as in (a) shows no cross reactivity between 
the monoclonal anti-α-GAL or polyclonal anti-α-NAGAL. Anti-α-GAL recognizes 
only the wild type α-GAL and α-GALSA which suggest that the engineered enzyme 
with α-NAGAL active retained its α-GAL backbone, likewise the engineered α-
NAGALEL though exclusively turns over α-GAL substrate retained its α-NAGAL 
immunogenicity. 
a. b. 
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Table 5.2 and Figure 5.4 a, b, c). The structures give a view of the small 
molecule/product and its interaction with the residues at the active site. α-GALSA 
superimposed to the 2.0 Å wild type α-GAL structure with galactose bound at the active 
site shows the α-GAL substrate galactose and the active site residues are 
indistinguishable with the exception of the two mutated residues (E203S; L206A) at the 
recognition loop (see Figure 5.5a) (Guce 2009). Similarly, α-GALSA bound to α-N-
acetylgalactosamine superimposes on the 1.9 Å wild type α-NAGAL structure, showing  
that the active sites superimpose well, with a root mean square deviation of 0.25 Å for 15 
amino acid residues (see Figure 5.5b) (Clark and Garman 2009; Guce 2009).  
This is the first structure of α-GAL enzyme with α-N-acetylgalactosamine bound 
at the active site, made possible by the extra space introduced by the smaller Ser and Ala 
residues. The residues at the catalytic center of α-GALSA with both α-N-
acetylgalactosamine and galactose soak show that the important contacts to small 
molecule are maintained as described in Chapter 1.  As shown in the crystal structure 
with α-N-acetylgalactosamine, mutating E203 and L206 to smaller side chains opens up a 
cavity in the active site for the N-acetyl group at C2 of the sugar ring. The engineered 
enzyme can now accommodate, bind and turnover alpha-linked N-acetylgalactosamine 
substrate. Modeling α-GalNAc in the active site of wild type α-GAL counterpart shows 
steric clashes between the α-GalNAc substrate because E203 and L206 occupy the same 
space as the bulkier N-acetyl group.  
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5.4.   Discussion 
Wild type α-GAL and α-NAGAL were used as a starting point to change the 
specificity of the enzyme to that of the homologous enzyme. We used the structures of 
two related enzymes as the starting point for the protein engineering exercise, then we 
verified our design by determining the x-ray structures of α-GALSA with different 
substrate soaks. The structures reveal that the entire basis for substrate specificity for α-
GAL and α-NAGAL enzymes is contained in the two residues in the recognition loop. By 
switching the two critical residues at the recognition loop, the specificity of the α-GAL 
enzyme was changed to that of α-NAGAL similarly α-NAGAL to α-GAL.  
The E203 and L206 of α-GAL discriminate between the terminal α-galactose 
versus α-N-acetylgalactosamine substrates. By mutating E203S and L206A, the activity 
of α-GALSA behaves more like α-NAGAL enzyme than like the α-GAL enzyme from 
which we started. The activity assay, kinetics experiments, and structure all support the 
rationally designed α-GALSA protein to alter specificity and switch activity to behave like 
α-NAGAL. This experiment shows a simple case of protein design, where changing two 
residues in the active site of an enzyme leads to new enzymatic function. This approach 
might be extended to engineering a number of distinct enzymatic activities into a 
common scaffold, which could be a valuable tool for alternative enzyme replacement 
therapy for lysosomal storage diseases or among homologous disease-causing protein.  
ERT is the principal treatment for most lysosomal storage disease and has been 
shown to be effective in reducing accumulation of substrate and thereby slowing of 
disease progression (Eng, Banikazemi et al. 2001; Eng, Guffon et al. 2001; Germain 
2002; Schoenmakere 2003; Wilcox, Banikazemi et al. 2004). However, ERT involves the
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               Table 5.2 Crystallographic statistics of α-GALSA 
 
Soak : Glycerol α-Galactose α-N-acetylgalactosamine* 
PDB code:    
Protein    
Expression system Tn5 Tn5 Tn5 
Space group P212121 P212121 C2221 
Cell lengths, Å 59.57, 106.92, 181.51 59.50, 105.85, 181.85 89.15, 139.41, 182.94 
Cell angles, °    
 
X-ray data 
   
X-ray source BNL X6A BNL X6A BNL X6A 
Wavelength, Å    
Resolution (last shell) 45.27 - 2.85 (2.90 - 2.85) 49.63 – 3.04 (3.23 – 3.11) 47.35 – 2.81 (2.90 – 2.80) 
Observations 136,330 172,299 211,219 
Unique observations 
(last shell) 
27,897  
(1334) 
23,638 
(2297) 
28,304 
(2809) 
Completeness, %  
(last shell) 
99.3 
(99.9) 
100.0 
(100.0) 
100.0 
(100.0) 
Multiplicity (last shell) 4.9 (4.9) 7.3 (7.4) 7.5 (7.5) 
Rsym (last shell) 0.177 (0.616) 0.271 (0.859) 0.217 (0.812) 
I/σI (last shell) 9.1 (2.2) 7.6 (2.5) 11.0 (2.8) 
 
Refinement 
   
Rwork/Rfree, % 22.6/26.7 21.4/24.4 21.2/26.2 
No. of atoms 6658 6557 6551 
   Protein 6320 6303 783 
   Carbohydrates 170 218 16 
   Water 132 36 49 
   Others 36 0 2 
Ave. B, Å2 22.8 28.4 33.3 
  * Table 5.2 is continued onto the next page 
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Ramachandran Plot 
   
   Favored (%) 89.5 89.9 84.1 
   Allow (%) 9.6 9.3 13.8 
   Generous (%) 0.7 0.4 1.5 
   Forbidden (%) 0.1 0.3 0.6 
    
RMS deviations    
   Bonds (Å) 0.0089 0.0119  
   Angles (°) 1.214 1.1413  
                    * refinement in progress 
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Figure 5.4  α-GALSA active site with small molecule soaks 
 
(a), (b), and (c) shows electron density of the ligand at the α-GALSA active site. 
The electron density corresponds to a σA-weighted 2Fo-Fc omit map calculated in 
SFCHECK contoured at 1.5 σ. The substitution of a smaller side chains at the 
active site produced a gap that could now fit a bulkier N-acetyl group at the C2 
position.  
 
   
 
 
a.   
α-GALSA  
+ α-GalNAc 
b. 
    α-GALSA  
+ α-Gal 
c. 
    α-GALSA  
+ Glycerol 
  138 
 
                                            
 
 
                                             
 
Figure 5.5 Superimposition of the active site of α-GAL, α-NAGAL and  
                   α-GALSA 
 
(a) α-GAL and α-GALSA with α-galactose bound at the active site, active site 
residues are indistinguishable except of the two residues at the recognition loop 
(E203S; L206A); (b) α-NAGAL and α-GALSA active sites with α-N-
acetylgalactosamine superimposes with an rmsd of 0.23 Å. 
 
a.  
α-GAL + α-galactose 
α-GALSA + α-galactose 
b.  
α-NAGAL + α-GalNAc 
α-GALSA + α-GalNAc 
  139 
introduction of a recombinant protein into the bloodstream of patients. Since many Fabry 
disease patients make no functional α-GAL protein, injection of recombinant enzyme can 
lead to severe immune complications. Independent clinical studies report a large 
percentage (56-88%) of Fabry disease patients develops IgG antibodies when infused 
with recombinant α-GAL (Eng, Guffon et al. 2001; Linthorst, Hollak et al. 2004; 
Schiffmann, Ries et al. 2006; Vedder, Breunig et al. 2008). The immune response in 
these patients could cause enzyme replacement therapy to be less effective due to 
neutralizing effect of the antibodies (Garman, Munroe et al. 2004; Wang, Lozier et al. 
2008). 
Here we have shown that the mutation of the two residues at the recognition loop 
of α-GAL protein converts the activity of α-GAL into α-NAGAL. The reverse 
experiment is also true, because others in the lab have engineered α-NAGAL into α-
GAL. Using our understanding of α-GAL ligand specificity, α-NAGAL (which Fabry 
disease patients make normally) was engineered to function as α-GAL.  The α-NAGAL 
recognition loop was engineered to produce a protein that cleaves terminal α-galactose. 
Since Fabry disease patients have normal levels of α-NAGAL, we predict the engineered 
protein will not be treated as foreign by the immune system of Fabry patients. The 
interconverted enzymes might be a promising avenue for enzyme replacement therapy for 
Fabry disease and other lysosomal storage disease.  
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5.5.   Methods 
5.5.1.   α-GALSA expression and purification  
The α-galactosidase A mutant α-GALSA was generated from site directed 
mutagenesis of wild type human α-galactosidase A gene (GLA) in pIB/V5-His-TOPO® 
vector (Invitrogen), pIB/V5-His-TOPO-α-GAL. α-GAL mutation was incorporated into 
the pIB/V5-His-TOPO-α-gal construct with PhusionTM site-directed mutagensis kit 
(Finnzymes) according to the manufacturer’s specifications. Forward (5ʹ′-PO4-G TAC 
TCC TGT TCG TGG CCT GCT TAT ATG TGG CCC-3ʹ′, mutations in bold), and 
reverse primers (5ʹ′-PO4-CAC AAT GCT TCT GCC AGT CCT ATT CAG GGC-
3ʹ′), were used to introduce the mutations into the GLA gene (IDT Inc., Coralville IA).  
The mutation was confirmed by sequencing the isolated and purified DNA (Genewiz 
Inc., USA).  
Mutant DNA was transfected into Tn5 cells as previously described in Chapter 2. 
α-GALSA protein secreted to the supernatant was purified using Ni affinity tag and anion 
exchange chromatography as described in Chapters 2 and 4.  
 
5.5.2.   α-GALSA activity assay and kinetics 
The specific activity and kinetic parameters of α-GALSA and α-NAGALEL were 
assayed by monitoring the hydrolysis of para-nitrophenyl-α-galactopyranoside (pNP-α-
gal; Sigma Aldrich, St. Loius Mo, N0877) and para-nitrophenyl 2-Acetamido-2-deoxy-α 
-D-galactopyranoside (pNP-α-GalNAc; Toronto Research Chemicals Inc., Canada) at 
400 nm. The specific activity of purified α-GALSA and α-NAGALEL was measured by the 
addition of 0.012 mg/mL enzyme to 5 mM pNP-α-gal substrate or pNP-α-GalNAc in 100 
  141 
mM citrate/phosphate buffer pH 4.5.  After incubation for 10 min, the reaction was 
quenched by the addition of 250 µL of borate buffer, pH 9.8. Absorbance at 400 nm was 
measured using a microplate reader at room temperature. Activities were measured by 
subtracting the blank and adjusting for the dilution factor.  
The kinetic parameters of the enzymatic reaction were determined by monitoring 
the amount of product cleaved by the α-GAL and α-NAGAL mutant enzymes over time 
at varying substrate concentrations. The reaction mixture containing 10 µL of α-GALSA 
and α-NAGALEL mutant (0.01 mg/mL) and 140 µL of increasing concentration of 
substrate (0-50 mM pNP-α-gal; 0-10 mM pNP-α-GalNAc) was incubated at 37°C. The 
reaction was quenched by adding 10 µL of the reaction mixture to 290 µL of borate 
buffer, pH 9.8 every minute for 10-15 minutes.  The amount of para-nitrophenolate 
cleaved at each substrate concentration was plotted against time yielding initial velocities 
(V0) for each substrate concentration.  Vmax and Km values were calculated as described 
in Equation 3.1. All stock pNP-α-GalNAc and pNP-α-gal solutions were dissolved in 
citrate buffer (100mM citric acid, 100mM NaH2PO4, pH 4.5), and all enzyme solutions 
diluted in 100mM citric acid, 100mM NaH2PO4, 0.1% BSA, pH 4.5.  All kinetic 
experiments were performed in triplicate and verified by two separate experimenters. 
 
5.5.3.  Tm measurement (CD) of α-GALSA 
CD wavelength scan and thermal melts were carried out on a Jasco J715 
spectropolarimeter equipped with a PTC-348WI temperature controller. The CD signal at 
222 nm of α-GALSA and α-NAGALEL mutant (1.2-5 µM in 10 mM phospate buffer, pH 
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6.5) were monitored at increasing temperature at a temperature speed of 1°C/min from 
25-90°C as previously described in Chapter 3. 
 
5.5.4.  Western blot analysis of α-GALSA and α-NAGALEL mutant 
Purified enzyme (wild type α-GAL and α-NAGAL; and mutant enzymes α-
GALSA and α-NAGALEL) were separated on 10% SDS polyacrylamide gels by mixing 
supernatant samples with 6x SDS loading buffer with β-mercaptoethanol and boiling for 
10 minutes. The four samples were run in triplicate. One SDS gel was stained with 
codeBlue (Pierce) to visualize protein loaded to the gel. The other two SDS gels were 
transferred to a nitrocellulose membrane (Millipore). The first membrane was incubated 
with a monoclonal chicken anti-α-GAL primary antibody (Genetel Labs, OA0005, 
1:2000 dilution) and detected with alkaline phosphatase (AP) labeled anti-chicken 
secondary IgG (Genetel Labs, RCYAP, 1:5000 dilution). The second membrane was 
incubated with a polyclonal rabbit anti-α-NAGAL primary antibody (1:100000 dilution) 
and detected with AP labeled anti-rabbit secondary IgG (Rockland, 611-1502, 1:5000 
dilution).  All four enzymes run between 43 and 56 kDa. 
 
5.5.5.  Crystallography 
 All crystals were grown using the hanging drop vapor diffusion method at 20°C 
incubator. Crystals that grew in the space group P212121 were optimized using 
microseeding to increase crystal size.  
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5.5.5.1.  Crystal conditions 
Glycerol and galactose soak: Small crystals were obtained from 1:1 mixture of 
reservoir solution (8% (w/v) PEG 8K, 0.1 M sodium cacodylate pH 6.5, and 22 mM 
magnesium acetate) with a 7.0 mg/mL protein solution (10 mM sodium phosphate buffer, 
pH 6.5). The crystals were crushed and used to seed a pre-equilibrated 1:1 mixture of 
reservoir solution and stock protein solution. Crystals appeared in the seeded solution 
after two weeks. Crystals were transferred and harvested to a similar solution with 20% 
glycerol (glycerol bound structure) or with 20% glycerol and 200 mM galactose 
(galactose bound structure). Both crystals grew in the P212121 space group. 
α-N-acetylgalactosamine soak: Crystals grown in space group C2221 were grown 
using a reservoir solution (12.0% PEG 8K, 0.1 M sodium cacodylate pH 6.5, and 22 mM 
magnesium acetate). A single crystal was transferred into a harvest solution (15.0% PEG 
8k, 100 mM sodium cacodylate pH 6.5, 0.022 M magnesium acetate, and 200 mM α-N-
acetylgalactosamine). The crystal was flash cooled in liquid nitrogen in harvest solution 
supplemented with 20% glycerol as a cryoprotectant. 
 
5.5.5.2.  Data collection and refinement 
Several crystals were screened in-house using a RU-H3R rotating anode generator 
(Rigaku).  Crystals that diffracted to around 4 – 3.5 Å were transported to the 
Brookhaven National Laboratory Synchrotron Light Source where data sets were 
collected at the X6A beamline. X-ray images were processed using HKL2000 software 
package. Rigid body refinement was used to generate solutions for α-GALSA with 
glycerol and galactose soaked. The α-GALSA structure with α-GalNAc soak was phased 
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by molecular replacement in the CCP4 program AMoRe using the 1.9 Å D170A α-GAL 
mutant structure (PBD code 3HG3) (Guce 2009). 
For all structures: Atomic models were built into electron density using the 
program O, and refinement and water placement were done using REFMAC (Jones, Zou 
et al. 1991). Coordinates were superimposed using LSQMAN, molecular docking studies 
were performed in O and in PyMol (Jones, Zou et al. 1991; Kleywegt 1997; DeLano 
2008). Figures were made in MolScript, pymol and POVScript+ (Kraulis, Fenn) (DeLano 
2008). 
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CHAPTER 6 
 
 
FUTURE DIRECTION 
 
The mechanistic studies done on α-GAL described in Chapter 2 represent the first 
complete crystallographic evidence of the catalytic mechanism of a retaining enzyme and 
of glycoside hydrolase family 27 enzymes. This structural study also includes two novel 
structures for both family 27 enzymes and α-GAL enzyme; one is a substrate bound (1.9 
Å) and the other is the covalent intermediate (2.3 Å), respectively. Enzymes belonging to 
family 27 of the glycoside hydrolase have conserved active site residues therefore the 
catalytic mechanism determined in this study is most likely identical for the entire family. 
In addition, the high-resolution structure α-GAL solved with covalent intermediate bound 
in the active site revealed two new conformation of the sugar; (1) a skew boat 
conformation that mimics the covalent intermediate, and (2) the half chair conformation 
transition state-like inhibitors. This opens the door for a new class of potent inhibitors 
that could be pharmacological chaperone candidates for α-GAL and other alpha-retaining 
enzymes. Designed novel mechanism-based inhibitors would selectively bind to the 
active site of the target protein and could be screened for its chaperoning effect. In 
addition these new small molecule inhibitors would belong to a different chemical patent 
space. Potent inhibitors of family 27 or retaining glycosidase have immense clinical 
relevance as well. As an example, a disease called “ gastric dumping syndrome” causing 
uncontrolled or delayed bowel movement is a result of an excess of insulin secretion after 
a sharp increase in blood glucose level (Harju and Nordback 1987; Hasegawa, Yoneda et 
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al. 1998). Known inhibitors of α-glucosidase (EC 3.2.1.20, a family 27 as well as a 
retaining enzyme) such as acarbose are available drug for the treatment of non-insulin-
dependent diabetes mellitus (NIDDM) (Hermans, Kroos et al. 1991; Bischoff 1994; 
Spengler 1995). Interestingly, acarbose is also a type 2 diabetes drugs that prevents the 
breakdown and release of glucose from the polysaccharide substrate in the stomach thus 
regulating the blood glucose level in patients (Josse 1995; Campbell, White et al. 1996; 
Martin and Montgomery 1996). Acarbose in particular is a polysaccharide drug that 
resembles a transition state structure (Yoon and Robyt 2002). Retaining enzymes like the 
one described above will have a similar catalytic mechanism where new class of 
inhibitors could be designed based on to the novel mechanism-based inhibitors described 
here. The assays optimized to assess the chaperoning effect of a new chaperone molecule 
as described in Chapter 3 and 4 could be used to screen for chaperoning-activity. 
Substrate reduction therapy is also a treatment option for other lysosomal storage disease 
where potent inhibitors could be used. Industrial applications also include modulating 
leaf development in plants and seed germination in legumes. Additionally, discovery of 
the second sugar-binding site away from the active site is a potential site to bind a small 
pharmacological chaperone molecule without competitively inhibiting the enzyme 
function. These structures provide new insights for drug design efforts on 
pharmacological chaperones or tight inhibitors of α-GAL and homologous enzymes.  
The molecular mechanism of the chaperoning effect of DGJ elucidated through 
biophysical techniques and structural studies described in Chapter 3 enabled us to 
understand the biochemistry behind pharmacological chaperones as well as the basic 
concept for the potency of DGJ as a chaperone. The biochemical experiments mentioned 
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in this study is the first biophysical evidence of pharmacological chaperone, specifically 
DGJ, stabilizing α-GAL enzymes at physiologically relevant pH conditions. The studies 
done with α-GAL described in this thesis will act as a model system to understanding 
pharmacological chaperones for other lysosomal storage diseases. The mechanistic 
insights from the experiments developed for wild type α-GAL also provide valuable 
information on the basic design of pharmacological chaperones for other enzymes.  
Pioneering work on the effect in the stability of α-GAL in the presence of DGJ led to a 
new model for pharmacological chaperone therapy and other avenues of research such as 
stability-activity correlation and trafficking experiments. As a follow up experiment to 
the stability-activity correlation of wild type α-GAL, monitoring enzyme activity as a 
function of temperature is being proposed. To investigate further the observed 
chaperoning effect of DGJ at sub-stoichiometric concentrations, chimera protein with two 
different active sites is being considered. We propose an obligate dimer of α-GAL with 
two different active sites, one that will accommodate its natural substrate and the other 
that will bind α-GalNAc, as discussed in Chapter 5. This will enable us to interrogate the 
effect of DGJ on the other half of the dimer using the assays developed in Chapter 3. By 
filling the α-GALSA active site with a bigger inhibitor, we could measure the chaperoning 
effect and inhibition of the single monomer.  
Experiments described in Chapter 4 have validated the effect of DGJ to known α-
GAL mutants. The guidelines that we have developed in Chapter 4 to predict the 
response of Fabry disease-causing mutations to DGJ is a useful clinical tool to estimate 
patient response. We are now in the position to test these predictions using the 
biochemical experiments developed and described in Chapters 3 and 4. Expressing 
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mutants that are described in Chapter 4 and testing them to see the chaperoning effect of 
DGJ. This would further confirm the effect of DGJ to these mutants as well as test the 
validity of the rules/guidelines described in Chapter 4. This will lead to a better, cheaper 
and safer treatment and management option for Fabry disease patients other than enzyme 
replacement therapy. 
Finally the engineering studies in α-GAL have established the role of the two 
recognition loop residues for ligand specificity. The rational design of the active site 
residues have proven the possibility of designing homologous recombinant enzymes for 
replacement therapy to prevent adverse immune response from patients. Altering the 
active site of an enzyme indigenous to the host designed to function similar to the 
deficient enzyme in any of the lysosomal storage disease and/or disease requiring enzyme 
replacement. In this way the immune system would recognize the engineered enzyme 
similar to α-GALSA as “self” at the same time step up to the role of cleaving the 
accumulated substrate. This has a great impact in the design of recombinant enzymes for 
enzyme replacement therapy to increase efficiency of the treatment and reduce adverse 
immunogenicity side effects. As a follow up to the engineered α-GALSA enzyme to probe 
the role of the two residues in the recognition loop, the other residues at the active site 
could also be rationally mutated to interrogate its function and effect to enzyme activity, 
stability and catalysis.  
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APPENDIX A 
 
THE STRUCTURE OF HUMAN α-GALACTOSIDASE A AND IMPLICATIONS 
FOR FABRY DISEASE (BOOK CHAPTER SECTION)  
 
This is a section of a book chapter on inherited diseases particularly the lysosomal 
storage disorder, Fabry disease. (Abigail I. Guce and Scott C. Garman), in press. 
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7.1 Overview of the structure 
The three-dimensional structure of human α-galactosidase A was determined by 
x-ray crystallography in 2004 (1), revealing the locations of the atoms in the 
glycoprotein. The crystal structure showed a homodimeric molecule with each monomer 
containing two domains. The N-terminal domain is a classic (β/α)8 barrel, and the C-
terminal domain contains eight antiparallel β strands packed into a β sandwich (Figure 
7.1). Residues 32-328 comprise the N-terminal domain, and residues 329-421 fold into 
the C-terminal antiparallel β domain. The C-terminal residues 421-429 are disordered in 
most crystal structures, and the 31-residue signal sequence is removed during the folding 
of the protein in the endoplasmic reticulum. The lozenge-shaped dimer has overall 
dimensions of approximately 75 x 75 x 50Å.  
The N-terminal domain contains the active site, which is located at the C-terminal 
end of β strands β1-β7, near the center of the β barrel. The active site appears as a small 
depression on the surface of the molecule. The function of the C-terminal domain is 
unclear, but it is conserved in all members of the family, including α-galactosidases from 
rice and from Trichoderma reesei (2, 3). The interface between the N- and C-terminal 
domains of human α-galactosidase A is extensive, burying 2500Å2 of surface area, 
including many hydrophobic interactions. The dimer interface is also extensive, with 
2200Å2 of buried surface area.  
Three N-linked carbohydrates are found on the surface of the molecule, away 
from the location of the active site and away from the dimer interface. The carbohydrate 
residues attach to aspartic acid residues N139, N192, and N215 and extend from the 
surface of the molecule. N-linked carbohydrates are critical for the correct folding and 
trafficking of the molecule in the cell (4-6). The N-linked carbohydrates are highly 
heterogeneous in composition, as judged from the distribution of carbohydrates on the 
recombinant glycoproteins used in enzyme replacement therapies (7). The N139 site 
contains complex carbohydrate with two to four branches and from zero to four sialic 
acid residues per chain. The N192 and N215 carbohydrates are mixtures of complex, 
hybrid, and oligomannose glycoforms, each with variable amounts of phosphorylation 
and sialylation (7). Assuming independence of the three N-linked glycosylation sites, the 
recombinant enzymes used in enzyme replacement therapies represent approximately 500 
and 1300 different glycoforms. 
The dimer has a pronounced negative charge, with 22 more acidic residues than 
basic residues in the polypeptide sequence. This results in a dimer with a highly negative 
electrostatic potential surface at neutral pH (Figure 7.2). With the large excess of acidic 
residues over basic residues, the α-galactosidase A protein has a pronounced negative 
charge at neutral pH and little overall charge at lysosomal pH. The calculated isoelectric 
point of the mature polypeptide is 5.2, and because of the negative charges on the 
carbohydrate, the glycoprotein migrates at approximately pH 4.5 on an isoelectric 
focusing gel (7). 
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7.2 Active site and ligand binding 
The correct function of α-galactosidase A requires the enzyme to discriminate 
between α-galactosides and the many other saccharides in the lysosome. The enzyme 
manages this by folding into a three dimensional fold that gathers 15 residues into an 
active site configuration specific for α-galactosides (Figure 7.3). The active site is formed 
from the side chain residues of W47, D92, D93, Y134, C142, K168, D170, C172, E203, 
L206, Y207, R227, D231, D266, and M267. C142 and C172 make a disulfide bond. The 
two active sites in the dimer are separated by approximately 50Å.  
A number of crystal structures of human α-galactosidase A have now been 
determined, revealing details of ligand binding interactions (1, 8). The cocrystal 
structures of human α-galactosidase A with the catalytic product α-galactose bound 
reveal that the enzyme makes contacts to each functional group on the ligand (Figure 
7.3). When galactose monosaccharide (an equilibrium mixture of α and β anomers) is 
soaked into crystals of human α-galactosidase A, only the α anomer appears in the active 
site. In contrast, the rice and Trichoderma reesei α-galactosidase active sites are able to 
accommodate both the α and β anomers of galactose (2, 3). In human α-galactosidase A, 
Y207 (one of three active site residues not conserved in the rice and Trichoderma reesei 
α-galactosidase sequences) sterically occludes binding of β-galactose. 
The chemical chaperone 1-deoxygalactonojirimycin (DGJ) was originally 
modeled into the binding site of human α-galactosidase A (9); later a crystal structure of 
the complex was determined (8). DGJ, an iminosugar analog of galactose, has identical 
binding interactions to the protein as galactose does. Thus the chemical chaperone acts as 
a competitive inhibitor of the α-galactosidase A enzyme. The binding of DGJ helps 
stabilize the folded conformation of wild type and mutant α-galactosidase A 
glycoproteins, allowing for more efficient delivery of the enzyme to the lysosome.  
7.3 Catalytic mechanism 
The α-galactosidase A enzyme uses a double displacement reaction mechanism 
(10), where two consecutive nucleophilic attacks on the anomeric carbon of the substrate 
lead to breakage of the glycosidic linkage with overall retention of the anomer in the 
product. This double displacement mechanism requires two carboxylates, one acting as a 
nucleophile and one acting as an acid and then a base over the course of the reaction 
mechanism. In human α-galactosidase A, the catalytic nucleophile is D170 and the 
catalytic acid/base is D231. The double displacement reaction mechanism can be broken 
down into discrete steps (Figure 7.4). First, the D170 nucleophile attacks C1 of the 
substrate, breaking the glycosidic linkage (with the donation of a proton by D231). This 
results in a covalent glycosyl-enzyme intermediate, and the free portion of the cleaved 
product diffuses away. Second, D231, acting as a base, deprotonates a water molecule, 
which attacks C1 of the glycosyl-enzyme intermediate, breaking the bond between the 
protein and the sugar and generating α-galactose as the catalytic product. Finally, the α-
galactose product diffuses out of the active site, regenerating the empty enzyme for 
another catalytic cycle.  
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7.4 Fabry disease mutations 
Fabry disease phenotypes fall into three general classifications, depending on the 
degree of residual enzymatic activity. The classical or severe phenotype leads to 
dysfunction in multiple organ systems (including the skin, eyes, heart, kidneys), while 
two other milder phenotypes (which typically show some residual enzymatic activity) 
have symptoms restricted to the heart and kidney respectively. The structure of the 
human α-galactosidase A glycoprotein allows for some degree of personalized medicine 
in Fabry disease, where a patient’s treatment might be chosen in light of the individual’s 
α-galactosidase A gene sequence. Using the database of mutations identified in Fabry 
patients, it may be possible to predict the course and severity of the disease depending on 
the specific mutation in the α-galactosidase A gene sequence.  
 There	   have	   been	   a	   large	   number	   of	   mutations	   identified	   in	   Fabry	   disease	  patients.	   The	   database	   of	   point	   and	   stop	   mutations	   in	   Fabry	   disease	   patients	  contains	  257	  point	  mutations	  and	  43	  stop	  mutations.	  The	  effect	  of	  the	  mutations	  on	  the	  α-­‐galactosidase	  A	  glycoprotein	  is	  summarized	  in	  Table	  7.1.	  The	  full	  database	  of	  mutations	   is	   considerably	   larger,	   because	   it	   includes	   insertions	   and	  deletions	   that	  lead	   to	   frame	   shifts,	   mutations	   that	   lead	   to	   splice	   defects,	   and	   mutations	   in	   the	  promoter	  region	  of	  the	  gene,	  but	  in	  this	  chapter,	  we	  address	  only	  the	  mutations	  that	  affect	  the	  structure	  of	  the	  protein.	  	  The	  mutations	  in	  α-­‐galactosidase	  A	  that	  perturb	  the	  structure	  of	  the	  protein	  can	   be	   grouped	   into	   three	   broad	   categories.	   First,	   there	   are	   mutations	   that	  compromise	  the	  active	  site	  of	  the	  enzyme,	  leading	  to	  loss	  of	  enzyme	  activity.	  Second,	  perturbations	   in	   the	  hydrophobic	  core	  of	   the	  protein	   lead	   to	   folding	  defects	   in	   the	  enzyme.	   This	   class	   comprises	   the	   largest	   group	   of	   mutations	   in	   Fabry	   disease,	  indicating	   that	   Fabry	   disease	   is	   usually	   a	   protein	   folding	   disease.	   The	   rest	   of	   the	  mutations	  are	  grouped	  into	  a	  third	  category,	  which	  includes	  mutations	  that	  lead	  to	  broken	   disulfide	   bonds,	   loss	   of	   N-­‐linked	   glycosylation	   sites,	   mutations	   with	   no	  obvious	  explanation,	  and	  others.	  Figure	  7.5	  maps	  the	  mutations	  onto	  the	  structure,	  showing	  that	  most	  of	  the	  molecular	  defects	  that	   lead	  to	  Fabry	  disease	  fall	   far	  from	  the	   active	   site	   of	   the	   enzyme.	  Over	   half	   of	   the	   residues	   in	   the	  mature	   protein	   are	  found	  mutated	  in	  the	  database	  of	  Fabry	  disease	  patients.	  	  
 
Fabry disease can serve as model for the entire family of lysosomal storage 
disorders because of the wealth of informational available at the genetic, clinical, and 
structural levels. The extensive database of mutations identified in Fabry disease patients, 
combined with the three-dimensional structure of the glycoprotein, leads to a unique 
molecular understanding of the disease. Additionally, the family of lysosomal storage 
diseases have many similar traits, so better understanding of the molecular defects in 
Fabry disease will lead to better understanding of the entire family. Finally, the three-
dimensional structure of α-galactosidase A shows that Fabry disease is typically a disease 
of protein folding, so it can serve as a model for other protein folding diseases, including 
Alzheimer’s and Parkinson’s diseases. 
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7.6 Table 
 
Table 1: α-Galactosidase A protein mutants in Fabry disease  
 
Wild type 
protein 
sequence 
Fabry 
disease  
sequence: 
severe / 
(variant) 
 
 
Importance in α-galactosidase A 
Side chain 
accessible 
surface 
area (Å2) 
 
Mutation 
category 
 
 
 
Reference 
1 M I AUG start  Other (11) 
  T    (12) 
  R    (13) 
14 L P in signal sequence  Other (14) 
16 L P in signal sequence  Other (15) 
19 L P in signal sequence  Other (16) 
20 A (P) in signal sequence  Other (17) 
31 A V in signal sequence  Other (12) 
32 L P signal sequence cleavage site 5.7 Other (18) 
34 N S H-bond to N224 1.5 Buried (19) 
35 G R G phi/psi, R collides with N192 carbohydrate 8.3 Other (20) 
40 P S  0.0 Buried (21) 
  L    (22) 
42 M V no room for beta branch 0.8 Buried (23) 
  T    (13) 
  L    (24) 
43 G D no room for side chain 0.0 Buried (25) 
  R    (26) 
  V    (13) 
44 W X stop 0.0 Other (27) 
46 H R next to W47 in the active site 0.0 Buried (12) 
  Y    (28) 
47 W L active site residue 2.6 Active (29) 
  G    (28) 
48 E K H-bond to main chain E48 and N272 0.0 Other (30) 
49 R L located on dimer interface 2.0 Buried (20) 
  S    (23) 
  P    (28) 
  G    (26) 
50 F C buried in hydrophobic pocket 0.7 Buried (13) 
51 M K contacts to active site W47 and dimer interface 10.1 Active (31) 
  I    (32) 
52 C S disulfide required near the active site 12.0 Other (33) 
  R    (11) 
  X stop   (34) 
56 C G disulfide bond 13.2 Other (19) 
  F    (33) 
  Y    (23) 
  X stop   (35) 
59 E K ion pairs across dimer interface to H406 7.6 Other (33) 
63 C Y disulfide bond 0.7 Other (36) 
65 S T near disulfide bond 3.5 Buried (37) 
66 E Q partially buried in ion pair 3.3 Buried (38) 
  K    (36) 
  G    (32) 
68 L F buried in hydrophobic pocket 0.2 Buried (13) 
72 M V totally buried 0.0 Buried (39) 
  R    (40) 
  I    (26) 
73 A V totally buried 0.0 Buried (32) 
78 S X stop 21.7 Other (41) 
79 E X stop 13.2 Other (42) 
81 W X stop 0.1 Other (43) 
  S buried in hydrophobic pocket  Buried (30) 
  159 
85 G D restricted phi/psi in turn 7.3 Other (18) 
86 Y C H-bond to main chain L311 0.0 Other (12) 
  X stop   (44) 
88 Y D buried in hydrophobic pocket, initiates β2 3.8 Buried (29) 
89 L R buried in hydrophobic pocket 0.0 Buried (43) 
  P    (12) 
91 I (T) buried in hydrophobic pocket 0.0 Buried (12) 
92 D H active site residue 0.0 Active (23) 
  Y    (12) 
  N    (31) 
93 D G active site residue 0.0 Active (23) 
  N    (35) 
94 C Y disulfide bond 0.0 Other (12) 
  S    (28) 
95 W S buried in hydrophobic pocket 0.0 Buried (22) 
  X stop  Other (30) 
97 A V mostly buried in turns, no room for larger side  4.7 Buried (12) 
  P chain   (45) 
99 Q X stop 27.0 Other (43) 
100 R K ion pairs to D155, stacked on Y151 2.5 Other (43) 
  T    (12) 
103 E Q totally exposed 18.9 - (36) 
107 Q X stop 12.9 Other (23) 
112 R C mostly buried, guanidium group in ion pair 2.2 Other (38) 
  (H)    (43) 
  S    (35) 
113 F (L) completely buried in packed hydrophobic core 0.0 Buried (12) 
  S    (28) 
118 R C totally exposed 13.3 - (32) 
119 Q  X stop 17.6 Other (23) 
121 A P buried, little room for large side chain 0.1 Buried (46) 
128 G E restricted phi/psi in turn 8.2 Other (11) 
129 L P Buried, located between α4 and β4 0.0 Buried (47) 
131 L P completely buried 0.0 Buried (43) 
132 G R no room for side chain 0.0 Buried (13) 
134 Y S active site residue 0.0 Active (12) 
  X stop   (22) 
135 A V buried in a hydrophobic pocket 0.1 Buried (35) 
136 D H buried 0.0 Buried (31) 
138 G R buried, no room for side chain 0.0 Buried (12) 
  E    (26) 
141 T I H-bond with D93 0.0 Active (13) 
142 C Y active site residue, disulfide bond 3.9 Active (48) 
  R    (34) 
  X stop   (34) 
  W    (36) 
143 A P larger side chain disrupts C52-C94 disulfide 5.2 Other (43) 
  T    (12) 
144 G V in turn, G restricted phi/psi 7.9 Other (43) 
146 P (S) partially buried in hydrophobic pocket 3.0 Other (49) 
147 G R able to accommodate a small side chain 1.3 - (36) 
148 S R H-bond to D155, little room for large side chain 0.0 Buried (12) 
  N    (22) 
151 Y  X stop 10.8 Other (35) 
152 Y X stop 1.7 Other (13) 
155 D H H-bond to Y100 0.0 Buried (50) 
156 A T buried, no room for larger side chain 0.0 Buried (43) 
  V    (48) 
157 Q X stop 15.0 Exposed (43) 
162 W R mostly buried in hydrophobic pocket 4.2 Buried (19) 
  C    (51) 
  X stop   (52) 
163 G V in turn, restricted phi/psi 1.0 Other (12) 
165 D V buried ion pair to H125 2.1 Buried (20) 
166 L V buried, little room for branch at beta carbon 1.0 Buried (48) 
167 L P buried in hydrophobic pocket 0.1 Buried (53) 
  160 
168 K R active site residue 1.9 Active (13) 
169 F S buried in hydrophobic pocket 0.0 Buried (29) 
170 D V active site mutation, nucleophile 0.0 Active (12) 
  H    (30) 
171 G D no room for larger side chain 0.0 Buried (35) 
  R    (50) 
172 C Y active site residue, disulfide bond 11.7 Active (43) 
  R    (22) 
  F    (31) 
  G    (54) 
  W    (36) 
177 L X stop 12.0 Other (35) 
183 G D buried, no room for side chain 0.3 Buried (34) 
  S    (13) 
187 M V totally buried, no room for branched beta carbon 0.0 Buried (22) 
191 L P buried in hydrophobic pocket 1.3 Buried (29) 
  Q    (31) 
194 T I little room for longer side chain 0.4 Buried (36) 
199 V M buried, little room for longer side chain 0.3 Buried (13) 
201 S F buried, no room for larger side chain 2.4 Buried (35) 
202 C W disulfide bond 0.0 Other (49) 
  Y    (12) 
204 W X stop 0.1 Other (22) 
205 P T buried hydrophobic residue 0.0 Buried (11) 
  R    (13) 
  L    (36) 
207 Y S active site residue, H-bond to D170 5.5 Active (13) 
215 N (S) mutation disrupts N-linked glycosylation 12.0 Other (55) 
216 Y D buried hydrophobic residue 1.1 Buried (12) 
220 R X stop 7.0 Other (56) 
221 Q X stop 17.1 Other (13) 
222 Y X stop 4.7 Other (57) 
223 C G disulfide bond 0.0 Other (58) 
  R    (13) 
  Y    (13) 
224 N D buried H-bonding network to N34 0.0 Other (41) 
  S    (22) 
225 H R buried H-bonding to T41, S201, and H225 0.0 Other (59) 
226 W X stop 0.0 Other (20) 
  R buried in hydrophobic pocket  Buried (22) 
  C    (30) 
227 R Q active site residue 0.2 Active (19) 
  X stop   (55) 
230 A T affects critical D231 in active site 45.4 Active (22) 
231 D N active site residue 9.2 Active (60) 
234 D Y H-bond network to main chain D234, F273 and  0.1 Other (13) 
  E G274   (35) 
235 S C initiates α6 helix 2.7 Buried (34) 
236 W C H-bond to E358 1.6 Other (23) 
  L    (34) 
  X Stop   (26) 
239 I T buried in hydrophobic pocket 0.0 Buried (61) 
242 I N buried in hydrophobic pocket 0.3 Buried (42) 
243 L F buried in hydrophobic pocket, no room for F 0.0 Buried (26) 
244 D N ion pair to R356 12.4 Other (43) 
  H    (34) 
245 W X stop 3.6 Other (26) 
247 S P H-bond to Q330, no room for P 2.8 Buried (31) 
  C    (26) 
22 55 00    Q   X stop 27.3 Other (31) 
22 55 77    AA    P no room for P 0.0 Buried (29) 
22 55 88    G   R buried, restricted phi/psi in turn 1.5 Buried (28) 
22 55 99    PP    L P259 and G260 form beta turn 10.5 Other (34) 
      R    (31) 
22 66 00    G   A buried in turn, restricted phi/psi 0.0 Buried (48) 
22 66 11    G   D buried in turn, no room for side chain 0.0 Buried (42) 
  161 
22 66 22    W   C buried in a hydrophobic pocket, stack with P259 0.0 Buried (36) 
22 66 33    NN    S buried H-bonding network to W226 and N228 1.3 Buried (12) 
22 66 44    DD    V near active site residue 2.2 Active (19) 
      Y    (35) 
22 66 55    PP    R buried, little room for longer side chain 1.8 Buried (51) 
      L    (36) 
22 66 66    DD    V near active site residue 0.8 Active (19) 
      H    (22) 
      N    (44) 
      E    (26) 
22 66 77    M   I buried, little room for branch at beta carbon 0.3 Buried (34) 
22 66 88    LL    S buried hydrophobic residue 0.0 Buried (36) 
22 66 99    VV    A completely buried 0.0 Buried (55) 
22 77 00    II    T buried hydrophobic residue 0.0 Buried (36) 
22 77 11    G   C in turn, restricted phi/psi, no room for C side chain 3.3 Other (13) 
22 77 22    NN    K H-bond to E48, no room for K side chain 0.0 Other (33) 
22 77 66    SS    N H-bond to Q279 on dimer axis 0.9 Other (36) 
      G    (35) 
22 77 77    W   X stop 6.6 Other (34) 
22 77 99    Q   (E) H-bond to main chain G274 on dimer axis 0.2 Other (38) 
      H    (28) 
      R    (30) 
22 88 00    Q   H little room for larger side chain 5.0 Other (28) 
      K    (50) 
22 88 22    TT    N H-bond to main chain N278 0.0 Other (31) 
22 88 44    M   T buried in hydrophobic pocket 0.3 Buried (11) 
22 88 55    AA    P buried in hydrophobic pocket 0.0 Buried (35) 
22 88 77    W   X stop 0.0 Other (55) 
      G buried hydrophobic residue  Buried (23) 
      C    (22) 
22 88 88    AA    D buried in hydrophobic pocket on helix 7 0.9 Buried (43) 
      P    (13) 
22 88 99    II    F no room for F side chain 0.0 Buried (34) 
22 99 33    PP    S Buried 0.0 Buried (29) 
      A    (13) 
22 99 44    LL    X stop 0.4 Other (28) 
22 99 66    M   (V) completely buried in a hydrophobic pocket 0.0 Buried (62) 
      (I)    (17) 
22 99 77    SS    F No room for F side chain 0.0 Buried (19) 
      C    (26) 
22 99 88    NN    K H-bond to active site W47 and to I270 main chain 0.0 Active (11) 
      H     (23) 
      S    (12) 
33 00 00    LL    H no room for aromatic side chain 0.0 Buried (36) 
      F    (35) 
33 00 11    RR    (Q) partially buried, ion pair to D299 4.1 Other (27) 
      X stop   (43) 
      P    (31) 
      G    (63) 
33 00 33    II    N partially buried in hydrophobic pocket 1.7 Buried (13) 
33 11 00    LL    F domain interface 0.2 Buried (64) 
313 D Y domain interface, little room for Y side chain 7.3 Buried (19) 
316 V E domain interface helix 0.1 Buried (36) 
317 I T buried in a hydrophobic pocket 2.4 Buried (13) 
  N    (36) 
320 N K H-bond to Q321 and main chain W287 0.2 Other (48) 
  Y    (22) 
  I    (36) 
321 Q E H-bond network to N320 and T39 7.0 Other (34) 
  X stop   (36) 
325 G D no room for D side chain 0.4 Buried (36) 
327 Q K H-bond to N263 0.3 Other (55) 
  E    (36) 
328 G R No room for side chain 0.2 Buried (38) 
  A    (19) 
  V    (35) 
  162 
330 Q  X stop 3.8 Other (50) 
333 Q X  stop 18.2 Other (46) 
338 E  K H-bond to R356 and Q330 1.0 Other (35) 
  X stop   (35) 
340 W X stop 0.1 Other (19) 
  R buried at the domain interface  Buried (23) 
341 E K H-bond to F329 and main chain G373 0.1 Other (65) 
  D    (13) 
342 R X stop 0.0 Other (55) 
  Q guanidium group in H-bond network    (49) 
344 L P buried in domain interface 1.3 Buried (36) 
345 S P linker between β10 and β11, totally exposed 16.5 Other (36) 
349 W X stop 2.2 Other (31) 
350 A P buried, domain interface 0.0 Buried (36) 
352 A D buried, domain interface 0.0 Buried (53) 
355 N K H-bond with R363 0.1 Other (26) 
356 R W ion pair with D244 of N term domain 5.0 Other (66) 
357 Q X stop 8.3 Other (67) 
358 E K ion pair to K240 and H-bond to W236  4.6 Other (67) 
  G    (26) 
360 G S G360 and G361 in a turn at dimer interface 0.4 Other (50) 
361 G R no room for larger side chain 3.7 Other (26) 
362 P L initiates β12 strand between domain interface 12.1 Other (13) 
363 R H guanidinium packs on F337 5.3 Other (29) 
  C    (13) 
365 Y X stop 3.9 Other (68) 
373 G S buried, no room for side chain 0.0 Buried (48) 
  D    (69) 
377 A D buried in hydrophobic pocket 0.1 Buried (28) 
378 C Y disulfide bond 0.0 Other (34) 
382 C W disulfide bond 0.0 Other (70) 
  Y    (30) 
383 F (-) deletion shifts register of β13 7.2 Other (72) 
384 I N buried in hydrophobic pocket 0.0 Buried (13) 
385 T P P kinks strand β13 6.6 Other (13) 
386 Q X stop 0.3 Other (12) 
396 F X stop 13.7 Other (13) 
398 E X stop 21.5 Other (19) 
  K unknown  Exposed (13) 
399 W X stop 10.5 Other (12) 
401 S X stop 10.3 Other (13) 
404 R (-) deletion shifts register of β15 20.3 Other (19) 
407 I K no room for long side chain 0.1 Buried (30) 
409 P T buried, initiates strand β16 0.0 Buried (28) 
  A    (28) 
  S    (26) 
410 T K buried, no room for K side chain 0.0 Buried (31) 
  (A) A introduces hole into hydrophobic pocket  Buried (57) 
411 G D buried, no room for D side chain 0.1 Buried (41) 
414 L S domain interface 0.0 Buried (30) 
415 L P buried, P kinks strand β16 0.0 Buried (71) 
  163 
                 
Figure 7.1: Overview of the α-galactosidase A dimer  
The α-galactosidase A polypeptide trace is shown with a rainbow from blue at the N-
terminus to red at the C-terminus. This color scheme is repeated in Table 1. N-linked 
carbohydrates are shown as bonds, and the galactose ligand is shown as spheres, marking 
the active site in the first domain. 
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Figure 7.2: The electrostatic surface of α-Galactosidase A  
The α-galactosidase A dimer surface is shown colored by electrostatics as calculated by 
the program CCP4mg. The dimer is colored by electrostatic potential, from -10 kBT/e 
(red) to +10 kBT/e (blue), with the galactose ligand colored green and the N-linked 
carbohydrates yellow. The overall dimer is markedly negatively charged, consistent with 
a molecule that is most stable in the low pH of the lysosome. 
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Figure 7.3: The α-galactosidase A active site and binding interactions 
Top: The α-galactosidase A active site is shown with a galactose ligand (green) bound. 
The surface indicates the complementary shapes of the protein and the ligand in the 
active site. The residues in active site are labeled, and interactions between the protein 
and the ligand are shown as dashed lines.  
Bottom: The interactions between the protein and the α-galactose ligand are detailed. Red 
dashed lines represent hydrogen bonds, and blue dashed lines represent van der Waals 
interactions. Note that the protein makes contacts to every functional group on the 
protein.  
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Figure 7.4: The α-galactosidase A catalytic mechanism 
α-Galactosidase A uses a double displacement reaction mechanism, where the substrate 
undergoes two successive nucleophilic attacks on the same chiral carbon. First, D170 
makes a nucleophilic attack on C1 of the substrate, breaking the glycosidic linkage and 
generating a covalent intermediate. Second, a water molecule (deprotonated by D231) 
makes a nucleophilic attack on the same carbon, breaking the covalent bond between the 
enzyme and ligand and generating the product of the reaction, α-galactose. When the 
product diffuses from the active site, the enzyme is ready for another cycle of catalysis. 
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Figure 7.5: Fabry disease mutations and the α-galactosidase A protein 
The α-galactosidase A dimer is shown as in ribbon form. Residues affected in the severe 
form of Fabry disease are colored blue, and those affected in the variant phenotypes of 
Fabry disease are colored yellow. Overall, more than half of the residues in the protein 
have been implicated in Fabry disease. The residues affected in the variant phenotypes 
tend to be more exposed than those found in the severe phenotype. 
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THE CATALYTIC MECHANISM OF HUMAN α-GALACTOSIDASE  
Guce, A.I., Clark, N.E., Salgado, E.N., Ivanen, D.R., Kulminskaya, A.A., Brumer 3rd , H., 
and Garman, S.C. 2010.  J. Biol. Chem: 285: 3625-3632. 
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The enzyme !-galactosidase (!-GAL, also known as !-GAL
A; E.C. 3.2.1.22) is responsible for the breakdown of !-galacto-
sides in the lysosome. Defects in human !-GAL lead to the de-
velopment of Fabry disease, a lysosomal storage disorder char-
acterized by the buildup of !-galactosylated substrates in the
tissues. !-GAL is an active target of clinical research: there are
currently two treatment options for Fabry disease, recombinant
enzyme replacement therapy (approved in the United States in
2003) and pharmacological chaperone therapy (currently in
clinical trials). Previously, we have reported the structure of
human !-GAL, which revealed the overall structure of the
enzyme and established the locations of hundreds of mutations
that lead to the development of Fabry disease. Here, we describe
the catalytic mechanism of the enzyme derived from x-ray crys-
tal structures of each of the four stages of the double displace-
ment reaction mechanism. Use of a difluoro-!-galactopyrano-
side allowed trapping of a covalent intermediate. The ensemble
of structures reveals distortion of the ligand into a 1S3 skew (or
twist) boat conformation in themiddle of the reaction cycle. The
high resolution structures of each step in the catalytic cycle will
allow for improved drug design efforts on!-GAL and other gly-
coside hydrolase family 27 enzymes by developing ligands that
specifically target different states of the catalytic cycle. Addi-
tionally, the structures revealed a second ligand-binding site
suitable for targeting by novel pharmacological chaperones.
The degradation of macromolecules, including glycopep-
tides and glycolipids, occurs in the lysosome via catabolic
enzymes. For example, glycosidases cleave the oligosaccha-
rides from glycoproteins and glycolipids into smaller compo-
nents used by the cell. One such lysosomal enzyme is !-galac-
tosidase (!-GAL,3 also known as !-GAL A; E.C. 3.2.1.22),
which catalyzes the removal of a terminal !-galactose residue
from polysaccharides, glycolipids, and glycopeptides (1). !-
GAL also has the ability to convert human blood group B to
blood groupO (2, 3). The reaction catalyzed by!-GAL is shown
in Fig. 1A.
Defects in human !-GAL lead to Fabry disease, an X-linked
inherited disorder affecting 1 in every 40,000 males character-
ized by chronic pain, vascular degeneration, cardiac abnormal-
ities, and other symptoms (1). The disease displays distinct phe-
notypes correlated with the amount of residual enzymatic
activity: a severe form affecting multiple organ systems includ-
ing the eyes, liver, kidney, and heart; and a milder phenotype
with symptoms restricted to cardiac and/or renal abnormali-
ties. The severe phenotype generally results from a complete
loss of enzymatic activity in affected individuals, whereas
patients with milder phenotypes typically show some residual
enzyme activity. The data base of independent Fabry disease
mutations now numbers in the hundreds, from thousands of
patients. Most Fabry disease patients have a single point muta-
tion in their GLA gene coding for !-GAL, and over 400 mis-
sense and nonsense mutations have been identified in different
patients (4). Fabry disease is a lysosomal storage disorder, a
family of over 40 diseases characterized by the accumulation of
a substrate in the absence of a functional lysosomal enzyme.
The family includes inherited diseases such asTay-Sachs, Sand-
hoff, and Gaucher diseases.
Lysosomal storage diseases are active subjects of clinical
research. In Gaucher disease (a defect in the lysosomal en-
zyme "-glucosidase), enzyme replacement therapy in pediat-
ric patients successfully treats disease and is currently in use in
over 3500 patients from 55 countries (5). Gaucher disease was
the first lysosomal storage disease approved for treatment with
recombinant enzyme replacement therapy in 1994 (6), and
Fabry disease became the second in 2003 (7, 8). Because recom-
binant enzymes typically will not cross the blood-brain barrier,
enzyme replacement therapy is unsuitable for patients with
lysosomal storage disorders that manifest neurological symp-
toms (9), and pharmacological chaperone therapy has been
proposed instead. Fabry disease was the first lysosomal storage
disease to show the potential efficacy of pharmacological chap-
erone therapy, with two small molecule compounds, 1-deoxy-
galactonojirimycin (DGJ) (10, 11) and galactose (12), proposed
as pharmacological chaperones in Fabry patients.
* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grant R01 DK76877 (to S. C. G.) and by National Science Foundation Inte-
grativeGraduate Education andResearch Traineeship 0654128 (toN. E. C.).
The atomic coordinates and structure factors (codes 3HG2, 3HG3, 3HG4, and
3HG5) have been deposited in the Protein Data Bank, Research Collaboratory
for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://
www.rcsb.org/).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Movie S1.
1 Both authors contributed equally to this work.
2 Towhomcorrespondenceshouldbeaddressed:DeptofBiochemistry&Molec-
ular Biology, 710NorthPleasant St., UniversityofMassachusetts, Amherst,MA
01003. Fax: 413-545-3291; E-mail: garman@biochem.umass.edu.
3 The abbreviations used are: !-GAL, !-galactosidase; DGJ, 1-deoxygalac-
tonojirimycin; GH, glycosidehydrolase; PEG, polyethyleneglycol; PDB, Pro-
tein Data Bank; TNP-2,2-di-F-!-Gal, 2!,4!,6!-trinitrophenyl-2-deoxy-2,2-
difluoro-!-D-galactopyranoside.
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!-GAL is an !-retaining enzyme, where both substrate and
product have anomeric carbons with ! configurations. The
mechanism of!-retaining glycosidases was originally proposed
by Koshland to be a double displacement reaction mechanism,
where two consecutive nucleophilic attacks on the anomeric
carbon lead to overall retention of the anomeric configuration
(13, 14). This reaction mechanism requires two carboxylates,
one acting as nucleophile and one acting as an acid/base (15).
The mechanism is proposed to go through oxocarbenium ion-
like transition states at two stages in the cycle. In glycoside
hydrolases, addition of electronegative fluorine atoms to the 2
or 5 position of the hexoside slows the reaction, allowing for
trapping of a covalent intermediate (16). This strategy, com-
binedwithmutation of the acid/base carboxylate, helped clarify
the mechanism of lysozyme (17) after many years of study. In
glycoside hydrolase family 27 (GH27), which includes human
!-GAL and 395 other sequences (18), fluorinated substrates
have been used to map the catalytic nucleophile by mass spec-
trometry (19, 20). The identical catalytic mechanism is con-
served across glycoside hydrolase clan D (21), which includes
1927 sequences in families 27, 31, and 36 (18).
Previously, we reported structures of human !-GAL at 3.25
and 3.45 Å resolution (22). Additionally, others have recently
determined three structures of partially deglycosylated human
!-GAL at resolutions of 2.2–3.0 Å (23). Taken as a group, the
five structures showed no significant changes in the protein
upon binding of ligands including galactose or the pharmaco-
logical chaperoneDGJ.We used a combination of genetic engi-
neering, microseeding techniques, and synthetic substrates to
improve the resolution of the crystals to 1.9 Å and to interro-
gate the catalytic mechanism of the enzyme. Here we report a
series of four new structures of the human !-GAL glycoprotein
representing each stage in the catalytic cycle (Fig. 1B). The
covalent intermediate stage shows a novel conformation of the
ligand in the active site, a distorted skew boat conformation of
the sugar. The structures reveal conformational changes in the
ligand over the course of the reaction cycle, suggesting novel
mechanism-based inhibitors. Additionally, the structures
reveal a second sugar-binding site distal from the active site,
which is ideal for targeting by a new class of pharmacological
chaperones.
EXPERIMENTAL PROCEDURES
Molecular Biology
Human!-GALwas expressed inTrichoplusia ni (Tn5) insect
cells. The wild-type GLA gene was subcloned by PCR from a
pOTB7 vector (OpenBiosystems) using Phusion DNA Polym-
erase (Finnzymes) with forward (5!-ACA ATG CAG CTG
AGGAACCCAGAACTACAT-3!) and reverse (5!-TTAATG
ATG ATG ATG ATG ATG AAG TAA GTC TTT TAA TGA
CAT-3!) primers. The purified PCR product was incubated at
72 °C for 15minwithTaq polymerase (NewEnglandBiolabs) to
add single 3!-deoxyadenosine overhangs for subsequent TOPO
TA cloning into a pIB/V5-His-TOPO vector (Invitrogen). The
resulting pIB/V5-His-TOPO-!-GAL construct contains the
wild-type !-GAL sequence (including the N-terminal signal
sequence) and a C-terminal His6 tag.
The D170A mutant was generated from the above wild-type
construct by site-directed mutagenesis using forward (5!-
[PO4]CTG CTA AAA TTT GCT GGT TGT TAC TGT GAC
AG-3!, mutation in bold) and reverse (5!-[PO4]ATCTACTCC
CCA GTC AGC AAA GGT CTG-3!) PCR primers and con-
firmed by sequencing.
Cell Transfection
Approximately 2.0 " 106 adherent Tn5 cells were trans-
fected with a 2-ml mixture containing SFX-Insect medium
(Hyclone), 1.8 "g of plasmid DNA, and Hilymax (Dojindo
Labs). After 3 days, 100 "g/ml blasticidin in fresh SFX was
added to select for stable transfectants, and supernatants were
tested for protein expression. Stable adherent cells were resus-
pended in SFX medium for larger scale suspension cultures.
Protein Expression and Purification
Stable cells expressing D170A !-GAL mutant protein were
grown to 5–6 " 106 cell/ml for 3 days. The supernatant was
concentrated and buffer exchanged with nickel binding buffer
(50 mM Na3PO4, 500 mM NaCl, and 20 mM imidazole, pH 7.0)
using a Prep/Scale tangential flow filtration cartridge (Milli-
pore). Retentate was loaded onto a Ni2#-Sepharose 6 Fast Flow
column (GE Healthcare) and eluted with a gradient of 0–50%
elution buffer (50 mM Na3PO4, 500 mM NaCl, and 1 M imida-
zole, pH 7.0). Fractions containing pure !-GAL, as determined
by SDS-PAGEanalysis, were pooled, concentrated to 2.0mg/ml
FIGURE 1. !-GAL reaction and trapping stages for crystallographic anal-
ysis. A, double displacement reaction mechanism in human !-GAL. Asp-170
acts as the nucleophile, and Asp-231 acts as an acid and then a base over the
course of the reaction cycle. B, structures of the different stages in the cata-
lytic cycle. Empty enzyme (blue) required a cryoprotectant sterically excluded
from the active site. The substrate-bound structure (green) resulted from
deletion of the active site nucleophile, followed by addition of a disaccharide
substrate. The covalent intermediate (yellow) used a difluoro-substituted ga-
lactoside to slow the second stage of the reaction. The product-bound struc-
ture (red) resulted fromproduct inhibition of the enzyme. The color scheme is
maintained throughout.
Human!-Galactosidase Catalytic Mechanism
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using a 10-kDa molecular mass cutoff spin concentrator (Sar-
torius), and stored in 10 mM Na3PO4 buffer, pH 6.5.
Kinetic Assays
!-GAL hydrolysis of the synthetic substrate para-nitrophe-
nyl-!-galactose (pNP-!-Gal) (Toronto Research Chemicals) at
37 °C was monitored by absorbance at 400 nm and an extinc-
tion coefficient of 18.1 mM!1 cm!1. 1 "g of enzyme in 100 mM
citrate/phosphate buffer pH 4.5 was added to 8 substrate con-
centrations of pNP-!-Gal from 0.1 to 50 mM. Every minute for
10 min, sample absorbance was measured after adding 200 mM
Na3BO3buffer, pH9.8. Statisticswere calculated from triplicate
measurements. Km, Vmax, and kcat were calculated in Kaleida-
Graph from a weighted fit of Michaelis-Menten hyperbola.
Sugars and Sugar Analogues
TNP-2,2-di-F-!-Gal was prepared as described (14, 19).
Thioethyl-!-galactose was prepared from 2,3,4,6-tetraacetyl-
thioethyl-!-D-galactose (Toronto Research Chemicals) by treat-
ment with HCl for 1 h and neutralization with NaOH. Mass
spectrometry confirmed that the hydrolysis of the four acetyls
had run to completion. Galactose, lactose, and melibiose were
obtained from Sigma.
Crystallization and X-ray Data Collection
Empty, Intermediate, and Product—Crystals were grown as
described in Ref. 22, except that microseeding techniques
increased the size of the crystals from 100 to 400 "m in the
longest dimension, leading to much improved diffraction. Seed
crystals were grown in 25% PEG 4000, 200 mM (NH4)2SO4, and
100 mM NaCH3COO, pH 4.6 mixed 1:1 with 9 mg/ml !-GAL
stock. The crystals were crushed, diluted 1:100,000, and added
to a 1:1:1 mixture of crystallization buffer, protein stock, and
water. Crystals appeared in the seeded solution after a few days.
Crystals were harvested into buffer containing 30% PEG 4000,
200 mM (NH4)2SO4, and 100 mM NaCH3COO. Crystals were
then transferred to similar solutions supplemented with ligand:
15% !-lactose (empty structure), 20 mM TNP-2,2-di-F-!-Gal
(covalent intermediate), or 5% D-(")-galactose (product-
bound). For the covalent intermediate structure, salt concen-
trations were reduced to 100 mM (NH4)2SO4 and 50 mM
NaCH3COO, and 15%N-acetylglucosaminewas used as a cryo-
protectant. Five crystals were transferred into the TNP-2,2-di-
F-!-Gal solution; all but one shattered immediately after trans-
fer. Ice rings limited the quality of the galactose-soaked crystal
diffraction data. After flash-cooling the crystals, diffraction
data were collected on a RU-H3R generator (Rigaku) and pro-
cessedwithHKL2000 (24). TheP3221 crystals diffract anisotro-
pically, with#1.9 Å resolution limits along the c axis and#2.8
Å diffraction limits in perpendicular directions; we limited the
overall resolution to 2.3 Å based upon I/#I criteria. The isotro-
pic integration of the anisotropic diffraction data resulted in
poor merging statistics. The structures were phased by Fourier
synthesis using the 3.25 Å human !-GAL coordinates (PDB
code 1R46) (22).
Substrate—The crystals of Asp-170 !-GAL mutant were
obtained by hanging-drop vapor diffusion at 20 °C. Crystals
were obtained from a 1:1 mixture of reservoir solution
(12% PEG 8K, 0.1 M sodium cacodylate pH 6.5, and 22 mM
Mg(CH3COO)2) and 2.0 mg/ml protein in 10 mM Na3PO4, pH
6.5. Prior to freezing and data collection, crystals were trans-
ferred stepwise into reservoir solution with 100 mM melibiose
(Sigma), and then into a cryoprotectant solution (40% PEG 8K,
0.1 M sodium cacodylate pH 6.5, 22 mM Mg(CH3COO)2, 20%
ethylene glycol, and 100 mM melibiose). Crystals were flash-
cooled in liquid nitrogen, and x-ray data were collected at 100K
at beamline X25 at the Brookhaven National Laboratory. X-ray
images were processed using HKL2000 (24) in space group
P212121 and phased by molecular replacement in AMoRe (25)
using the coordinates of the galactose-soaked crystal.
For all structures, atomic models were built using the pro-
gram O (26), with refinement in REFMAC5 (25). Ramachand-
ran plots were computed using PROCHECK (27). Coordinates
were superimposed using LSQMAN (28), and accessible sur-
face areaswere calculated inAREAIMOL (25).Molecular dock-
ing studies were performed inO (26) and in Pymol (29). Figures
were made in MolScript (30) and POVScript" (31). Coordi-
nates and structure factors are deposited in the Protein Data
Bank under accession codes 3HG2, 3HG3, 3HG4, and 3HG5.
RESULTS
Overall Description of the Structures
Human !-GAL is a homodimer where each monomer has
two domains, anN-terminal ($/!)8 barrel containing the active
site and a C-terminal antiparallel $ domain. The homodimer
contains two active sites separated by 43 Å. Previous reports
have suggested cooperativity between the two active sites (with
a Hill coefficient of 1.9) (32), but the three-dimensional struc-
tures show no evidence for cooperativity within the dimer:
there are no substantial differences between the twomonomers
in the asymmetric unit (root mean square deviation of 0.4–0.5
Å for 390 C! atoms), or among the four steps in the catalytic
cycle.
Stages in the Catalytic Cycle
We determined four crystal structures representing each
stage in the catalytic cycle of human !-GAL: the empty enzyme
at 2.3 Å, the substrate-bound enzyme at 1.9 Å, the covalent
intermediate at 2.3 Å, and the product-soaked enzyme at 2.3 Å.
Overall the four structures give a snapshot of the catalytic
mechanism of the enzyme at each stage. Crystallographic sta-
tistics are shown in Table 1. Omit map electron density of the
active site contents and interaction maps of the active sites
show that most protein:ligand interactions are conserved dur-
ing the cycle (Fig. 2). Details of each stage in the cycle follow
below.
Empty Active Site—Determining the structure of the empty
enzyme was not straightforward. Using 20% glycerol or ethyl-
ene glycol as a cryoprotectant resulted in an active site contain-
ing bound cryoprotectant. The use of larger cryoprotectants
(glucose and lactose) that are sterically occluded from the active
site allowed for determination of the structure of the empty
enzyme.
The empty enzyme shows a collection of water molecules
that approximate the locations of the atoms in the galactose
ligand (Fig. 2A). Three waters reflect the positions of oxygens
Human!-Galactosidase Catalytic Mechanism
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O2 (0.92 Å away), O3 (0.27 Å), andO6 (0.21 Å) of the galactose,
and twowaters reflect the positions of carbonsC1 (0.51Å away)
and C4 (1.1 Å) of the galactose.
Substrate-bound—To determine the structure of the sub-
strate-bound crystal, we initially soaked a non-hydrolyzable
substrate analogue into the active site. In two different experi-
ments, 25 mM thioethyl-!-D-galactose was added to the crys-
tals; however the active site was unoccupied in each of those
experiments (data not shown). We modeled the thioethyl-!-D-
galactose structure based upon the thiomethyl-!-D-galactosyl
component of the antibiotic clindamycin (33), and the thioethyl
group had steric clashes with the protein residues in their nor-
mal location.
We then turned to engineering the protein to capture sub-
strate-bound !-GAL.Wemade a mutant protein D170A, lack-
ing the active site nucleophile, in insect cells. We performed
kinetic studies of wild-type and D170A mutant enzymes using
the synthetic substrate para-nitrophenyl-!-D-galactoside. The
wild-type enzyme had a Km of 8.3! 0.5 mM and a kcat of 63.5!
0.1 s"1, (comparable to the two recombinant !-GALs used in
enzyme replacement therapy, Ref. 34) whereas the mutant
enzyme had no detectable activity (kcat # 0.1 s"1). We grew
crystals of the D170Amutant protein and soaked 100 mMmel-
ibiose (D-Gal-!1–6-D-Glc) into the crystals. The electron den-
sity reveals that the melibiose substrate binds to the active site
(Fig. 2B) with the glucose portion of the substrate extending out
of the active site of the enzyme. The galactoside portion of the
melibiose substrate is in standard 4C1 chair conformation. As
expected for an enzyme with exquisite specificity for the termi-
nal !-galactoside but little specificity beyond the glycosidic
linkage, the enzymemakes specific interactionswith each func-
tional group on the galactoside portion of themelibiose, but few
interactions with the glucoside portion of the disaccharide.
Interactions between the galactoside of melibiose and the pro-
tein are summarized in Fig. 2B.
Covalent Intermediate—To trap a covalent intermediate, we
used the synthetic substrate TNP-2,2-di-F-!-Gal (14, 19). The
fluoro substituents attached to the 2 position of the galactopy-
ranose ring destabilize the two oxocarbenium ion-like transi-
tion states in the catalytic mechanism, but the excellent leaving
group TNP allows the first nucleophilic attack to proceed. The
second nucleophilic attack by a deprotonated water mole-
cule is slowed considerably, allowing us to trap the interme-
diate (Fig. 3A). Cryogenic temperatures increased the lifetime
of the covalent complex, allowing collection of complete x-ray
data. Although fluoro sugars have been used inmass spectrom-
etry experiments to identify the catalytic nucleophile of !-GAL
from Phanerochaete chrysosporium (19) and Coffea arabica
(20), this is the first three-dimensional structure of a covalent
complex in the family. The trapped fluoro intermediate is likely
to be identical in conformation to the natural intermediate, by
extension from studies on Drosophila melanogaster !-manno-
sidase II, where three covalent intermediates show the same
conformation independent of fluorine substitution (35).
The electron density for the covalent intermediate shows
clear connectivity between C1 of the ligand and O"2 of the
TABLE 1
Crystallographic statistics
Active site: Empty Substrate Intermediate Product
PDB code: 3HG2 3HG3 3HG4 3HG5
Protein
Protein sequence Wild type D170A Wild type Wild type
Space group P3221 P212121 P3221 P3221
Cell lengths, Å 90.8, 90.8, 217.2 59.5, 106.1, 181.7 90.2, 90.2, 216.6 90.8, 90.8, 217.2
Cell angles, ° 90, 90, 120 90, 90, 90 90, 90, 120 90, 90, 120
X-ray data
X-ray source Cu anode BNL X25 Cu anode Cu anode
Wavelength, Å 1.54 1.0085 1.54 1.54
Resolution (last shell) 50-2.3 (2.38-2.3) 50-1.90 (1.97-1.9) 50-2.3 (2.38-2.3) 50-2.3 (2.38-2.3)
Observations 637,404 1,248,391 739,029 398,547
Unique observations 45,612 90,308 46,337 47,076
Completeness, % (last shell) 97.2 (95.4) 98.6 (88.4) 99.7 (100.0) 99.9 (100.0)
Multiplicity (last shell) 14.0 (14.2) 13.8 (9.9) 15.9 (16.0) 8.5 (8.4)
Rsym (last shell)a 0.115 (0.818) 0.088 (0.755) 0.112 (0.944) 0.099 (0.989)
I/#I (last shell) 25.5 (3.5) 30.2 (3.1) 28.3 (3.4) 21.4 (2.3)
Refinement
Rwork/Rfree,b % 17.6/20.2 16.5/19.7 16.5/22.1 19.1/22.7
No. of atoms 6767 7539 7251 6694
Protein 6255 6377 6262 6255
Carbohydrate 156 216 276 167
Water 329 893 682 236
Other 27 53 31 36
Average B, Å2 36.4 23.1 49.8 43.4
Ramachandran Plotc
Favored (%) 90.7 92.1 90.0 90.5
Allowed (%) 8.4 7.0 9.4 8.4
Generous (%) 0.6 0.9 0.4 0.7
Forbidden (%) 0.3 0.0 0.1 0.3
RMS deviations
Bonds (Å) 0.008 0.006 0.008 0.008
Angles (°) 1.128 1.058 1.159 1.175
a Rsym$ %h%i!Ih,i"#Ih&!/%h%i!Ih,i!, where Ih,i is the ith intensity measurement of reflection h and#Ih& is the average intensity of that reflection.
b Rwork, Rfree$ %h!FP" FC!/%h!FP!, where FC is the calculated and FP is the observed structure factor amplitude of reflection h for the working or free set, respectively.
c Ramachandran statistics are calculated in PROCHECK.
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catalytic nucleophile Asp-170 (Fig. 2C). The covalent interme-
diate is in a 1S3 skew (or twist) boat conformation. The confor-
mation of the covalent intermediate is distorted from the
favored chair conformation of the sugar ring. The ligand is held
in this distorted conformation at one end by the covalent bond
between C1 of the ligand and O!2 of Asp-170 and at the other
end of the ligand by van derWaals interactions betweenTrp-47
and the 4-, 5-, and 6 carbons on the " face of the sugar (Fig. 3B).
FIGURE 2. Ligand density and interactions. A–D, first and second columns show side and top views of the electron density for the ligand in the four different
structures. The third column shows the interactions around the ligand in the active site, where red lines represent hydrogen bonds and blue lines represent van
der Waals interactions. Empty (A), substrate-bound (B), covalent intermediate (C), and product-bound structures (D) are shown, respectively. The electron
density corresponds to a #A-weighted 2Fo-Fc total omit map calculated in SFCHECK (25), contoured at 1.5# in A and 2.0# in B–D, with a cover radius drawn
around residues and/or waters in the active site.
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Product-bound—We determined the structure of the
product-bound crystal by soaking in the catalytic product
galactose. Although galactose solution contained a 70:30
mixture of ! and " anomers of
galactose, the active site selects for
the " anomer only (Fig. 2D). This
selectivity is unique to the animal
kingdom enzymes in GH27, as dif-
ferences in the active site residues
in the rice and Trichoderma reesei
"-GAL structures accommodate
both " and ! anomers of galactose
in the active site (36, 37). The
galactose in the product soak is
in a standard 4C1 conformation.
After the second nucleophilic attack
on the anomeric carbon, the ligand
reverts to a low energy conformation
from its distorted state in the covalent
intermediate structure.
A Second Ligand-binding Site in
Human!-GAL
In our crystal soaks, we have dis-
covered a second ligand-binding
site on the surface of the "-GAL
molecule, at the interface between
the two domains of the monomer.
In three of the four structures
presented here, a monosaccharide
packs on the surface of Tyr-329
and forms hydrogen bonds with
Asp-255 and Lys-374. (In the fourth
structure, the D170A melibiose
soak, the disaccharide is sterically excluded from the second
binding site, and a PEG molecule is found there.)
The second ligand-binding site prefers the ! anomer of
galactose (Fig. 4). When D-galactose (approximately a 70:30
mixture of ! and " anomers) is added to the crystals, the pri-
mary binding site (the active site) binds only the " anomer, and
the secondary binding site binds only the ! anomer. The sec-
ondary binding site binds ligand when the crystals are soaked
with 15% lactose (empty active site), 100 mM melibiose (sub-
strate bound in active site), or 20% galactose (product in active
site). Additionally, when 20% glucose is added to the crystals,
glucose binds in the second binding site (data not shown). The
second binding site uses the plane of Tyr-329 to pack against
the ! face of the monosaccharide, a common protein/carbohy-
drate interaction (38). Electron density in the second site is
likely a result of fortuitous binding in the presence of high con-
centrations of sugars used as cryoprotectants. The second bind-
ing site is comparable in size to the active site: there are 154 Å2
of protein surface area buried when !-galactose binds to the
protein at the second site, larger than the 107 Å2 of protein
surface buried when "-galactose binds in the active site.
DISCUSSION
In this report, we describe four structures of human "-GAL
with improved resolution, allowing us to examine the catalytic
mechanism of the enzyme in detail. The structures here repre-
sent the first member of GH27 with crystallographic evidence
FIGURE 3. Covalent intermediate and ligand deformation. A, reaction mechanism for the TNP-2,2-di-F-"-Gal
substrate. The first step of the reaction remains fast because of the good leaving group, but the second step slows,
allowing for trapping of the covalent intermediate species.B–D, close-up views of the substrate-bound, covalent
intermediate, and product-bound ligands. The catalytic nucleophile Asp-170, the catalytic acid/base Asp-231, and
theconservedTrp-47are labeled.The ligandconformationchanges from4C1 to
1S3 to
4C1geometryover thecourse
of the reaction. Themodeled transition states in4H3 half-chair conformations are shown in the insets.
FIGURE 4. The second ligand-binding site in human !-GAL. The second
ligand-binding site is centered on Tyr-329, at the interface betweendomain 1
and domain 2 of the structure. A surface drawn around all the atoms reveals a
pocket that is selective for !-galactose. The electron density from the galac-
tose-soaked crystal shows a #A-weighted 2Fo-Fc total omit map calculated in
SFCHECK, contoured at 1.1# with a cover radius drawn around the ligand.
Residues Glu-251, Asp-255, Tyr-329, and Lys-374 are shown.
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for each step in the reaction mechanism. Given the strict con-
servation in the binding site residues within the GH27 family
and the conserved mechanism across clan D (14), the mecha-
nistic studies presented here extend to the entire clan of over
1900 protein sequences. To demonstrate the mechanism, we
modeled the entire catalytic cycle of the enzyme, including the
conformational changes of the ligand over the course of the
reaction (supplemental Movie S1).
Pharmacological Chaperones—The discovery of a second
ligand-binding site on the !-GAL molecule leads to another
approach for pharmacological chaperoning for the treatment of
Fabrydisease.Pharmacological chaperonesbindto the foldedcon-
formation of a protein and help to stabilize it. The current gener-
ation of pharmacological chaperones for the treatment of Fabry
disease, including galactose and DGJ, are substrate and product
analogues that bind to the active site of the folded glycoprotein.
Because they bind to the active site, they act as competitive inhib-
itors as well as chaperones; thus they must depart from the active
site before the enzyme can hydrolyze substrate. An alternative
approach, asnotedby thePetskogroup (23),might capitalizeupon
a pharmacological chaperone-binding site distal to the !-GAL
active site, which would stabilize the molecule without competi-
tively inhibiting the enzyme. Here we report such a site. The sec-
ond binding site has distinct substrate specificity from the active
site: whenwe soaked in amixture of both the! and the" anomers
of galactose, the! anomer bound specifically at the active site and
the" anomer bound specifically at the second ligand-binding site.
Thus, we predict that a new class of pharmacological chaperones
can be directed to bind to the second ligand-binding site.
Ligand Geometry in Retaining Glycosidases—The conforma-
tional pathways of!-retaining enzymes represent something of
a paradox. For the pathways with known structures of covalent
intermediates, some (including GH29, GH31, GH38, and now
GH27) show distorted sugars in the covalent intermediate, but
others (such as GH13 and GH77) show distorted sugars in the
noncovalent substrate complex. For example, human !-N-
acetylgalactosaminidase (GH27) has a strained 1S3 intermedi-
ate (39), Thermotoga maritima !-L-fucosidase (GH29) has a
strained 3S1 intermediate (40), Escherichia coli !-glucosidase
YicI (GH31) has a strained 1S3 intermediate (41), andDrosoph-
ilamelanogasterGolgi !-mannosidase II (GH38) has a strained
1S5 intermediate (35). However, the !-amylase family enzymes
Bacillus circulans cyclodextrin glucanotransferase (GH13) and
Thermus thermophilus amylomaltase (GH77) have covalent
intermediates in the low energy 4C1 conformation, but distort
the sugars in the noncovalent Michaelis complexes (42, 43).
The results presented here clarify the mechanisms of retaining
!-glycosidases. When coupled with the other glycosidases with
detailed structural information, some general rules emerge. First,
retainingenzymesneedtoalign thesyn lonepairof thenucleophile
to attack the accessible side of the anomeric carbon opposite the
leaving group. In the !-retaining enzymes !-galactosidase, !-fu-
cosidase,!-glucosidase, and!-mannosidase, littledistortion in the
substrate is required toachieve the in-lineattackof thenucleophile
(35, 40, 41). Second, the same sugar conformations can be used
very differently in glycosidase reactionmechanisms. For example,
in "-retaining glucosidases (and other "-retaining enzymes),
access to in-line attack of the anomeric carbon is achieved by dis-
torting the substrate into 1S3 geometry, and the subsequent cova-
lent intermediateadopts the lowenergy4C1conformation (42,43).
This is the exact inverse of the!-GAL and !-glucosidase mecha-
nisms (41), where the substrate has the 4C1 conformation and the
covalent intermediate has 1S3 geometry. On the Stoddart map of
pyranose ring interconversions (44),"-glucosidase and!-galacto-
sidase travel the same path between 4C1 and 1S3 conformations,
but in opposite directions, reminiscent of the!- and "- retaining
mannosidases, which traverse a path between1S5 and OS2 confor-
mations in opposite directions (35).
Mechanism-based Inhibitors—Galactose and DGJ have
shown promise as pharmacological chaperones for treatment
of Fabry disease, but they are the catalytic product and a prod-
uct analogue respectively. With pharmacological chaperones
for Fabry disease, in vitro inhibition correlates with intracellu-
lar !-GAL activity enhancement (10), so tighter binding com-
pounds could be promising candidates for pharmacological
chaperone therapy. Imino sugars such as DGJ are generally not
good mimics of transition state geometry (45), but transition
state or covalent intermediate mimics might now be developed
from the human !-GAL structures reported here.
The carbohydrate conformations found in the !-GAL cata-
lytic cycle suggest two new classes of inhibitors for human
!-GAL (and, by extension, the entire GH27 family). The first
class of inhibitors are analogues of the 1S3 skew boat covalent
intermediate. Whereas there are currently no inhibitors of
!-GAL with this configuration, other glycosidases have potent
inhibitors that mimic the covalent intermediate, such as the
Golgi !-mannosidase inhibitor mannostatin (46).
The second class of novel inhibitors suggested by our !-GAL
mechanistic studies are transition state analogues.Wemodeled
the conformation of the sugar ring during the two transition
states of the catalytic mechanism as 4H3 (half-chair) conforma-
tions (Fig. 3, insets). Thus, a new class of inhibitors for !-GAL
(and other related family 27 glycosidases) might adopt a 4H3
half-chair (or the closely related 4E envelope) conformation of
the ring. Transition state mimics have not been developed for
!-GAL, however, transition state analogues have been devel-
oped as selective inhibitors of mannosidases and other glycosi-
dases (45, 47, 48).
The active site residues of GH27 members are highly con-
served, so we predict that the two classes of mechanism-based
inhibitors above would be effective for all GH27 members and
potentially for the entire 1927 glycosidases in clan D. Given the
huge variety of catabolic and anabolic processes that use glyco-
sidases (e.g. digestion, lysosomal degradation, ER-associated
degradation, and biosynthesis), potent inhibitors of glycosi-
dases are valuable commercial and research products (49).
Inhibitors of clan D glycosidases would have broad applica-
tions, including, for example, modulating leaf development in
plants (50), seed germination in legumes (51), and substrate
reduction therapy in galactosemia (52).
In summary, we have discovered a second ligand-binding site
on human !-GAL that is suitable for binding by a novel phar-
macological chaperone. Second, the structures described
herein open the door to designing a new family of mechanism-
based inhibitors for the entire family and clan of glycosidases.
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Role of Conserved Tyrosine Residues in NiSOD Catalysis: A Case of Convergent
Evolution†
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ABSTRACT: Superoxide dismutases rely on protein structural elements to adjust the redox potential of the
metallocenter to an optimum value near 300 mV (vs NHE), to provide a source of protons for catalysis,
and to control the access of anions to the active site. These aspects of the catalytic mechanism are examined
herein for recombinant preparations of the nickel-dependent SOD (NiSOD) from Streptomyces coelicolor
and for a series of mutants that affect a key tyrosine residue, Tyr9 (Y9F-, Y62F-, Y9F/Y62F-, and D3A-
NiSOD). Structural aspects of the nickel sites are examined by a combination of EPR and X-ray absorption
spectroscopies, and by single-crystal X-ray diffraction at ∼1.9 Å resolution in the case of Y9F- and D3A-
NiSODs. The functional effects of the mutations are examined by kinetic studies employing pulse radiolytic
generation of O2- and by redox titrations. These studies reveal that although the structure of the nickel
center in NiSOD is unique, the ligand environment is designed to optimize the redox potential at 290 mV
and results in the oxidation of 50% of the nickel centers in the oxidized hexamer. Kinetic investigations
show that all of the mutant proteins have considerable activity. In the case of Y9F-NiSOD, the enzyme
exhibits saturation behavior that is not observed in wild-type (WT) NiSOD and suggests that release of
peroxide is inhibited. The crystal structure of Y9F-NiSOD reveals an anion binding site that is occupied
by either Cl- or Br- and is located close to but not within bonding distance of the nickel center. The
structure of D3A-NiSOD reveals that in addition to affecting the interaction between subunits, this mutation
repositions Tyr9 and leads to altered chemistry with peroxide. Comparisons with Mn(SOD) and Fe(SOD)
reveal that although different strategies for adjusting the redox potential and supply of protons are employed,
NiSOD has evolved a similar strategy for controlling the access of anions to the active site.
Superoxide dismutases (SODs)1 are enzymes that catalyze
the conversion of superoxide to molecular oxygen and
hydrogen peroxide (eqs 4-3) and are thus part of cellular
defenses against damage due to reactive oxygen species
(ROS) (1-4).
SODs utilize one-electron redox-active metal centers to carry
out catalysis. There are four known SODs categorized by
the metal present: (1) Cu/Zn, (2) Mn, (3) Fe, and (4) Ni.
These four SODs fall into three protein classes based on
amino acid sequence homology, with Fe and Mn in the same
class. In addition to having no sequence homology with other
SODs (5), NiSOD has other notable differences. Nickel is
the only metal found in a SOD where the aquated ion does
not react with O2- (1), presumably because the redox
potential of Ni(OH2)62+/3+ (>2 V) (6) lies outside of the
potentials for oxidation and reduction of O2-. In SODs, the
protein component serves at least three important functions
with regard to catalysis: to adjust the redox potential of the
metallocenter (7-10), to provide a source of protons (11, 12),
and to control the access of anions to the active site (13-16).
In NiSOD, the mechanism by which the protein tunes the
redox potential of nickel is also distinct from those of other
SODs in that it is the only metal center that employs cysteine
† This work was supported by National Science Foundation Grants
MCB-0321482 and CHE-0809188 to M.J.M. S.C.G. acknowledges the
University of Massachusetts and the Charles H. Hood Foundation for
support. The U.S. Department of Energy, Division of Materials Sciences
and Division of Chemical Sciences, supported XAS and X-ray
diffraction data collection at the National Synchrotron Light Source
(NSLS) at Brookhaven National Laboratory. The National Institutes
of Health supports beamlines X3B and X6A at NSLS. Pulse radiolysis
studies were funded under Contract DE-AC02-98CH10886 with the
U.S. Department of Energy.
* To whom correspondence should be addressed. Phone: (413) 545-
4876. Fax: (413) 545-4490. E-mail: mmaroney@chemistry.umass.edu.
‡ Department of Chemistry, University of Massachusetts.
§ Brookhaven National Laboratory.
| Department of Biochemistry and Molecular Biology, University
of Massachusetts.
1 Abbreviations: SOD, superoxide dismutase; XAS, X-ray absorption
spectroscopy; EPR, electron paramagnetic resonance; NHE, normal
hydrogen electrode; ROS, reactive oxygen species; PDTC, bis[pyridine-
2,6-bis(thiocarboxylate)]nickel(III); EXAFS, extended X-ray absorption
spectroscopy; XANES, X-ray absorption near edge structure; ICP-OES,
inductively coupled plasma optical emission spectroscopy; ESI-MS,
electrospray ionization mass spectrometry; DSC, differential scanning
calorimetry; Amp, ampicillin; Cam, chloramphenicol; OD, optical
density; FPLC, fast protein liquid chromatography; IPTG, isopropyl
!-D-1-thiogalactopyranoside; PDB, Protein Data Bank; PCR, poly-
merase chain reaction.
M(n+1) + O2
•- f M(n) + O2 (1)
M(n) + 2H+ + O2
•- f M(n+1) + H2O2 (2)
2O2
•- + 2H+ f O2 + H2O2 (3)
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thiolate ligands (17-21), which at first glance would seem
to be incompatible with a catalytic center that produces
oxygen and peroxide (22-24).
Crystal structures of NiSOD reveal a five-coordinate
pyramidal site that is associated with an oxidized Ni(III)
center (Figure 1), and a four-coordinate planar site associated
with a reduced Ni(II) center (17, 21). The nickel ligands
derive from three amino acid residues: the N-terminal amino
group of His1, an amidate N-donor from Cys2, and side chain
thiolates from Cys2 and Cys6. The fifth ligand in the Ni(III)
site is provided by the imidazole side chain of His1 (His-
on), which is unbound in the Ni(II) (His-off) site (17, 21).
There are four tyrosine residues in the amino acid sequence
of Streptomyces coelicolor NiSOD, two of which (Tyr9 and
Tyr62) are conserved in nearly all NiSODs (see the Sup-
porting Information). Tyr9 is positioned near the vacant
coordination site opposite the His1 imidazole ligand in the
His-on structure (O-Ni distance of 5.47 Å) and is involved
in H-bonding with two ordered water molecules in the active
site, neither of which is a nickel ligand (O-Ni distances of
2.57 and 3.15 Å). These water molecules are also H-bonded
to amide protons from Cys6 and Asp3. The other conserved
tyrosine, Tyr62, is near Tyr9 and ∼13 Å from the nickel
center.
The SOD proteins supply protons for the production of
H2O2 and control access of anions to the active sites (7-10).
NiSOD lacks an aqua ligand that has been associated with
redox tuning and proton supply (8) in MnSOD and FeSOD,
but the thiolate ligands may serve an analogous role (25, 26).
Anion access is controlled in SODs using a combination of
size constraint (27), electrostatic steering (28-30), and, in
the cases of MnSOD (12, 31, 32) and FeSOD (15, 33), a
“gatekeeper” tyrosine and neighboring phenylalanine (27).
Herein, we probe the role of the conserved tyrosine residues
and the aspartate (Asp3) in the Ni hook domain for insights
into the NiSOD mechanism using a combination of mu-
tagenesis to systematically perturb the tyrosine residues,
crystallographic and spectroscopic studies to assess the
structural ramifications of the mutations, and kinetics using
pulse radiolytic generation of superoxide to examine function.
The mutation of Tyr9 led to the serendipitous isolation and
the first crystallographic characterization of an anion complex
of NiSOD (Cl- and Br-). In addition to intersubunit
interactions, Asp3 also affects the position of Tyr9 in a way
that changes the function of the active site. The results point
to a role for Tyr9 in the mechanism for regulating anion
access that has many features in common with other SODs,
particularly MnSOD. Thus, NiSOD represents a fascinating
case of molecular convergent evolution.
EXPERIMENTAL PROCEDURES
Molecular Biological Methods. The sodN gene from H15
(the native gene has a 14-amino acid leader sequence that is
cleaved in vivo, leaving H15 as the first amino acid after
post-translation modification) forward was cloned out of the
pET3a-SODN vector using PCR amplification with the
primers 5′-GGTATTGAGGGTCGCCACTGCGACCTGC-
CCTG-3′ (5′SODN15) and 5′-AGAGGAGAGTTAGAGC-
CCTTTGTTAGCAGCCGG-3′ (3′SODNU). The PCR prod-
uct was purified from a 1% agarose gel. Treatment of the
PCR product with T4 DNA polymerase created overhangs
complementary to ligation independent cloning (LIC) vector
pET30 Xa/LIC (Novagen). The sodN gene was annealed into
the vector directly after the factor Xa recognition site (IEGR)
so that upon cleavage with factor Xa, H1 would be the
N-terminal residue. This 47-amino acid N-terminal extension
also contains a His tag used during purification to isolate
the fusion peptide (vide infra). The insert was annealed to
the vector, and NovaBlue (Novagen) competent cells were
transformed with the pET30 Xa/LIC plasmid containing the
sodN gene. The NovaBlue cells were plated on LB medium
containing 34 µg/mL kanamycin (kan) and grown overnight
at 37 °C. Plasmid mini preps (Qiagen) were performed after
single colonies were grown in 3 mL of LB kan medium
overnight. BL21(DE3) pLysS (Novagen) competent cells
were transformed with plasmid pET-30Xa/LIC-SODNH15
(pSODNH15) and were plated and grown overnight at 37
°C on LB medium containing kan and 30 µg/mL chloram-
phenicol (cam). Single colonies were grown overnight in 3
mL cultures (LB kan/cam) and diluted 1:100 in 100 mL of
fresh medium. Cells were grown at 37 °C to an OD at 600
nm of 0.6 and induced with isopropyl !-D-thiogalactoside
(IPTG), at a final concentration of 0.8 mM. After 3 h, the
cells were harvested via centrifugation, and SDS-PAGE was
conducted on cell extract to determine expression of the
target fusion protein. Plasmids producing proteins of the ap-
propriate molecular mass (18 kDa) were submitted to the
University of Massachusetts DNA sequencing facility to
confirm the presence of the His-tagged wild-type (WT) gene.
Single colonies of cells containing the pSODNH15 plasmid
were grown in a 10 mL culture (LB cam/kan) overnight at
37 °C with shaking and then added to 1 L of prewarmed
fresh medium. Cultures were grown to an OD at 600 nm of
0.6 and induced (0.8 mM IPTG) for 3 h. Cells were harvested
by centrifugation, resuspended in 50 mL of Ni-NTA binding
buffer [10 mM imidazole, 50 mM sodium phosphate, and
300 mM sodium chloride (pH 8.0)] with 1 mM phenyl-
methanesulfonyl fluoride (PMSF), and frozen at -80 °C.
Cells were thawed, and 100 µL of a DNase I solution [10
mg/mL DNase I, 10 mM magnesium chloride, 20 mM Tris
(pH 7.5), and 40% glycerol] was added and the mixture
incubated at 37 °C until the viscosity of the solution was
significantly reduced. All chromatographic purifications
employed an AKTA-FPLC system (Amersham Biosciences).
The cell lysate was then loaded onto a column (Pharmacia
HR10) containing Ni-NTA His ·Bind Superflow resin
FIGURE 1: Active site from one monomer of the homohexameric
NiSOD from S. coelicolor, showing the first nine residues and Tyr62
(17). The nickel is shown in the five-coordinate pyramidal oxidized
His-on form. PDB entry 1T6U. The image was generated with
PyMOL (75).
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(Novagen). Nonspecifically or weakly bound proteins were
removed by using a step gradient of 0 to 30% elute buffer
[250 mM imidazole, 50 mM sodium phosphate, and 300 mM
sodium chloride (pH 8.0)]. Following a wash step, the fusion
protein was eluted from the column with 100% elute buffer.
The eluted protein was then dialyzed into factor Xa buffer
[5 mM calcium chloride, 50 mM Tris, and 100 mM sodium
chloride (pH 8.0)] that contained 0.25 mM PMSF to prepare
the sample for N-terminal processing.
N-Terminal processing (required to remove the leader
sequence, which contains the His tag for purification) was
accomplished by cleaving the fusion protein at the IEGR
site using factor Xa. The cleavage reaction was performed
at 4 °C until the reaction was complete, as monitored by
SDS-PAGE. Subsequently, the reaction mixture was dia-
lyzed against 20 mM Tris-HCl (pH 8.0) to remove excess
salt. Anion exchange chromatography (Pharmacia FPLC-
Mono Q) using a 350 mM sodium chloride gradient over 10
column volumes at a slow flow rate of 0.5 mL/min gave
pure apo-NiSOD in the first fractions off the column, as
confirmed by the molecular weights of the products obtained
from ESI-MS (Table 3) and by Edman N-terminal peptide
sequencing (Midwest Analytical, Inc., St. Louis, MO). The
oligomeric state of the protein (hexamer) was confirmed by
size-exclusion chromatography and by ESI-MS under non-
denaturing conditions (Supporting Information, vide infra).
Reconstitution of the recombinant, N-terminally processed
apo-NiSOD was achieved by addition of a 3-fold excess of
dithiothreitol (DTT) for 2 h in an anaerobic chamber (Coy
Laboratory Products Inc., Grass Lakes, MI) followed by
addition of a 5-fold excess of NiCl2. The properties of the
reconstituted enzyme were virtually identical to those previ-
ously reported for native enzymes (see Results).
D3A-NiSOD. The mutation of Asp3 to Ala was made by
PCR. The PCR used the WT-NiSOD gene along with
3′SODNU and the mutagenesis primer 5′-GGTAT-
TGAGGGTCGCCACTGCGCGCTGCCCTGCGGCG-3′. The
PCR product was gel purified (2% agarose), and the gene
was ligated into the pET30 Xa/LIC vector and then trans-
formed, overexpressed, purified, processed, and reconstituted
with nickel chloride (NiCl2) in the same manner as WT-
NiSOD (vide supra).
To probe the nature of a protein-based radical signal
observed in the product of the reaction of D3A-NiSOD with
H2O2, a sample of this mutant in which all four tyrosine
residues present were substituted with d4-Tyr was prepared.
Thus, all four aromatic protons are substituted with deuterons
in each Tyr residue. To incorporate d4-Tyr into D3A-NiSOD,
Escherichia coli BL21(DE3) pLysS cells were grown in LB
broth until they reached an OD at 600 nm of 0.6. The cells
were then spun down and resuspended in M9 medium
containing glyphosate (1 g/L), Trp, His, Phe, and d4-Tyr (0.5
g/L) and grown for an additional 30 min before being
induced with 1 mL of IPTG (200 mg/mL). Cells were grown
for an additional 3 h and then harvested. d4-Tyr-D3A-NiSOD
was purified and isolated as described above for WT-NiSOD.
Y9F-NiSOD. The Y9F point mutation was introduced in
two steps. Two fragments were created in two different PCRs
(reactions A and B) using the WT gene. Reaction A utilized
the 5′SODN15 primer and 5′-GCGGCGTGTTCGACCCT-
GCCCAG-3′, while reaction B used the 3′SODNU primer
alongwith5′-GGCCGTCCAGGAGAAGCTGGCCGGCAAC-
GACGACG-3′. The PCR fragments were gel purified (2%
agarose) and then combined with the 5′SODN15 and
3′SODNU primers in a third PCR to generate the NiSOD
gene with Tyr9 mutated to a Phe. The mutated gene was
ligated into the pET30 Xa/LIC vector as described for WT-
NiSOD (vide supra). The transformation, overexpression,
isolation, purification, and N-terminal processing of Y9F-
NiSOD were performed in the same manner described for
WT-NiSOD (vide supra).
Y62F- and Y9F/Y62F-NiSOD. Both Y62F- and Y9F/Y62F-
NiSOD were made using the QuikChange (Stratagene)
mutagenesis kit. Table 1 shows the primers and the parental
DNA that were used in the two PCRs. DNA isolated using
the Qiagen miniprep kit was sequenced at the W. M. Keck
DNA facility (Yale University, New Haven, CT) to ensure
that the correct mutation was present. Transformation,
induction, protein purification, and N-terminal processing
were preformed as described above for WT-NiSOD. The
protein product was confirmed by the molecular weight of
the fusion protein determined using ESI-MS (Table 3, vide
infra).
Quaternary Structure and Stability. The oligomeric states
as well as the stabilities of WT and mutant NiSODs were
determined by a combination of three techniques: size-
exclusion chromatography, ESI-MS under nondenaturing
conditions, and differential scanning calorimetry (DSC). Size-
exclusion chromatography employed solutions of WT-
NiSOD or mutant NiSODs that were applied to a HiLoad
16/60 Superdex 200 (GE lifesciences) column. The column
was standardized with albumin (67 kDa), ovalbumin (43
kDa), chymotrypsinogen (25 kDa), and ribonuclease A (13.7
kDa). All reconstituted NiSOD samples eluted with molec-
ular weights appropriate for homohexamers. To determine
the MW of the expression products, ESI-MS was performed
using a Bruker Esquire mass spectrometer on solutions of
denatured proteins in an aqueous ammonium acetate solution
(final concentration of 5 mM) with 3% acetic acid and 50%
MeOH. To confirm the oligomeric state of the enzyme, ESI-
MS was also performed on a JMS-700 MStation magnetic
sector (double focusing) mass spectrometer under “nonde-
naturing conditions”. To prevent oligomeric breakdown, the
orifice voltage was turned to 0 V and the skimmer voltage
was set to 120 V. A solution of 60 µM NiSOD monomer
dissolved in 10 mM ammonium acetate solution was used.
Under these conditions, WT-NiSOD exhibits peaks charac-
teristic of the hexameric holoprotein and little else (see the
Supporting Information).
Differential scanning calorimetry thermograms were mea-
sured with a Microcal VP-DSC with 0.5 mL of sample and
reference cells. NiSOD samples were concentrated to 2-5
Table 1: Mutagenic Primers for Y62F- and Y9F/Y62F-NiSOD
mutant forward primer reverse primer parental DNA
Y62F-NiSOD 5′-GCTGTGGAGCGACTTCTTCAAGCCCCCGC-3′ 5′-GCGGGGGCTTGAAGAAGTCGCTCCACAGC-3′ WT-NiSOD
Y9F/Y62F-NiSOD 5′-GCTGTGGAGCGACTTCTTCAAGCCCCCGC-3′ 5′-GCGGGGGCTTGAAGAAGTCGCTCCACAGC-3′ Y9F-NiSOD
3356 Biochemistry, Vol. 48, No. 15, 2009 Herbst et al.
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µM hexamer (Y62F- and Y9F/Y62F-NiSOD) or 100-140
µM in hexamer (WT-, D3A-, Y9F-NiSOD) in buffer [50 mM
Tris-HCl (pH 8.0)], degassed under vacuum, and added via
syringe to the sample and reference cells. Spectra were
collected at 30 psi between 6 and 100 °C at a scan rate of
30 °C/h. Baseline correction and normalization were per-
formed with the Microcal interface to the Origin graphing
program. Peak maxima were taken as melting temperatures,
Tm. The values of Tm obtained are listed in Table 3, and
thermograms are included as Supporting Information.
Electron Paramagnetic Resonance (EPR). X-Band EPR
spectra were recorded on a Bruker ELEXSYS E-500 X-band
spectrometer. Samples in polycarbonate XAS holders were
inserted into a liquid N2 finger dewar. The data were collected
over a 1000 G field centered at 3000 G. The modulation
receiver and signal-channel parameters were as follows:
modulation frequency of 100 kHz, modulation amplitude of
10 G, and time constant of 327 ms. The microwave power
was set to 20 mW with a frequency of 9.46 GHz. To
determine the number of Ni(III) centers present in each
mutant NiSOD, spin integration was performed on each EPR
spectrum. The concentration of Ni in each sample was
determined using ICP-OES (λ ) 231.604 nm) on a Perkin-
Elmer Optima 4300 DV instrument. The resulting EPR
spectra were then integrated twice and compared to a spin
standard with a known concentration, bis[pyridine-2,6-
bis(thiocarboxylate)]nickel(III) (NiPDTC) (34), to determine
the percentage of Ni centers that were in the oxidized state
(Table 3).
Redox Titrations. A modification of the procedure of Reiter
et al. was used to determine the E1/2 values of WT-NiSOD
and the various mutants (35). Solutions of NiSOD (3 mL,
100-200 µM) were prepared in 100 mM potassium phos-
phate buffer (pH 7.5) with 100 mM potassium chloride as a
supporting electrolyte. Samples were degassed and kept
under argon throughout the experiment. Electrochemical
potentials were monitored with an Extech Instruments True
rms digital multimeter connected to a platinum wire and a
Ag/AgCl reference electrode. Optical spectra were monitored
on a Hewlett-Packard 8452A diode array spectrophotometer
equipped with a thermostated cell holder that held all samples
at 25 °C.
Prior to the experiment, the samples were treated with
KMnO4 (3 µL aliquots of a 6 mM aqueous solution) until
the absorbance at 380 nm was at a maximum, ensuring the
Table 2: NiSOD Mutant Data Collection and Refinement Statistics
in house synchrotron
NiSOD mutant Y9F (Cl) [3G4X]a Y9F (Cl) [3G4Z] Y9F (Br) D3A [3G50]
Data Collection
wavelength (Å) 1.5418 0.9184
resolution (last shell) (Å) 50-2.01 (50-2.02) 20.9-1.87 (1.94-1.87) (1.94-1.87) 21.57-1.90 (1.97-1.90)
cell parameters (C2221) a, b, c (Å) 60.09, 112.57, 111.87 59.87, 111.58, 111.55 59.99, 112.46, 110.96 59.99, 112.27, 111.70
no. of observations 118668 211352 127478 238695
no. of unique observations (last shell) 25413 (2175) 29628 (2765) 29651 (2757) 29881 (2929)
multiplicity (last shell) 4.7 (4.4) 7.1 (5.7) 4.3 (3.2) 8.0 (7.2)
completeness (%) (last shell) 99.4 (97.8) 95.3 (91.0) 94.2 (89.1) 99.9 (99.9)
Rsym (last shell) 0.054 (0.515) 0.030 (0.337) 0.038 (0.732) 0.046 (0.929)
I/σI (last shell) 28.0 (3.1) 42.1 (3.0) 28.5 (1.6) 41.6 (2.3)
Refinement
Rwork/Rfree (%) 16.8/23.7 18.3/25.4 18.6/24.0
average B-factor (Å2) 26.8 30.7 38.0
no. of atoms 3213 3249 3058
no. of waters 389 458 291
a PDB codes listed in [].
Table 3: Analytical Data for WT-NiSOD and Its Mutants
E1/2 (mV vs NHE)
NiSOD
sample
ESI-MS MWa
(calcd value)
quaternary
structured
no. of
Ni atoms
per protein EPR as isolated [% Ni(III)]
kinetics,e kcalc × 108 M-1 s-1
at pH 7.5 [range of O2-
concentrations (µM)]
reductive
titration
oxidative
titration Tm (°C)
WT 18171.2b (18169.6) hexamer 0.88 g ) 2.30, 2.23, 2.01;
Azz ) 24.9 G [51(2)]
7.07 (1.93-5.97) 290(4) 279(6) 84.8
D3A 13160.9c (13157.0) hexamer with
decreased stability
1.11 g ) 2.30, 2.24, 2.01;
Azz ) 24.9 G [48(2)]
2.09 (1.68-5.99) 308(3) 290(7) 73.9
Y9F 13183.4c (13185.0) hexamer 0.72 g ) 2.30, 2.23, 2.01;
Azz ) 24.9 G [53(2)]
3.71 (1.54-2.38) 297(5) 299(8) 86.3
Y62F 18154.1b (18153.3) hexamer 0.90 g ) 2.30, 2.23, 2.01;
Azz ) 24.9 G [48(2)]
6.42 (2.09-9.8]) ND ND 82.4
Y9F Y62F 18137.5b (18137.2) hexamer 0.74 g ) 2.30, 2.23, 2.01;
Azz ) 24.4 G [46(2)]
2.41 (2.18-4.12) ND ND 74.7
a ESI-MS measurements were conducted under denaturing conditions resulting in monomer MW values of processed NiSOD or fusion peptide.
b Fusion peptide. c Processed NiSOD. d From size-exclusion chromatography and/or ESI-MS under nondenaturing conditions (see Experimenta
Procedures). e Rates determined under first-order conditions; kcalc ) kobs/[Ni], where [Ni] ) 2 µM. The value of kcalc was determined by averaging the
values over the range of O2- concentrations where there is no apparent decrease in kobs.
Table 4: XANES Analysis of Dithionite-Reduced WT-NiSOD and
Mutant Enzymes
sample
edge energy
(eV)
1s f 3d peak
area (×10-2 eV) geometry ref
WT 8340.5(2) 4.7(5) planar, CN ) 4 47
Y9F 8339.5(2) 5(2) planar, CN ) 4 this work
Y62F 8339.3(2) 3.2(4) planar, CN ) 4 this work
Y9F/Y62F 8340.0(2) 5.8(5) SPY, CN ) 5 this work
D3A 8342.0(2) 4.5(5) planar, CN ) 4 this work
Structure and Function of NiSOD Biochemistry, Vol. 48, No. 15, 2009 3357
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enzyme was in its most oxidized form. Reductive titrations
were performed by adding aliquots (1-5 µL) of reduced
methylviologen [6 mM, electrochemically prepared with a
Bioanalytical Systems (BAS) CV50W instrument using a
BAS bulk electrolysis cell under argon; concentration was
confirmed by measuring the absorption of the MV+ solution
at 606 nm, ε ) 13700 cm-1 M-1 (36)] via a Hamilton
gastight syringe. After complete reduction, the oxidative
titrations were performed in a similar manner by the addition
of small aliquots (1-5 µL) from a 6 mM KMnO4 stock
solution (degassed).
The data were plotted as absorbance (at 378 nm) versus
potential (converted to NHE) and fit to eq 4, which was
derived from the Nernst equation by the method of Bernhardt
et al. (37)
absorbance )
Aox × 10
n(E-E◦)/59 + Ared
1 + 10n(E-E◦)/59
(4)
where Aox is the absorbance of the solution when all the
species are in the oxidized form, Ared is the absorbance of
the solution when all the species are present in the reduced
form, n is the number of electrons being transferred during
the reaction, and E° is the midpoint potential of the redox
reaction. To obtain the reported E° values for NiSOD
samples, n was fixed at 1.0 and the other three parameters
were allowed to vary.
X-ray Absorption Spectroscopy. X-ray absorption spec-
troscopy (XAS) data collection and analysis were performed
as previously described (38). Ni K-edge XAS data were
collected on beamline X9B at the National Synchrotron Light
Source (Brookhaven National Laboratory). Samples of frozen
protein solutions [1-3 mM, based on Ni content, in 20 mM
Tris-HCl (pH 8.0)] were placed in polycarbonate holders
inserted into aluminum blocks and held near 50 K using a
He displex cryostat. The ring conditions for data collection
were 2.8 GeV and 120-300 mA. A sagittally focusing
Si(111) double-crystal monochromator and a 13-channel Ge
fluorescence detector (Canberra) were used for data collec-
tion. X-ray absorption near-edge spectroscopy (XANES) data
was collected from -200 to 200 eV relative to the Ni edge.
The edge energy reported was taken to be the maximum of
the first derivative of the XANES spectrum. Extended X-ray
absorption fine structure (EXAFS) was collected to 9307 eV
(k ) 16 Å-1). The X-ray energy for the K-edge of Ni was
internally calibrated to 8331.6 eV using transmission data
from a Ni foil. The data shown are the average of four to
eight scans and were analyzed using EXAFS123 for XANES
data (39), and SixPack was used for EXAFS analysis (40).
Scattering parameters for EXAFS fitting were generated
using FEFF 8 (41). SixPack builds on the ifeffit engine (41, 42)
and uses iterative FEFF calculations to fit EXAFS data during
model refinement and is thus an improvement over previous
methods that employ a static set of calculated scattering
parameters. To compare different models to the same data
set, ifeffit uses three goodness of fit parameters, "2, reduced
"2, and the R-factor. "2 is given by eq 5
"2 )
Nidp
Nε2
∑
i)1
N
{[Re(fi)]2 + [Im(fi)]2} (5)
where Nidp is the number of independent data points, Nε2 is
the number of uncertainties to minimize, Re(fi) is the real
part of the EXAFS fitting function, and Im(fi) is the
imaginary part of the EXAFS fitting function. Reduced "2
) "2/(Nind- Nvarys) (where Nvarys is the the number of refining
parameters) and represents the degrees of freedom in the fit.
Ifeffit also calculates the R-factor for the fit, which is given
by eq 6 and is scaled to the magnitude of the data, making
it proportional to "2.
To compare different models (fits), the R-factor and
reduced "2 parameters can be assessed to determine which
model is the best fit, in which case both parameters should
be minimized. Although the R-factor will always improve
with an increasing number of adjustable parameters, reduced
"2 will go through a minimum and then increase, indicating
that the model is over fitting the data.
Crystallography. Crystallization experiments were per-
formed using the hanging-drop vapor-diffusion method. All
crystals grew after 2-3 weeks at 20 °C. Crystals of Y9F-
NiSOD (Cl) were obtained by mixing 1 µL of the reservoir
solution [0.05 M CaCl2, 0.1 M Bis-Tris (pH 6.5 with HCl),
and 25% (v/v) PEG MME (Fluka) 550] with 1 µL of a
protein solution at 8.0 mg/mL in a buffer of 50 mM Tris-
HCl (pH 8.0). Prior to being frozen and data collection, the
crystals were transferred stepwise into a cryoprotectant
solution containing 40% (v/v) PEG MME (Fluka) 550, 0.05
M CaCl2, and 0.1 M Bis-Tris (pH 6.5 with HCl).
To produce crystals of Y9F-NiSOD (Br) with bromide in
place of chloride, the protein was exchanged into a buffer
solution containing 50 mM Tris-HBr (pH 8.0). Crystals of
Y9F-NiSOD (Br) were obtained by mixing 1 µL of the
reservoir solution [0.1 M Bis-Tris (pH 6.5 with HBr) and
30% (v/v) PEG MME (Fluka) 550] with 1 µL of a protein
solution at 8.0 mg/mL. Prior to being frozen and data
collection, the crystals were transferred stepwise into a
cryoprotectant solution containing 40% (v/v) PEG MME
(Fluka) 550 and 0.1 M Bis-Tris (pH 6.5 with HBr).
Crystals of D3A-NiSOD were obtained by mixing 1 µL
of the reservoir solution [0.05 M MgCl2, 0.1 M HEPES (pH
7.5), and 30% (v/v) PEG MME (Fluka) 550] with 1 µL of
a protein solution at 8.2 mg/mL in 50 mM Tris-HCl (pH
8.0). Prior to being frozen and data collection, the crystals
were transferred stepwise into a final cryoprotectant solution
containing 40% (v/v) PEG MME (Fluka) 550, 0.5 M MgCl2,
and 0.1 M Bis-Tris (pH 6.5).
Crystals were frozen in liquid nitrogen and then transferred
into a gaseous nitrogen stream at 100 K for X-ray data
collection. Data collection was performed at National
Synchrotron Light Source (NSLS) beamline X6A at the
Brookhaven National Laboratory. All data were collected at
13500 eV (0.9184 Å), which is above the Br absorption edge
energy. Each frame consisted of 0.75° rotation taken for
exposures of 5 s [for Y9F (Cl-) and Y9F (Br-)] or 15 s (for
D3A). X-ray images were integrated, indexed, and scaled
using HKL2000 (43). The diffraction data were scaled in
space group C2221, leading to a solvent content of 47% and
R )
∑
i)1
N
{[Re(fi)]2 + [Im(fi)]2}
∑
i)1
N
{[Re(x˜datai)]2 + [Im(x˜datai)]2}
(6)
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three subunits in the asymmetric unit. Data collection and
refinement statistics are given in Table 2.
Molecular replacement calculations were performed in the
CCP4 program MolRep (44) using a trimeric search model
derived from the native NiSOD structure (PDB entry 1T6Q)
(1). The starting model for manual building was the native
structure with the first 10 amino acids and the solvent
molecules omitted. Rigid body refinement and positional
refinement with 3-fold noncrystallographic symmetry (NCS)
imposed were performed using the CCP4 program Refmac5
(44), and 2Fo - Fc and Fo - Fc electron density maps
showed substantial density representing the omitted parts of
the model. The entire model, including the 10 N-terminal
amino acids, was built into the electron density using the O
graphics program (45). Weighted 2Fo- Fc and Fo- Fc maps
were examined at each stage of the refinement. In later
rounds of refinement, heteroatoms, such as the Ni2+/3+, Cl-,
and Br- ions, were assigned to electron density peaks. The
experimental electron density was of very high quality except
for that of the seven N-terminal residues, where 3-fold
averaging was imposed to aid in map interpretation. The final
statistics for the model are presented in Table 2. To determine
if the electron density near the Ni in the Y9F-NiSOD
structure was Cl- or water, crystals were grown using Br-
instead of Cl-. After the determination that the Cl- was
replaced with Br-, the Y9F (Br) structure was not fully
refined because the Y9F (Cl) data were of better quality.
The quality of the model was assessed with PROCHECK
(46).
Kinetics. The kinetics of superoxide dismutation was
examined using pulse radiolytic generation of superoxide and
was carried out at Brookhaven National Laboratory as
previously described (47). Samples of NiSOD (final con-
centration of 2 µM, based on the Ni concentration) were
placed into a 2 cm cuvette that contained phosphate buffer
(10 mM), formate (30 mM), and ethylenediaminetetraacetic
acid (EDTA, 5 µM). The sample was then pulsed from a
2.0 MeV van de Graaff accelerator, varying the pulse width
(100-2000 ns), resulting in a range of initial superoxide
concentrations (2-40 µM). The disappearance of the absor-
bance at 260 nm that corresponds to O2- was fit to a first-
order process (Figure 7 of the Supporting Information).
Catalytic rate constants were determined by dividing the first-
order rate by the nickel concentration, assuming all of the
nickel is bound and active in the enzyme. The rate of O2-
disappearance in the absence of NiSOD was measured for
the O2- concentrations and pHs used and was, in all cases,
at least 1 order of magnitude slower than the enzymatically
driven rate. The rate constants are reported on a per Ni basis
as determined by the Ni content of each sample. Nickel
content was determined by ICP-OES using the Ni wavelength
of 231.604 nm.
Reactions with H2O2. Both WT- and D3A-NiSOD in 20
mM Tris-HCl (pH 8) were treated anaerobically with a 10-
fold excess of H2O2 at room temperature. The peroxide
concentration was determined by titration with a standard
solution of potassium permanganate (48). After 10 min, the
peroxide was buffer exchanged using spin concentrators
(Vivaspin, 5K MW cutoff) and five 1:10 dilutions with
buffer. The resulting enzyme solutions were examined by
pulse radiolysis to determine if any activity was lost. A
portion of each solution was set aside for MW determination
by ESI-MS to determine if oxygen incorporation had
occurred.
RESULTS
Protein Characterization. Data regarding the molecular
weight of expressed protein, the quaternary structure, the Tm,
and the Ni content following reconstitution of recombinant
proteins are summarized in Table 3. All of the recombinant
proteins had the MW expected for the amino acid substitu-
tions involved, and all were present largely as homohexamers
following reconstitution with NiCl2. In the case of D3A-
NiSOD, a significant amount of monomeric protein was also
observed in the nondenaturing mass spectrum (see the
Supporting Information); however, this was not observed by
size-exclusion chromatography, indicating that the protein
is not completely stable to the ESI-MS conditions. These
results are consistent with the lower Tm value obtained from
DSC analysis (Table 3). WT and Y9F had high thermal
stabilities with Tm values of 84.8 and 86.3 °C, respectively,
whereas D3A had a lower thermal stability (Tm ) 73.9 °C),
which may be attributed to weaker interactions between
subunits in the hexamer (vide infra).
Electron Paramagnetic Resonance. EPR spectroscopy was
used to examine the redox state of the nickel center in the
resting enzymes and probe the electronic structure of the
Ni(III) site in mutant NiSODs. The EPR data show that the
Ni(III) center present in all the mutants is similar to that of
WT-NiSOD. As isolated, native NiSOD has a distinctive
rhombic EPR spectrum that arises from a five-coordinate,
low-spin, S ) 1/2 Ni(III) center, with the unpaired electron
in dz2. X-Band EPR spectra of the WT recombinant NiSOD,
tyrosine mutants (Y9F, Y62F, and Y9F/Y62F) and D3A
(Table 3) also exhibit typical rhombic Ni(III) signals with
strong N-hyperfine splittings on the gz feature (Az ) 24.9
G) arising from the apical imidazole bound to the Ni(III)
center (47, 49). The electronic structure of the Ni(III) center
was not expected to be greatly perturbed by mutations in
the second coordination sphere, and this was confirmed by
the spectra obtained (Table 3). When Tyr9 is mutated to Phe,
subtle hyperfine structure on the gy feature that is not resolved
in the spectrum of WT-NiSOD is observed (Supporting
Information).
Careful integration of the Ni(III) signal in WT-NiSOD
indicates that the EPR signal accounts for only half of the
nickel present in the samples (Table 3). All samples were
approximately 50:50 Ni(III):Ni(II). Excess potassium per-
manganate or hexachloroiridate was used in attempts to
oxidize the remaining Ni(II) centers in as-isolated WT-
NiSOD. In both cases, no additional oxidation was seen.
These results do not coincide with a previous report in which
excess ferricyanide was used to reach a maximum level of
oxidation of 72% Ni(III) in WT-NiSO (17). However, it
should be noted that both permanganate and hexachloroiri-
date are stronger oxidants than ferricyanide, which has a
redox potential (360 mV) that is barely above the midpoint
potential of the enzyme.
In summary, the EPR results from the nickel center are
consistent with a resting oxidized state that contains 50%
Ni(III) and 50% Ni(II), which is not significantly perturbed
by mutation of Tyr9 or Asp3.
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X-ray Absorption Spectroscopy. XAS studies were used
to confirm that the nickel center was bound to the correct
protein site in the reconstituted WT protein and to character-
ize the nickel site in the mutant NiSODs, as well as to
supplement the results of the crystallographic investigations
of the nickel sites in Y9F-NiSOD and D3A-NiSOD and
allow comparisons with other mutants. Since the oxidized
enzymes always contain a mixture of oxidized and reduced
nickel centers, the samples studied were all reduced with
sodium dithionite prior to XAS data collection and were EPR
silent. The results for the XAS experiments on the tyrosine
mutants of NiSOD are summarized in Tables 4 and Tables
5 and Figure 2.
XANES. XANES (X-ray absorption near edge structure)
yields information about the coordination number and
geometry of the nickel site. Nickel has vacancies in the 3d
manifold, which give rise to transitions in the XANES region
of the XAS spectrum that are dependent on the geometry
and coordination number of the metal site. These transitions
include the 1s f 3d and 1s f 4pz (plus shakedown
contributions), which occur near 8331 and 8336 eV, respec-
tively, in Ni(II) complexes (50). In WT-NiSOD and in the
mutant NiSODs, both transitions are observed, which
indicates either a square planar or five-coordinate pyramidal
nickel center geometry (50). The peak areas of the 1s f 3d
transition (Table 4) lie on the line between four-coordinate
planar species (0-0.04 eV) and five-coordinate pyramidal
species (0.04-0.09 eV) and indicate the sites that are most
likely distorted four-coordinate planar in nature, consistent
with what was previously reported for native Streptomyces
seoulensis reduced NiSOD (47). The edge energies observed
for the reduced species compare well with those of the native
S. seoulensis enzyme.
EXAFS. The EXAFS (extended X-ray absorption fine
structure) region of the XAS spectrum provides information
regarding the type of scattering atoms present and their
distance from the central metal ion. Table 5 and Figure 2
compare the best fits obtained for WT-NiSOD and mutant
NiSODs. To evaluate the change in fitting method, we
collected data for reduced WT-NiSOD and compared them
to previously published data (47). The fit is quite similar
except that the Ni-N bond length is ∼0.08 Å shorter than
previously found. However, prior model studies indicate that
it can be difficult to obtain a distance with low error for
N-scattering atoms in a complex where the EXAFS is
dominated by scattering from S atoms (50). The new fits
include atoms in the second coordination sphere, which are
main chain carbon atoms from His1 and Cys2 as well as the
!-carbon from Cys2 as seen in the two crystal structures of
NiSOD (17, 21). These atoms are rigidly positioned by
Table 5: EXAFS Analysis for Dithionite-Reduced NiSOD Samples
sample N R (Å) σ2 (×103 Å-2) ∆E° (eV) reduced #2 R-factor
WTa 2N 1.91(1) 1(2) -3.4 N/A 0.64c
2S 2.160(4) 0(4) -3.2
WTb 2N 1.83(4) 10(4) -17(3) 22.8 0.11
2S 2.16(2) 7(1)
2C 2.73(4) 3(5)
2C 2.90(5)
Y9F 2N 1.95(2) 5(2) -7(2) 22.2 0.06
1S 2.23(2) 3(1)
1S 2.52(3) 6(4)
2C 3.00(4) 4(4)
Y62F 1N 1.90(3) 5(4) -10(2) 11.2 0.04
1N 2.2(2)
2S 2.17(3) 5(2)
3C 2.85(3) 2(2)
2C 3.03(4)
D3A 3N 2.08(2) 2.3(9) -7(1) 9.04 0.04
2S 2.13(1) 8(3)
2C 2.95(6) 12(8)
Y9F/Y62F 2N 2.02(6) 12(6) -5(3) 14.7 0.09
1S 2.20(2) 2(1)
1S 2.46(4) 6(3)
2C 3.02(5) 6(6)
a WT reduced NiSOD from ref 48. b WT reduced NiSOD from this
work and fit using SixPack. c GOF parameter calculated by EXAFS123
(39).
FIGURE 2: Comparison of XAS data for tyrosine mutant NiSODs:
WT (yellow), Y9F (blue), Y62F (purple), Y9F/Y62F (red), and D3A
(green). The main panels show normalized XANES spectra. The
insets show unfiltered EXAFS data in solid colored lines and fits
(black) from Table 5. The range of the k space fits is 2-12.5 Å-1
for all data.
Table 6: Redox Potentials
sample E° (mV) (vs NHE) Aox Ared Na
WT, reduction 290(4) 0.76(1) 0.19(1) 1
WT, oxidation 279(6) 0.91(2) 0.16(5) 1
D3A, reduction 308(3) 0.815(9) 0.24(1) 1
D3A, oxidation 290(7) 0.91(3) 0.16(6) 1
Y9F, reduction 297(5) 0.54(2) 0.15(2) 1
Y9F, oxidation 299(8) 1.12(9) 0.06(6) 1
a N is the number of electrons per Ni(III) center. This value was held
constant in fitting the absorption data to obtain E°.
3360 Biochemistry, Vol. 48, No. 15, 2009 Herbst et al.
  185 
 
chelate rings, and their inclusion improves the fits. The single
mutation, Y9F-NiSOD, alters the structure around the Ni
center. The best fit for Y9F-NiSOD contains two shells of
sulfur donors at different distances. The first sulfur donor
lies at 2.23 Å, while the other sulfur ligand is longer and
lies at 2.52 Å. This splitting of the two sulfur ligands into
two distances is also seen in the double mutation Y9F/Y62F-
NiSOD, which has a fit similar to that of Y9F-NiSOD (Table
5). D3A- and Y62F-NiSOD have fits that are more similar
to that of WT-NiSOD with both S donors at the same Ni-S
distance. For D3A-NiSOD, the Ni-S bond distance found
was similar to that in WT-NiSOD (0.03 Å shorter), where
Y62F-NiSOD had a slightly longer Ni-S bond (0.07 Å) than
WT-NiSOD (Table 5). The WT- and D3A-NiSOD fits differ
by the addition of one Ni-N vector in the D3A-NiSOD fit,
and the Ni-N bonds are longer in D3A-NiSOD [2.08(2) Å
vs 1.83(4) Å in WT-NiSOD]. The fit obtained for Y62F-
NiSOD is slightly different in that the best fit splits the two
nitrogen scatterers into different shells with one ligand at
1.90 Å and the other at 2.2 Å.
The data indicate that when Tyr9 is altered by loss of the
OH group, different Ni-S distances are obtained. This
structural perturbation is confirmed by single-crystal dif-
fraction studies (vide infra) and may result from the alteration
of a H-bonding network in the Ni hook domain. Alterna-
tively, the results may indicate that the nickel site is a mixture
of low- and high-spin Ni centers, given the similarity of the
two distances to low-spin (51) and high spin (50, 51) nickel
thiolate model complexes.
PROTEIN STRUCTURE
NiSOD Crystallographic Results. The crystal structures of
two NiSOD mutants, Y9F and D3A, were determined to 1.9
Å. Both the Y9F- and D3A-NiSOD mutant structures are
present as hexamers with a trimer in the crystallographic
asymmetric unit. In an effort to understand the structure and
function of NiSOD, the structures of Y9F- and D3A-NiSOD
were compared to WT-NiSOD, including both the holo and
apo forms (PDB entries 1T6U, 1T6I, and 1T6Q).
Y9F Crystal Structure. The Y9F crystal structure revealed
the presence of an anion-binding site near the active site in
NiSOD. The WT-NiSOD structure showed the presence of
two water molecules making hydrogen bonds to the hydroxyl
of the Tyr9 side chain (17). In our Y9F-NiSOD mutant,
electron density appears at locations similar to those of two
water molecules in the WT-NiSOD structure. During the
initial interpretation of the electron density, water molecules
were placed at these locations in the structure. However,
when a water molecule was refined in one of these locations,
Fo - Fc electron density maps showed residual electron
density and positive peaks. When that water molecule was
replaced with a chloride ion, the refinement then led to lower
Rfree values and the positive peak in the Fo - Fc map
disappeared. The location of the chloride ion is ideally suited
to anion binding, with the main chain amide nitrogen atoms
of residues 3, 6, and 7 pointing toward the chloride and <4
Å away.
To confirm the identity of the chloride and to probe the
specificity of the putative anion-binding pocket, chloride was
substituted with bromide in the crystallization of Y9F-
NiSOD. Diffraction data were collected above the bromine
absorption edge energy from crystals of both bromide and
chloride containing Y9F-NiSOD [NiSOD (Br) and NiSOD
(Cl), respectively]. The anomalous difference electron density
maps from NiSOD (Br) diffraction data revealed strong
density (more than eight standard deviations) in the anion-
binding site, unambiguously identifying the bromide ion. In
the NiSOD (Cl) crystals, no peak appeared at this location,
as chloride has a negligible anomalous signal at this energy.
As an internal control, the nickel ion appears in both
anomalous maps, because nickel has a slight anomalous
contribution (∼2 e- vs ∼4 e- for bromine) at this energy.
To test if the anion-binding site is a feature of the Y9F
structure alone, the same location in the WT-NiSOD structure
was examined. Intriguingly, the coordinates of WT-NiSOD
contain a water molecule at this position, but Fo - Fc maps
from those diffraction data show a positive peak, suggesting
that the wild-type crystals may also contain some amount
of chloride ion in the anion-binding pocket (Figure 3).
D3A Crystal Structure. The D3A mutation leads to the
loss of two ion pairs across the interface between neighboring
molecules in the hexamer. As a result, 12 ionic interactions
are lost when comparing the WT structure to the D3A
mutant, providing a plausible explanation for the lower
thermal stability of the D3A mutant protein. The carboxyl
group of Asp3 lost upon mutation to Ala leads to the loss of
a salt bridge between Asp3 of one chain and Lys89 of a
neighboring chain. The loss of the carboxyl group from the
side chain of residue 3 produces a gap in the interface
between monomers, allowing the N! atom of Lys89 to move
toward Ala3 ∼2.0 Å to fill the space. Lys89 is critical to the
network of salt bridges across the interface between mono-
mers in the hexamer. The movement of the Lys89 side chain
causes the neighboring Glu49 side chain to move by ∼2.0
Å toward Lys89. This movement of Glu49 weakens the ionic
interaction between Glu49 and His53 across the interface
between monomers. Therefore, mutating Asp3 to Ala results
in the loss of two ionic interactions across each interchain
interface (Asp3-Lys89 and Glu49-His53). With six of these
interfaces in the hexamer, the loss of 12 ion pairs per
hexamer could account for the decrease in the melting
temperature of the mutant from 84.8 to 73.9 °C.
As a result of the disruption in the intersubunit salt bridges
in the D3A structure, the “nickel hook” region is subtly
perturbed. Most notably, Tyr9 has moved ∼1 Å closer to
the nickel (Tyr9-O-Ni; WT-NiSOD distance of 5.47 Å; D3A-
NiSOD distance of 4.26 Å), and a water molecule (W1) has
been displaced from the anion-binding pocket (Figure 4).
Redox Chemistry. EPR and MCD spectroscopic methods
have been used to demonstrate that the nickel centers in the
resting oxidized and reduced proteins are low-spin Ni(III)
and diamagnetic Ni(II) centers, respectively (25). We have
used potentiometric titrations monitoring the absorbance at
380 nm assigned to a CysS f Ni LMCT transition in the
Ni(III) complex (25) to measure the potential of this redox
process (Figure 5). Using samples that were preoxidized with
KMnO4, the data from the initial reductive titrations were
fit to eq 4 to yield values of E° that are listed in Table 6.
Reoxidation of the reduced protein with KMnO4 shows that
the process is reversible. The potentials obtained from fitting
the oxiditative titrations are within experimental error of those
obtained from the reductive titrations (Table 6). The slight
increase in absorbance in the reoxidized enzyme likely
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reflects a small concentration of the protein due to solvent
loss during the long incubation under Ar that was required
to stabilize the potential at each point (ca. 30 min per point).
The E° value obtained for WT-NiSOD [290(4) mV vs NHE]
is approximately midway between the potentials for the
oxidation of O2- to O2.
These values are quite similar to the potentials obtained
from other SODs (see Discussion). The potentials obtained
for the Y9F- and D3A-NiSOD mutants are very similar to
the potential of WT-NiSOD, consistent with the high catalytic
rates observed for these mutants (vide infra). This result is
similar to that found for MnSOD, where mutation of Tyr34
does not affect the redox potential of the Mn center (52).
Kinetics. The rate of dismutation of superoxide by NiSOD
was determined by monitoring the decrease in the absorbance
of the superoxide anion at 260 nm (ε ) 2000 M-1 cm-1)
(53) generated by pulse radiolysis. Table 3 shows the
calculated catalytic rate constant for the different tyrosine
mutants of NiSOD as compared to WT. Y9F-NiSOD exhibits
a slightly perturbed value of kcalc that is∼63% of the activity
FIGURE 3: NiSOD hook domain. (A) WT-NiSOD N-terminal region showing the active site Ni ion (green sphere) and two water molecules
(red spheres). (B) Same region of the Y9F-NiSOD mutant. A chloride ion (orange sphere) at the anion-binding site replaces a water molecule.
(C) Same region of the Y9F-NiSOD (Br) structure. An anomalous difference map (red cage), contoured at 4σ, from data measured above
the bromide absorption edge energy. Only the bromide and nickel show an anomalous signal. (D) Same region of the Y9F-NiSOD (Cl)
structure. An anomalous difference map (black cage), contoured at 4σ, from data measured above the bromide absorption edge. Only the
nickel shows an anomalous signal. The Ni centers are modeled as the His-off state; the actual state is most likely a mixture of His-on and
His-off, but higher B-factors led to poorly resolved electron density at the N-terminus. Images were generated in PyMOL (75).
FIGURE 4: Salt bridge changes in the D3A-NiSOD mutant. (A) The D3A-NiSOD mutant is shown at the interface between neighboring
monomers (blue and cyan) in the hexamer. A weighted 2Fo - Fc map shows the electron density in the interface. (B) Superposition of this
interface from D3A-NiSOD (blue and cyan) onto the wild type (pink and magenta) shows the movement of Glu49 and Lys89. Images were
generated with PyMOL (75).
FIGURE 5: Redox titrations of WT-NiSOD. The green points are
the initial reduction of oxidized to reduced NiSOD, and the red
points were obtained by reoxidation of the same sample. The black
line depicts the best fit of the reductive titration (green dots) using
eq 4.
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of WT-NiSOD. This value is slightly lower than the value
obtained from S. seoulensis Y9F-NiSOD (21) (78%) using
a construct in which the SOD from Streptomyces liVidans
was knocked out and replaced with a mutated copy of S.
seoulensis (21). The SOD activity in that study was measured
by the standard cytochrome c assay in cell extract (21).
However, the studies presented here reveal that at high
substrate concentrations (above a 5-fold excess), Y9F-NiSOD
begins to exhibit saturation behavior. The disappearance of
the absorbance at 260 nm at high superoxide concentrations
relative to the enzyme concentration no longer fits a first-
order process and begins to exhibit a linear component
suggesting saturation behavior. The half-life for superoxide
disappearance at high substrate concentrations in the presence
of Y9F-NiSOD is lowered to ∼41% of that in the presence
of lower superoxide concentrations. Saturation kinetics is not
a feature of WT-NiSOD, which cannot be saturated under
these conditions. Saturation behavior is seen in MnSODs,
although in that case for both the WT and mutants (54, 55).
The other Tyr mutant, Y62F-NiSOD, has a catalytic rate
similar to that of WT-NiSOD and does not saturate,
demonstrating that this residue is not intimately involved in
the redox mechanism of NiSOD. This is not surprising
as Tyr62 sits approximately 13 Å from the Ni center (17, 21).
The double mutant, Y9F/Y62F-NiSOD, is generally similar
to the Y9F mutant (kcalc ∼ 35% of that of WT) and displays
evidence of saturation at high substrate concentrations,
consistent with the mutation at Tyr9.
The crystal structure of Y9F-NiSOD (vide supra) shows
that one of the water molecules found in the active site pocket
near the metal site of WT-NiSOD has been replaced with a
small anion (Cl- or Br-) from the buffer solution. Mutation
of Tyr9 may lead to an opening of the binding pocket, which
would allow small anions to compete for the binding site,
placing a negative charge in the path of the negatively
charged superoxide and leading to diminished catalytic rates
or a modification of the electrostatic component of the rate
constant. To test this hypothesis, ionic strength measurements
were carried out using Cl- and ClO4-. Figure 6 shows a
plot of the log of the calculated rate versus the square root
of the ionic strength for WT, Y9F, and Y62F. The results
are similar to those found for native NiSOD from S.
seoulensis (47) and do not show a change from WT-NiSOD
behavior as the ionic strength increases. These results suggest
that small anions are not competing with superoxide during
catalysis for the binding site.
Mutation of Asp3 to Ala results in a 50% decrease in
activity at pH 7.5 when compared to that of WT-NiSOD.
Upon further investigation, it was also determined that D3A-
NiSOD was much more sensitive to peroxide than WT-
NiSOD. To examine the nature of this sensitivity, both D3A-
and WT-NiSOD were incubated with H2O2 for 5 min, and
then the reductant or inhibitor was dialyzed away. These
samples were then tested for SOD activity using pulse
radiolytic generation of O2-. WT-NiSOD retained full
activity, whereas the activity of D3A-NiSOD was below the
detectable limit (data not shown). ESI-MS of D3A-NiSOD
before and after H2O2 incubation were identical (Supporting
Information), ruling out the possibility that the peroxide was
causing an oxidative modification of the protein, such as
conversion of the cysteine thiolate ligands to sulfinates (24),
which would likely result in a loss of activity. However,
incubation of D3A-NiSOD with peroxide did result in the
production of a tyrosyl radical EPR signal (vide infra), an
oxidative modification that does not affect the MW of the
enzyme.
As isolated, D3A-NiSOD has the same EPR parameters
as WT-NiSOD (Table 3). However, when treated with H2O2
[a reductant and inhibitor of NiSOD (56)] under anaerobic
conditions, a signal attributable to a protein-based radical at
g ) 2.004 emerges with a 1H hyperfine splitting pattern that
resembles a tyrosine radical (Figure 7) (57). Integration of
this signal versus Ni(PDTC) showed that∼8% of the enzyme
possessed the tyrosine radical. This assignment was con-
firmed by replacing all four tyrosine residues with d4-tyrosine,
where the protons on the aromatic ring are substituted with
deuterons. The resulting hyperfine splitting is clearly altered,
consistent with the assignment of the hyperfine to a tyrosyl
radical. (The deuterated sample is ∼50% less concentrated
than the nondeuterated sample.) This signal is not observed
FIGURE 6: Ionic strength dependence of NiSOD catalysis. Y9F- and
WT-NiSOD were reacted with both NaCl (red for WT and yellow
for Y9F) and NaClO4 (blue for WT and green for Y9F), while Y62F
was reacted with only NaCl (black). Pulse radiolytic conditions
were the same as those mentioned in Experimental Procedures,
except 0.5-0.0156 M NaCl or NaClO4 was added to the solution
being monitored to probe the effect of ionic strength.
FIGURE 7: X-Band EPR data from D3A-NiSOD. (A) As-isolated
D3A. (B) H2O2-treated D3A. (C) Enlargement of the region near g
) 2.00 expanded (solid line) and a simulation with parameters gx
) gy ) gz ) 2.004, Axx ) Ayy ) 5 G, and Azz ) 20 G (red dashed
line). (D) H2O2-treated D3A-NiSOD (d4-Tyr), showing alteration
of hyperfine splitting due to tyrosine ring protons. All spectra are
shown with the same intensity scale with the exception of panel
D, which has a scale half as large.
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to any significant extent in WT-NiSOD or any of the other
mutants and indicates that the interaction of the enzyme with
peroxide is fundamentally altered by the D3A mutation.
DISCUSSION
Redox Chemistry of the Nickel Site. The protein environ-
ments of the catalytic metal sites in SODs are responsible
for achieving at least three features of these enzymes:
adjusting the redox potential of the metal to a value that is
optimum for catalysis (ca. 300 mV) (8), controlling anion
access to the active site (27), and providing a source of
protons for formation of H2O2 (17, 21). The O2/O2- reduction
potential has been determined to be -160 mV (vs NHE),
and the O2-/H2O2 potential lies at 870 mV (vs NHE) (58).
The midpoint of these two potentials (365 mV vs NHE) is
the potential at which an optimal SOD catalyst would lie.
Nickel is an unusual choice of metal for an SOD because
the reduction potential of Niaq(III)/(II) is g2 V [1.94 V for
low-spin Ni(III) and 2.24 for high-spin Ni(III)] (6) and lies
well outside the biologically relevant range. Nonetheless, the
redox titrations of NiSOD presented above establish that the
redox potential of the nickel site is ∼290 mV, appropriate
for SOD catalysis. The other classes of SODs (Cu/Zn, Mn,
and Fe) all have reduction potentials near 300 mV (vs NHE)
with deviations up to∼100 mV (59-63). This demonstrates
that the protein environment is critical for tuning the
reduction potential of each metal to the optimal potential
for SOD catalysis. The reduction potential for hexa-aqua
complexes of Mn (1.5 V) and Fe (0.77 V) (8, 64) requires
a smaller adjustment by the protein than Ni does. The
suppression of the Em in Mn- and FeSOD is achieved by a
hydrogen bonding network that couples the protonation state
of an aqua ligand to the redox process of the metal (8). In
the case of NiSOD, no aqua ligand exists in any crystal
structure, and thus, the protonation state of such a ligand is
not available for adjusting the redox potential of Ni(III)/(II).
Furthermore, the shift in potential for the Fe(III)/(II) redox
couple in FeSOD has been attributed to the protonation state
of the aqua/hydroxo ligand (65); such a shift would not be
adequate for optimizing the potential of a nickel center in a
similar ligand environment. Instead, NiSOD relies on a
different ligand environment, one that includes cysteine
ligands, a feature of every redox active nickel enzyme that
utilizes the Ni(III)/(II) redox couple (66). Thus, NiSOD uses
a unique strategy to accomplish the same goal, a ∼300 mV
redox potential, that is found in every other SOD.
EPR integration of the Ni(III) signals in the resting,
oxidized enzyme accounts for only 50% of the Ni present
in WT-NiSOD and in the mutant enzymes, indicating that
NiSOD contains a 50:50 mixture of Ni(II) and Ni(III). The
amount of Ni present in NiSOD was determined by ICP-
OES (see Experimental Procedures) after extensive buffer
exchanging and treatment with Chelex to remove any
nonspecifically bound metal. EXAFS analysis confirms that
all of the Ni is bound in the active site, since each Ni center
has two S donor ligands, and there are only two cysteine
residues in the protein. Oxidation of resting, oxidized WT-
NiSOD with KMnO4 failed to increase the intensity of the
EPR signal arising from the five-coordinate Ni(III) center
(Supporting Information), indicating that the 50:50 mixture
is, in fact, the fully oxidized enzyme. Although these data
do not show why one nickel center is redox active and the
other one is not, a likely possibility is that the apical His1
imidazole ligand plays a role. The two nickel centers differ
by coordination of the imidazole ligand (His-on vs His-off),
and it seems likely that the Ni(II/III) redox potential of the
four-coordinate planar center is much higher than for the
five-coordinate complex. In this regard, it is noteworthy that
mutation of the apical His ligand to Gln (49) or Ala (67)
yields mutants that have a resting oxidation state that contains
only EPR-silent Ni(II). Other than a possible role in
maintaining charge neutrality in the hexamer during catalysis,
the biochemical rationale for the equal mix of the two
oxidation states remains to be elucidated but would seem to
require some cooperativity between active site centers to
maintain the equal balance of oxidized and reduced nickel
ions. Until now, the mechanism of communication between
active sites within the hexamer that are spaced ∼25 Å apart
has not been clear, but the structure of D3A-NiSOD suggests
a mode for maintaining the redox balance. As described
above, a network of ion pairs connect Asp3 to Lys89 to
Glu49 to His53 across the interface between neighboring
monomers (Figure 4) derived from different trimer subunits.
His53 also lies near a 2-fold symmetry axis of the hexamer
(which contains 32-point symmetry). The Nδ atom of His53
hydrogen bonds to a water molecule that lies directly on the
molecular 2-fold axis. Thus, the His53 side chains from two
monomers related by a molecular dyad make a water-
mediated hydrogen bond, raising the possibility that informa-
tion about one active site nickel may be communicated to a
neighboring active site nickel.
Human MnSOD (hMnSOD) is a homotetramer and forms
a dimer of dimers. A recent study examined the H-bonding
network between Glu162 and His163 (a metal ligand) by
mutating Glu162 to both an Ala and Asp. This H-bonding
network connects neighboring monomers across a dimer
interface and links two Mn centers (54). Both mutations
retained tetrameric structure and specificity for Mn over Fe
[in contrast, studies of the analogous mutation made in E.
coli MnSOD (EcMnSOD), a homodimer, show the mutant
enzyme preferred Fe over Mn (55)]. Both the human Glu162
mutations have diminished activity compared to WT-
hMnSOD (54), but each helps to elucidate fine points of how
hMnSOD carries out O2- dismutation. By performing pH
titrations on the enzyme and monitoring the electronic
absorption spectrum, the pKa of the system can be deter-
mined. WT-hMnSOD has a pKa of ∼9.5, which has been
attributed to ionization of Tyr34 (32, 68, 69). In the E162D-
hMnSOD mutant, the pKa decreases slightly to 8.7(2), while
the E162A-hMnSOD pKa is closer to the pKa of Tyr in water
[10.1(1)] (54). This can be explained by the interaction of
Glu162 and Tyr34, which are 6.2 Å apart. The H-bonding
network extends from the carboxylate of Glu162 to His143
through a solvent molecule to Tyr34. This network is
maintained in the E162D-hMnSOD mutant but is disrupted
in the E162A-hMnSOD mutant. This is analogous to the
backbone amide of Asp3 in NiSOD, which is connected to
the phenol proton on Tyr9 through a H-bonding network
involving ordered water in the pocket. This network is
perturbed in the D3A-NiSOD mutant, and perturbed kinetics
and peroxide sensitivity are observed. (It is noteworthy that
in hMnSOD, there is no functional difference between
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E162A and E162D mutants despite the structural difference.
In NiSOD, there is a functional difference.)
Roles of Tyr9 in NiSOD Catalysis. Mutations of conserved
second-coordination sphere residues, Tyr9, Asp3, and the
more distant Tyr62, do not lead to major perturbations of
the protein structure, or of either the electronic structure or
redox chemistry of the nickel site. However, both the Tyr9
and Asp3 mutations have significant effects on catalysis. In
the case of Y9F, there is a small decrease in kcalc and the
enzyme shows the onset of saturation behavior that is not a
feature of WT-NiSOD under the conditions studied. In the
case of D3A-NiSOD, the loss of activity is more pronounced;
the enzyme is somewhat less thermally stable and exhibits
distinct reactivity with H2O2.
The roles played by the Tyr9 residue in catalysis can
account for much of the altered functions of Y9F- and D3A-
NiSOD. The structure of WT-NiSOD reveals no water
molecules coordinated to either the five-coordinate pyramidal
His-on Ni(III) center or the reduced four-coordinate planar
His-off Ni(II) center. Tyr9 lies near the vacant sixth
coordination position with a Ni-O-Tyr9 distance of 5.47
Å. The position of Tyr9 is such that the phenol proton is
engaged in hydrogen bonds with two ordered water mol-
ecules, W1 at 2.56 Å and W2 at 2.84 Å, that also accept
hydrogen bonds from amide protons from Cys6 (W1) and
Asp3 (W2) (17, 21). In the Y9F mutant, loss of the phenol
group leads to a small perturbation in the position of the
phenyl ring, opening up the existing anion binding pocket
(Figure 3), and W1 is replaced with Cl-. This is the first
crystallographic characterization of an anion complex of
NiSOD and clearly identifies a likely binding site for the
substrate, O2-. That Cl- is not a nickel ligand is evidenced
by the 3.5 Å distance, the absence of a Ni-Cl vector in the
EXAFS spectrum, and the lack of chlorine hyperfine splitting
(even at 200 mM Cl-) in the EPR spectrum, particularly on
gz which exhibits large N hyperfine splitting (Az ) 25 G)
from the apical H1 imidazole ligand in the dz21 ground state.
Hyperfine splitting from the enzyme (likely due to the amide
and or N-terminal amine N-donor ligands) is partially
resolved on gy in Y9F-NiSOD. Similar hyperfine splitting
on the gy feature has also been observed in azide-inhibited
NiSOD (17). When 15N-labeled azide was used, the same
EPR spectrum was observed, indicating that the splitting was
due to an electronic and/or structural perturbation rather than
to azide binding (17). Further, the Cl- in the Y9F-NiSOD
structure is in the same location that was previously
suggested for azide (anion) binding (17). The Cl- anion has
hydrogen bonding interactions with both of the amides from
Cys6 (N-Cl distance of 3.4 Å) and Asp3 (N-Cl distance
of 3.4 Å), which provide a mechanism for a small perturba-
tion of the nickel site. The Cl- is positioned such that it could
interact with the phenol group of Tyr9 in WT-NiSOD, which
suggests possible roles for Tyr9 in the release of H2O2, and
in controlling access of anions to the active site. The size of
the pocket in WT-NiSOD is appropriate for only small anions
and is positioned near the nickel site but does not allow
anions to bind to the metal. Since there is no evidence of
anion binding to Ni in either His-on [Ni(III)] or His-off
[Ni(II)] sites, and assuming that O2- binds to the same site,
the structural data support an outer-sphere redox reaction
for both half-reactions as illustrated in Scheme 1.
In an outer-sphere mechanism, the superoxide would
displace the two water molecules (Scheme 1, I) and sit
between the backbone amides of Asp3 and Cys6 (Scheme
1, II). Electron transfer would occur, yielding molecular
oxygen and Ni(II) (Scheme 1, II f III). The second half of
the reaction starts the same as the first half, with superoxide
binding in the substrate binding pocket (Scheme 1, IV).
Electron transfer occurs concomitant with proton transfers,
leading to formation of peroxide and Ni(III). Loss of the
phenol group and opening of the anion-binding pocket lead
to a small perturbation in the position of the phenyl ring
and increased occupancy of the site by Cl- and Br- in the
absence of O2- (Figure 3). When the bound peroxide is
protonated, the phenol group could play a role in destabilizing
the binding of the product, H2O2, in the anion binding site
and inhibiting the direct interaction with the nickel site and
its oxidation-sensitive cysteine thiolate ligands. Slower
peroxide release in the absence of the phenol group could
account for the decrease in activity and the saturation
behavior observed in Y9F-NiSOD kinetics.
It has been shown that binding of azide to EcMnSOD is
temperature-dependent. At low temperatures, a six-coordinate
complex derived from complexation of azide is formed,
whereas at room temperature, the active site is five-coordinate
andlacksanazideligand,resemblingtherestingenzyme(31,70,71).
One hypothesis speculates that a “dead-end” complex of
EcMnSOD forms when superoxide binds to Mn2+-SOD,
causing oxidation of the Mn center and reduction of
superoxide to peroxide with concomitant transfer of a proton
from the bound water to yield a Mn center with bound
hydroperoxide and OH- (31). The Y34F mutation changes
the way the enzyme interacts with anions. When azide is
added to Y34F-Mn3+-SOD, the enzyme resembles the low-
temperature six-coordinate N3-Mn3+-SOD complex and
exhibits no temperature dependence (71). Thus, the “gate-
way” tyrosine seems to play a critical role in controlling
access of anions to the metal site in both Fe- and
MnSODs (15, 16, 71) by inhibiting anion binding at the metal
center. The same function for Tyr9 appears to be a feature
of NiSOD catalysis. Second-sphere residues such as Tyr34
also tune the lability of the peroxide product in MnSOD.
This is seen in the fact that the activity of Y34F-MnSOD is
more product-inhibited than that of WT-MnSOD (68).
Another possible explanation might be that mutation of
Tyr9 and loss of W1 from the active site perturb a hydrogen
bonding network that is important for supplying protons for
the formation of H2O2 (17, 21). This has also been proposed
for MnSOD, where the H-bonding network in the second
coordination sphere has been implicated as the source of
protons for the release of H2O2 (68, 72). Studies of Tyr34
from hMnSOD shows that replacing the Tyr with a Phe has
little effect on the protein fold or the geometry at the active
site; in fact, the thermal stability of the mutant is increased
when compared to that of WT-hMnSOD (68). Tyr34 is not
essential for MnSOD catalysis, as at low substrate concentra-
tions (compared to Km) Y34F-MnSOD has catalytic rates
similar to that of WT-MnSOD. This is shown by the fact
that the steady state constant, kcat/Km, is the nearly identical
for both Y34F- and WT-MnSOD and is near the diffusion
limit of 109 M-1 s-1. The only major perturbation is the
decrease in the maximal rate, kcat, which is approximately
10-fold lower for the mutant enzyme (68). This implies that
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Tyr34 may be involved in peroxide release or proton
donation either directly to the metal site or indirectly through
a H-bonding network that ties the Tyr34 to the Mn active
site (68). Mutation of Tyr34 has also been examined in
FeSOD from E. coli (EcFeSOD), and Y34F-FeSOD results
in a rate decrease of ∼60% when compared to that of WT-
FeSOD (33). The gateway Tyr residue in FeSOD also seems
to play a key role in controlling anion binding to the metal
site, which differs between the reduced and oxidized state
in FeSOD (15).
The importance of Tyr9 in controlling the access of H2O2
to the active site is supported by studies of D3A-NiSOD.
Although this mutant exhibits reduced activity relative to
WT-NiSOD, redox titration shows that this is not due to
alteration of the redox potential of the nickel site. Further,
the similar EPR spectrum obtained from Ni(III) centers in
the oxidized enzyme shows that the electronic structure of the
nickel site is not perturbed by the D3A mutation. Nonethe-
less, this mutant exhibits a drastically altered interaction with
H2O2. Unlike WT-NiSOD, which shows inhibition (activity
can be restored to normal levels upon removal of peroxide)
by H2O2, D3A-NiSOD is inactivated (loss of activity is
irreversible) by exposure to H2O2. This inactivation does not
result from oxygenation of the cysteine residues but appears
to involve the oxidation of Tyr9 to a tyrosyl radical as
detected by EPR. The crystal structure of D3A-NiSOD
reveals that in addition to the loss of two intersubunit
interactions per monomer resulting in a hexamer with lower
thermal stability, the position of Tyr9 is altered. In D3A-
NiSOD, the tyrosine is positioned such that the phenol group
is ∼1 Å closer to the nickel site (Figure 8). In this
configuration, it is in a position that would be less effective
in inhibiting access of H2O2 to the nickel site and could even
stabilize formation of a Ni-OOH peroxo or superoxo adduct
that results in oxidation of Tyr9.
Mutation of Tyr34 in MnSOD leads to a more product-
inhibited form of the enzyme, which is pronounced in
hMnSOD and not as evident in E. coli MnSOD (EcMnSOD)
(73). To probe this inhibition further, Phe66 from hMnSOD
was studied because it contributes to the local environment
of Tyr34 (74). Phe66 also lies at a dimer interface of
hMnSOD, and when this was mutated to an Ala, there were
no major perturbations as the enzyme acted in a manner very
Scheme 1: Proposed Outer-Sphere Mechanism for NiSODa
a Ni(III) is indicated by the His-on complex, while Ni(II) is denoted as a His-off complex, although removal of His1 during turnover may not
occur. Superoxide is denoted by the orange molecule, and water is denoted by red spheres. Images were generated with PyMOL (75).
FIGURE 8: Superposition of the Ni hook domains of WT-NiSOD
(blue), Y9F-NiSOD (purple), and D3A-NiSOD (orange) showing
the position of Y9 in each. This image was generated with PyMOL
(75).
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similar to that of WT-hMnSOD. F66L-hMnSOD exhibited
a decrease in the level of product inhibition and had
characteristics similar to that of EcMnSOD. Crystallographic
characterization of F66L-hMnSOD has provided insight into
why this particular mutant had a decreased level of product
inhibition. The substitution of Phe66 with Leu had an effect
on two residues. First, Gln119 moved approximately 1 Å
farther from the Mn site but maintained the same distance
between residues 66 and 119 as seen in WT-hMnSOD. Tyr34
also had a subtle movement of 0.3 Å away from the Mn
center. This movement is small and has a high uncertainty
due to the resolution of the structure (2.2 Å). This is
consistent with the data presented here in that inward
movement of the gateway tyrosine (Tyr9 of NiSOD and
Tyr34 of MnSOD) leads to a more product sensitive enzyme.
When the corresponding residue swings away from the metal
center, this inhibition is attenuated in hMnSOD and is not
seen in NiSOD.
The angle of the aromatic ring plane of residue 9 (Figure
8) may also act as a sensor for the presence of bound metal.
When the locations of Tyr9 in the holo- and apo-NiSOD
structures are compared, the angle of the residue 9 aromatic
ring plane changes by 15° between the two structures. This
difference is consistent in all 12 copies of the holoenzyme
monomer in PDB entry 1T6U and all six copies of the
apoenzyme in 1T6I and 1T6Q. Thus, the aromatic ring may
also be a sensor for the presence of a metal in the active site
of the enzyme. In the case of the Y9F-NiSOD mutant
structure, the angle of the aromatic ring of residue 9 is more
consistent with the apo structures, producing a structure
intermediate between the active holoenzyme and the inactive
apoenzyme. The Y9F mutant is the first structure in which
the angle of the residue 9 side chain is decoupled from the
presence of metal in the active site of the enzyme. This
observation is consistent with the result that the Y9F mutant
does not bind nickel as efficiently as the wild-type enzyme
(the crystals have only 60% occupancy). Additionally, the
eight N-terminal residues that comprise the Ni hook domain
have higher B-factors and lower quality density than the rest
of the structure, suggesting some heterogeneity in the region
around the Ni center. It appears that the Ni is required to
properly form a well-ordered static Ni hook region at the
N-terminus.
Structural Homology between MnSOD and NiSOD. The
analogous functional roles ascribed to Tyr9 in NiSOD and
Tyr34 in MnSOD are also reflected in their structural
relationship with their respective metal centers. Both tyrosine
phenol oxygen atoms lie at a M-O distance of ca. 5.5 Å
and are engaged in well-defined hydrogen bonding interac-
tions. In addition, both are close to a second aromatic residue.
In the case of MnSOD, Tyr34 lies between Phe66 and the
manganese center. The F66L-MnSOD mutation in hMnSOD
results in perturbation of the positions of water molecules
and hydrogen bonding interactions that leads to a mutant
enzyme that is less sensitive to peroxide inhibition (74). In
WT-NiSOD, Tyr62 lies ∼13 Å from the nickel center and
Tyr9 lies between it and the metal. Neither the structure of
the nickel site (XAS and EPR) nor the kinetic properties of
Y62F-NiSOD differ from significantly from those of WT-
NiSOD. Although no similar function has been found for
NiSOD Tyr62 and human MnSOD Phe66, they share the
same spatial relationship to the respective Tyr residues near
the metal sites. This is clearly shown in Figure 9, which
shows a superposition of the active site of the human
MnSOD structure (PDB entry 1LUV) and WT-NiSOD (PDB
entry 1T6U), where Phe66 from MnSOD and Tyr62 from
NiSOD were constrained to overlap. Thus, it can be seen
that despite the lack of any primary, secondary, tertiary, or
quaternary structure, the two enzymes have arrived at the
same mechanism for controlling access of anions and H2O2
to the active site.
SUPPORTING INFORMATION AVAILABLE
Amino acid sequence alignments for selected NiSODs,
DSC thermograms, ESI-MS under nondenaturing conditions,
EPR spectra of WT-NiSOD and mutant NiSODs and as-
isolated and KMnO4-oxidized WT-NiSOD, and tables of
EXAFS fits. This material is available free of charge via the
Internet at http://pubs.acs.org.
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